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ABSTRACT 
Articular cartilage is a highly organized, anisotropic tissue lining the ends of bones 
within synovial joints. Composed primarily of water, collagens, proteoglycans and 
chondrocytes which synergistically give rise to the tissue's mechanical and tribological 
properties. Fluid pressurization and resistance to fluid flow within the porous extracellular 
matrix of cartilage, coupled with the low hydraulic permeability of the tissue endow the 
tissue with a viscoelastic response to loading and aid to reduce the coefficient of friction 
between articulating surfaces, with the pressurized fluid supporting 95% of applied loads. 
Experiencing millions of articulations throughout an average lifetime, articular cartilage 
possesses distinct biotribological properties. These require effective lubrication, mediated 
by the synergistic interaction between fluid and boundary lubricants, to provide a low 
coefficient of friction and prevent wear at the cartilage surface.  
Osteoarthritis is the progressive deterioration of articular cartilage and synovial 
joint structure and function, leading to softer and wear prone tissue on account of altered 
biochemical composition of the extracellular matrix. Plain radiography remains the most 
accessible tool and the current standard of care to visualize musculoskeletal diseases and 
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injuries (e.g., osteoarthritis), but cannot directly visualize soft tissues or cartilage, and 
diagnoses are based solely on boney changes, which occur in the later stages of the disease. 
Coupled with no way to quantitatively assess tissue health prior to irreversible 
deterioration, there remains no cure for osteoarthritis. Integral to OA pathology are 
concomitant changes in the biochemical composition of synovial fluid that result in 
deterioration of rheological properties, contributing to increased cartilage wear.  
 To address both the lack of quantitative diagnosis methods and lack of 
chondroprotective therapies, this dissertation presents a dual faceted approach to 
quantitatively image articular cartilage health, coupled with lubrication strategies to 
improve cartilage lubrication, and preserve cartilage tissue. This dissertation describes the 
synthesis of tantalum oxide nanoparticles of varying surface charges for use as contrast 
agents for rapid, minimally invasive, non-destructive, and quantitative contrast-enhanced 
computed tomography to assess both the biochemical content and biomechanical integrity 
of articular cartilage. Ex vivo contrast enhanced computed tomography attenuation using 
the nanoparticle contrast agent reveals correlations between attenuation and the mechanical 
and biochemical properties of the tissue.  
 The lubrication strategy described within this dissertation involves introducing a 
rolling ball element between two surfaces to reduce friction. In this strategy, either single, 
globular macromolecules or nanoparticles are employed as ball bearings between 
articulating surfaces to reduce friction when asperities on the surfaces are in direct contact. 
Rheological characterization and construction of classical Stribeck curves using the 
lubricant formulations reveal that introducing the rolling element reduces the coefficient 
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of friction during boundary lubrication, while leaving the rheological properties of the base 
fluid intact. Ex vivo cartilage mechanical testing involving shear deformation under varying 
speeds and loads reveal improved biotribological performance compared to pure synovial 
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Biomimetic lubricant  A macromolecule or synthetic material that reduces 
friction or prevents wear in a biological system. 
Boundary lubrication  Lubrication mode characterized by a low speed and a 
high load, where asperities on opposing articulating 
surfaces are in direct contact, separated by a single 
molecular layer of lubricant. 
Coefficient of friction A dimensionless number that represents the ratio of 
the force and normal force between two surfaces 
sliding over one another. Depends on the nature of the 
material and surface roughness. Values less than 0.1 
are considered lubricious materials. 
Contrast Enhanced CT  Use of imaging agents to afford a temporary 
enhancement of contrast between tissues of similar 
compositions for use in a computed tomography scan. 
Donnan equilibrium theory  Equilibrium of charged particles near a semi-
permeable membrane, often failing to distribute 
evenly across the two sides of the membrane. The 
fixed negative charge of articular cartilage causes an 
imbalance of ions between external solution and 




Equilibrium compressive modulus  Measure of the stiffness of a material, which 
quantifies the relationship between stress (force per 
unit area) and strain (proportional deformation) 
Hersey number  A dimensionless lubrication parameter that is the 
product of viscosity and rotational speed over-load. 
Hydrodynamic lubrication  Lubrication mode marked by low loads and high 
speeds, with articulating surfaces fully separated by a 
fluid film. 
Interstitial fluid load support  Proportion of load supported by the fluid phase of a 
biphasic material. Upon loading, the fluid film 
becomes pressurized with the solid phase, bearing the 
load. 
Intraarticular  Within or administered into a joint cavity. 
k-edge  Increase in the attenuation coefficient of photons 
occurring when the incoming x-ray beam is just above 
the binding energy of the K shell electron of those 
atoms interacting with the x-ray beam. 
Mixed mode lubrication  Transitional region between boundary and full 
hydrodynamic lubrication, where some areas between 
articulating surfaces exist in boundary lubrication 
whereas others are fully separated by a fluid film and 
exist in hydrodynamic lubrication. 
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Nanolubricant   Colloidal suspension of nanoparticles within a base 
fluid. 
Nanoparticle   An ultrafine particle of matter between 1 and 500nm 
displaying unique material characteristic. 
Strain   Amount of deformation of a material per unit length 
in the direction of applied forces, relative to original 
length 
Stribeck curve  Depicts the non-linear function of friction as a 
function of the contact load, lubricant viscosity and 
velocity. 
Tribology  The study of friction, lubrication and wear 
Tribosupplementation  Intra-articular injection of a lubricating substance 
with the goal of preserving cartilage and re-
establishing boundary or hydrodynamic lubrication. 
Viscosupplementation  Intra-articular injection of a hyaluronic acid solution 
to improve synovial fluid elasticity and viscosity, to 
reduce pain and improve ambulation.   
Wear   Damaging, gradual removal, or deformation of 
materials in contact. Causes may be mechanical or 
chemical. 
Weight percent (weight basis)  Concentration that is determined from mass (g) per 
total mass (g) 
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CHAPTER ONE. Nanotechnology and Osteoarthritis: Clinical landscape and 
opportunities for advanced diagnostics 
1.1 Abstract 
 Osteoarthritis (OA) is a disease of the entire joint, often triggered by cartilage 
injury, mediated by a cascade of inflammatory pathways involving a complex interplay 
among metabolic, genetic, and enzymatic factors that alter the biochemical composition, 
microstructure and biomechanical performance. Clinically, OA is characterized by 
degradation of the articular cartilage, thickening of the subchondral bone, inflammation of 
the synovium, and degeneration of ligaments that in aggregate reduce joint function and 
diminish quality of life. OA is the most prevalent joint disease, affecting 140 million people 
worldwide; these numbers are only expected to increase, concomitant with societal and 
financial burden of care. This review encompasses the applications of nanotechnology to 
the diagnosis and treatment of osteoarthritis. Specifically, the focus is on OA treatment 
options and advancements in nanotechnology for the diagnosis of OA and imaging of 
articular cartilage, beginning with a concise evaluation of the clinical landscape of OA, 
along with current diagnosis and treatments, followed by an assessment of nanoparticle 
contrast agents for minimally invasive detection, diagnosis, and monitoring of OA via 
MRI, CT, and photoacoustic imaging techniques. We conclude by identifying 






Nanotechnology is the design, manipulation, and control of materials and 
phenomena at atomic, molecular, and macromolecular scales. Physical, rheological, and 
mechanical properties as well as biological responses of materials depend on their size.  At 
very small dimensions – i.e., nano-scale, 109 meters – materials exhibit novel properties 
including fluorescence, enhanced magnetism, augmented load capacity, and improved cell 
internalization, often the consequence of confined electronic structure and increased 
surface area. Nano is not new; early examples of nanomaterials date back centuries to 
craftsmen who created stained glass windows and wine glasses using silicate (Egyptian 
Blue), as well as gold and silver nanoparticles (Lycurgus cup).1,2 Nanotechnology is part 
of our daily lives, from Apple’s “iPod Nano” to protective sunscreens. In medicine, 
clinically approved nano-technologies include: 1) liposome encapsulated amphotericin B 
(AmBisome®), doxorubicin (Doxil®), and irinotecan (Onivyde®) for treating fungal 
infections, ovarian cancer, and pancreatic cancer, respectively; 2) iron nanoparticles 
(Ferumoxytol®) for treating of iron deficiency anemia; 3) albumin coated paclitaxel 
nanoparticles (Abraxane®) for treating metastatic breast cancer and non-small-cell lung 
cancer; 4) nanocrystals of Aprepitant® as an antiemetic; 5) dendritic polymers (Adherus®) 
as a tissue sealant. Currently, there is no FDA approved technology for the diagnosis or 
treatment of osteoarthritis (OA). However, opportunities abound, and results from pre-
clinical studies, described below, warrant continued efforts and translation to the clinic. 
Herein, we review applications for nanotechnology within the context of evaluating and 




1.3 Osteoarthritis  
OA is a chronic, synovial joint arthrosis afflicting 140 million people worldwide. 
Associated treatments cost $125 billion annually.3 OA is progressive; changes in joint 
structure and function appear relatively late in the disease process, but account for long-
term morbidity and disability experienced by OA patients. OA affects all synovial joint 
structures, including the synovium, joint capsule, cartilage, and bone. Biochemical,4 
mechanical ,5 metabolic ,6,7 and genetic8 factors are etiologically related to OA. While the 
etiology is multi-factorial, OA is typically induced by acute or chronic mechanical injury 
to hyaline cartilage - the smooth, hydrated tissue that lines articular joint surfaces (Figure 
1.2) - as a consequence of trauma, joint instability, ligamentous deficiency, skeletal 
malalignment, obesity or anatomic deformity. Mechanical overloading results in 
glycosaminoglycans (GAG) loss,9 collagen disorganization,10 fibrillation,11 tissue 
swelling,12 and surface wear13 and incites an inflammatory response mediated by a cascade 
of cytokines. Elevated cytokines in OA synovial fluid (e.g., IL-1β, TNF-α)14 induce 
enzyme-mediated (e.g., metalloproteinases and ADAMTS) cartilage degeneration.15 
Additionally, in OA, the synovial fluid’s capacity for both fluid and boundary lubrication 
decreases due to a reduction in hyaluronic acid Mw and lubricin degradation.16 In advanced 
OA, synovial fluid contains minimal hyaluronic acid and lubricin, further contributing to 
poor lubricity and higher coefficient of friction (similar to saline). 16 
Histopathologically, OA is characterized by the simultaneous presence of cartilage 
matrix degradation and repair including chondrocyte death, replication, and regeneration. 




metalloproteinases, and IL-1 which result in increased water content, depleted 
proteoglycans, collagen, and altered binding of proteoglycans to hyaluronic acid in the 
synovial fluid. As OA progresses, there is an increased production of matrix-degrading 
enzymes and pro-inflammatory cytokines, which damage cartilage further. Loss of GAG, 
an early hallmark of OA, results in increased tissue porosity thus increasing hydraulic 
permeability, and increasing the flux of water through the porous network, with more of 
the internal load support to the solid collagen network. Repetitive damage to the collagen 
network further decreases tensile stiffness with subsequent loss of tissue.  
OA is diagnosed based on clinical symptoms (e.g., pain, swelling, impaired 
function) and confirmed using imaging (e.g., plane radiographs, computed tomography 
(CT), magnetic resonance imaging (MRI)).  Unfortunately, imaging is biased toward 
visualizing late-stage OA pathoanatomy (i.e., cartilage volume loss, bone marrow edema, 
subchondral bone thickening, cyst formation and marginal osteophyte formation).17 The 
ability of hyaline cartilage for self-repair is limited, and irreversible breakdown occurs long 
before clinical symptoms and radiographic signs are evident. OA diagnosed at a late stage, 
after micro- and macroscopic changes in tissue structure have transpired, worsens the 
prognosis and limits treatment options.  
OA is incurable and difficult to treat. To ameliorate OA requires a comprehensive 
approach: 1) correct mechanical factors that contribute to acute or chronic injury of 
chondrocytes and wear of hyaline cartilage; 2) abrogate the inflammatory cascade and 
neutralize catabolic enzymes that degrade hyaline cartilage; 3) reconstitute degraded 




stage chondral lesions  
1.4 Osteoarthritis Diagnosis 
The inability to identify cartilage damage early, when chondroprotective or 
chondroregenerative strategies will be most effective, presents a clinical obstacle. 
Magnetic resonance imaging (MRI) and computed tomography (CT) are widely used to 
visualize musculoskeletal pathology. MRI possesses several advantages, including absence 
of ionizing radiation and capacity to examine the entire joint. Using semi-automated 
segmentation algorithms to create 3D surface representations of articular cartilage, MRI 
measures the thickness, volume and surface topography of articular cartilage.18-20 
Semiquantitative scales such as the Whole Organ MRI Score (WORMS)21 and the Boston-
Leeds Osteoarthritis Knee Score (BLOKS)22 are used to score multiple features in affected 
joints. Several MRI-based techniques (T1 mapping, T2 mapping, T1ρ, Na+ mapping and 
dGEMRIC) provide images that reflect the GAG and collagen content of articular 
cartilage.23 Predicated on Donnan equilibrium theory, delayed Gadolinium-enhanced MRI 
of cartilage (dGEMRIC) uses gadopentetic acid (Gd2−) as a mobile anionic probe that 
partitions throughout the cartilage ECM in inverse proportion to the fixed negative charge 
density conferred by GAG.24 - 27 Since T1 relaxation time varies inversely with the 
concentration of Gd2− diffused throughout the cartilage matrix, mapped T1 relaxation time 
directly indicates the spatial distribution and concentration of GAG distributed throughout 
the tissue, allowing differentiation between healthy and OA cartilage based on chemical 
composition.28-30  




does not attenuate x-rays well, standard CT does not readily measure thickness, volume, or 
surface topography of articular cartilage in vivo. Intra-articular injection of an iodinated 
contrast agent facilitates visualization of articular surfaces. Computed arthrotomography 
has been used for decades to image articular surfaces comprising the hip, shoulder, knee, 
elbow and foot.31  CT arthrography is particularly useful for defining intra-articular 
pathoanatomy, providing rapid image acquisition, 2D-tomographic and 3D image 
reconstruction capability, excellent contrast resolution and segmentation of cartilage from 
bone, without the need for specialized sequences.32,33 Similar to dGEMRIC, contrast-
enhanced computed tomography (CECT), uses an anionic, iodinated contrast agent 
(Ioxaglate) that partitions throughout the tissue in inverse relation to local cartilage GAG 
content. To enhance CT based quantitative assessment of anionic tissue GAG composition, 
Grinstaff and Snyder developed cationic contrast agents that partition directly into the 
tissue in accordance to Donnan equilibrium so as to maintain electroneutrality.33-38  
Nanoparticles of iron, gold, bismuth, or tantalum of less than 100 nm in diameter 
are of significant interest as medical imaging contrast agents.33,39–41 Advances in the 
synthesis of nanoparticles are yielding various types of nanoparticles for qualitative and 
quantitative medical applications. Utilizations of these for cartilage imaging is still rare⁠.42-
44 Articular cartilage permeability is low, possesses a fixed negative charge, and pore size 
is typically less than 10 nm hindering nanoparticle diffusion. 45,46 
1.4.1 Magnetic Resonance Imaging (MRI) 
MRI contrast agents contain paramagnetic or superparamagnetic metal ions that 




accumulate. 46 Superparamagnetic iron oxide nanoparticles (SPIONs) are extensively 
employed as MRI contrast agents, owing to their unique physical, chemical, magnetic and 
biocompatibility properties. SPIO agents, regulatory approved for clinical use, include 
ferumoxides (Feridex in the USA, Endorem in Europe) with a particle size of 120 to 180 
nm, and ferucarbotran (Resovist®) with a particle size of about 60 nm.47 Labens et al. 
report the first use of SPIONs as intra-articular MRI contrast agent for studying cartilage 
barrier function in a large animal model. 48 Injection of 12 nm SPIONs in matrix depleted 
and pristine porcine metacarpophalangeal joints followed by 1.5 T MRI pre- and post- 
imaging reveals an increased MRI signal in the matrix depleted porcine joints, indicating 
the MRI signal reflects the permeability caused by OA. Other uses for SPIONS in relation 
to OA are covered in a later section within this review. Yarmola et al. describe a 
SPION based technology (termed magnetic capture) for the determination of an OA 
biomarker in small volumes of synovial fluid in vitro and from a rat model of knee OA.49 
Magnetic capture capitalizes on the translational force experienced by SPIONs in a high-
gradient magnetic field to collect the magnetized material. A targeting molecule, in this 
case anti-CTXII to target the c-terminus telopeptide of type II collagen, is conjugated to 
the polymeric particles containing SPIONs within the core.49 The functionalized particles, 
after mixing with bovine synovial fluid and exposure to a magnetic field, aggregate on the 
magnetic probe. Intra-articular injection of the anti-CTXII particles in a rat stifle joint 
followed by collection with a magnetic probe reveals detectable levels of c-terminus 




1.4.2 Contrast-enhanced computed tomography (CECT)  
Cationic contrast agents accumulate in cartilage tissue to a greater extent than 
neutral or anionic agents, due to favorable electrostatic interactions between the cationic 
contrast agent and the anionic GAGs.35,50 Freedman et al. report 5-10 nm in diameter 
tantalum oxide (Ta2O5) nanoparticles with neutral phosphonate, cationic ammonium, or 
anionic carboxylate ligands as potential CECT agents. The cationic Ta2O5 NP readily 
diffuse into ex vivo bovine cartilage and human index finger cartilage compared to neutral 
and anionic NPs. After IA administration in an in vivo mouse stifle joint, the cationic NPs 
penetrate the entire depth of the cartilage and enable imaging of cartilage tissue. 51    
The concurrent loss of anionic GAGs and decrease in steric hindrance (due to 
increasing tissue porosity) induce contradictory effects on the diffusion of cationic contrast 
agents, reducing the diagnostic accuracy of CECT. Furthermore, demarcation of the 
synovial fluid-cartilage interface for measuring the thickness, volume and surface 
topography of contrast enhanced cartilage becomes more difficult as clear distinction of 
the tissue boundary diminishes with diffusion time. To overcome these shortcomings, 
Töyräs et al. describe the combined, simultaneous use of two or three cartilage permeable 
and impermeable contrast agents.52,53 Bismuth oxide nanoparticles, being too large to 
diffuse into cartilage, accumulate at the cartilage surface and provide a high contrast 
signal,52,54 while tissue-permeable agents (anionic, neutral, and cationic small molecule 
iodine, neutral gadolinium) diffuse within cartilage and provide an attenuation reflective 
of GAG content or porosity.52-55 CT’s capability to separate X-ray photon energy spectra 




1.4.3 Photoacoustic imaging (PA)  
Photoacoustic imaging (PA) integrates advantages of ultrasound with deep tissue 
penetration and optical imaging with high spatial resolution. Briefly, light energy absorbed 
by tissues causes a thermoelastic expansion generating ultrasound waves that are detected 
by a transducer. Optical absorption contrast images are obtained at penetration depths of 
only a few centimeters due to light scattering.  
PA is particularly suited for imaging of peripheral joints such as fingers, hands, 
elbows, shoulders, knees, and ankles and thus of interest for diagnosing arthritis.56,57 
Ishihara et al. show that PA estimates the biomechanical and  viscoelastic properties of 
tissue-engineered cartilage cultured from rabbit chondrocytes.58 Sun et al. report detection 
of osteoarthritis in an in vivo finger joint using three-dimensional quantitative 
photoacoustic tomography.59 Distal interphalangeal joints of female subjects, scanned in 
vivo, reveal differences in the absorption coefficients between healthy and osteoarthritic 
subjects. A homemade multispectral photoacoustic ultrasound computed tomography 
system, described by Liu et al., visually reconstructs the human finger joint systems 
including the skins, the blood vessels, the tendon, and the bone simultaneously.60 
PA contrast agents absorb the energy of an optical laser and convert it to thermal 
energy.61-63 Gold nanostructures ,64,65 carbon nanotubes,66 graphene-based nanomaterials 
among others are used for contrast enhancement.67 However examples of PA nano contrast 
agents for OA diagnosis are rare. Chen et al. describe an intra-articular injection of cationic 
charged melanin nanoparticles (MNPs) coated with poly-L-lysine (PLL) in a live mouse 




high GAG content) than an OA joint (with low GAG content) and importantly the PA 
signal intensity strongly correlates with sample GAG content (R2=0.83).  
1.5 Nanoparticles for Labeling and Targeting Chondrocytes and Stem Cells  
Nanoparticle-based labeling of chondrocytes and mesenchymal stem cells increases 
target specificity and enables non-invasive, long term tracking of cells once administered 
in vivo through fluorescence, MRI, or CT based imaging.69 Today, quantum dots, 
superparamagnetic iron oxide, and gold NPs are such tracers or labels. Mesenchymal stem 
cells (MSCs) are multipotent cells with potential to differentiate into various tissue types, 
including bone and cartilage. Quantum dots offer one solution to tracking MSCs, since they 
are resistant to chemical and metabolic degradation, possess long term photostability, and  
a narrow band emission coupled with broadband excitation.69 Furthermore, when 
conjugated with an anti-mortalin antibody, quantum dots, provide a stable fluorescent 
signal of MSCs which were seeded in a 3D scaffold up to 26 weeks post-transplantation 
into an osteochondral defect.70 This provides a better understanding of the healing process 
after MSC implantation. NPs afford an alternate way to track MSCs. MSCs when loaded 
with 20 nm, 40 nm, and 60 nm citrate-stabilized and poly-L-lysine coated gold NPs, are 
viable, and function normally. These NPs enable long-term tracking of MSC differentiation 
and migration which can elucidate the MSCs role in tissue repair (Figure 1.4).71 
Superparamagnetic iron oxide nanoparticles (SPIONs) are also tracers for MSCs. 
Tracking transplanted stem cells longitudinally in time and space enables non-invasive 
monitoring of cell delivery, bio-distribution, migration, survival, and tissue integration.72,73 




compounds such as poly-L-lysine, protamine sulfate, lipofectamine, and polyethylenimine 
are used to produce cationic SPION complexes that electrostatically attach to the anionic 
cell membranes.74-76  In an ex vivo model of human osteochondral fragments, possessing a 
central cartilage defect, human bone marrow MSCs labelled with SPIONs accumulate in 
the defect target region as followed by a T2-weighted MRI.77 To minimize dose-dependent 
toxic effects on MSCs by the uptake of SPIONs, Markides et al. use the commercially 
available Nanomag, a 250-nm SPION to enhance the intracellular activity of standard cell-
penetrating peptides, to track autologous mesenchymal stromal cells in an ovine 
osteochondral defect model.78 Van Buul et al. employ ferumoxides complexed to protamine 
sulfate to label human bone marrow-derived mesenchymal stem cells (hBMSCs).79 Using 
T2 or T2* MRI sequences, SPION-labeled cells appear as a hypo-intensity after injected in 
an OA joint model, do not impair hBMSC secretion profiles, and enable accurate 
visualization by MRI using a porcine knee model.79 Polyethylenimine (PEI)-wrapped 
SPION–labeled bone marrow–derived mesenchymal stem cells , reported by Chen et al., 
enable stem cell identification in repaired articular cartilage in a minipig model.74 To 
improve uptake efficiency, Pang et al. describe surface neutral ganglioside GD2 modified 
SPIONs, as neutral ganglioside GD2 is highly expressed on the surface of MSCs.80  
Magnetic NPs are also used to track chondrocytes in order to monitor growth, 
differentiation, and regeneration in osteochondral defect repair. Labeling human derived 
MSCs and chondroprogenitor cells with SPIONs does not hinder cell viability, MSC 
marker expression, or chondrocyte differentiation.72-74 Similarly, the SPION-labeling 




production of major cartilage matrix constituents in vitro or in vivo.73, 80-82 Ferumoxytol-
labeled matrix-associated stem cell implants (MASIs) show significant T2 shortening 
(22.2±3.2 ms vs 27.9±1.8 ms; P < .001) and no difference in cartilage repair outcomes 
compared with unlabeled control MASIs (P > .05) in a porcine model, as described by 
Theruvath et al.83 2 weeks after implantation, ferumoxytol-labeled apoptotic MASIs show 
a loss of iron signal and higher T2 relaxation times compared with ferumoxytol-labeled 
viable MASIs (26.6±4.9 ms vs 20.8±5.3 ms; P = .001).83 Standard MRI shows incomplete 
cartilage defect repair of apoptotic MASIs at 24 weeks. Signal loss at 2 weeks correlates 
with incomplete cartilage repair, diagnosed at histopathologic examination at 12-24 
weeks.83 Chen et al. describe an ultrasmall superparamagnetic iron oxide (USPIO)-labeled 
cellulose nanocrystal/silk fibroin-blended hydrogel system for noninvasive visualization 
and semiquantitative analysis of hydrogel degradation and cartilage regeneration in vitro 
and in rabbit cartilage regeneration in vivo.84 The USPIO-labeled hydrogel system allows 
for in vivo MRI detection of hydrogel absorption and neo-tissue replacement, confirmed 
via conventional Hematoxylin-eosin and Prussian blue staining.84 
 Zare et al. report a novel scaffold-free complex microtissue of chondrogenic and 
osteogenic cell sheets using magnetically labelled dental pulp stem cells.85 A magnetic 
force organizes the dental pulp stem cells, which have internalized Fe3O4 magnetic 
nanoparticles, to form a multilayered osteochondral complex after being seeded onto a 
graphene oxide sheet.85 Following implantation into nude mice, the stem cells differentiate 
into chondrocytes and osteoblasts.85 Su et al. further explore this strategy using iron-oxide 




incorporate chondrocytes onto biphasic scaffolds. Results indicate chondrocytes 
successfully incorporate the magnetic nanoparticles, reaching roughly 95% incorporation 
when the concentration of magnetic nanoparticles is greater than 250 µg/mL.86 Further, 
labeled chondrocytes, when seeded into the biphasic scaffold under a one Tesla magnetic 
field for 60 minutes, migrate and distribute more evenly between both layers, compared to 
the untreated group (i.e., no magnetic field).86  
1.6 Conclusions and perspectives  
Nanotechnology offers significant potential to enhance current OA management 
through new diagnostic capabilities. As discussed above a number of new technologies and 
materials are in pre-clinical development to address this multifactorial disease. With 
regards to the diagnostic front, nanoparticle contrast agents for use in MRI, CT, and PA 
afford additional qualitative and quantitative information on cartilage structure and lesions 
as well as GAG content and its spatial distribution within cartilage – a known biomarker 
for early OA.  
Although the application of nanotechnology in orthopaedics is still in its infancy, 
several new research opportunities exists to include 1) MRI and CT contrast agents that 
provide quantitative assessment of a tissue component other than GAG; 2) functional MRI 
or CT agents that provide information on the biochemical or metabolic state of the tissue; 
3) nanotracers for specific cells types; and 4) theranostics, which act simultaneously as a 
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Figure 1.1. Facets of nanotechnology investigated for a multitude of applications for 







Figure 1.2. Schematic of zonal differentiation within articular and a representative 







Figure 1.3. A – C) Basic mechanism for simultaneous use of three cartilage 
permeable/impermeable contrast agents. A) Cartilage bathed in contrast agents 
immediately post contrast agent injection. B) Healthy cartilage contrast agent uptake, 
CA4+ is proportional to the fixed charge density conferred by proteoglycans (PGs) and 
uptake is high in healthy cartilage but low in C) degraded cartilage. In degenerated 
cartilage the tissue water content increases and steric hindrance decreases allowing more 
contrast agent molecules (both CA4+ and gadoteridol) to penetrate the tissue. Bismuth 
nanoparticles (average diameter of 194 nm) are too large to be able to diffuse into either, 
thus maintaining the contrast at the articulating surface at all diffusion time points.32 D) 
histology and synchron micro computed tomography (microCT) slices of cartilage. 
Articulating surface and cracks are better visualized with the triple contrast agent owing 
to better contrast induced by bismuth nanoparticles that, due to their size, are too large to 






Figure 1.4. TEM images representing cellular internalization of SPIONs and quantum 
dots for labeling and tracking chondrocytes. A) Cellular uptake and subcellular 
localization of magnetic nanoparticles in chondrocytes treated with 250 µg/mL magnetic 
nanoparticles, arrows indicate the locations of magnetic particles in the cells.114 B) 
Superparamagnetic iron oxide nanoparticle (SPION)- labeled human bone marrow 
MSCs. Arrows indicate SPIONs in cytoplasm.104 (C-E) Mesenchymal stem cells (MSCs) 
labelled via internalizing quantum dots in reparative tissues, followed by the allogeneic 
transplantation of three‐dimensional cartilaginous aggregates into osteochondral defects 
of rabbits. (C) At 4 weeks, (D) at 8 weeks, (E) higher magnification of framed area in 





CHAPTER TWO: Tantalum Oxide Nanoparticles for Quantitative Contrast 
Enhanced Computed Tomography Assessment of Biochemical Composition and 
Biomechanics of Ex Vivo Human Cartilage 
2.1 Abstract 
Nanoparticle based contrast agents, when used in concert with imaging modalities 
such as computed tomography (CT), enhance visualization of tissues and boundary 
interfaces. However, determination of the physiological state of the tissue via quantitative 
assessment of biochemical or biomechanical properties remains elusive. We report the 
synthesis and characterization of tantalum oxide (Ta2O5) nanoparticle (NP) contrast agents 
for rapid, non-destructive, and quantitative contrast-enhanced computed tomography 
(CECT) to assess both the glycosaminoglycan (GAG) content and biomechanical integrity 
of human metacarpal phalangeal joint (MCPJ) articular cartilage. Ta2O5 NPs of 3-7 nm in 
diameter, coated with either poly(ethylene) glycol (neutral) or ammonium (cationic) 
ligands, readily diffuse into both healthy and osteoarthritic MCPJ cartilage. CECT 
attenuation for the cationic and neutral NPs correlates with GAG content (R2 = 0.8975, 
p<0.05 and 0.7054, respectively) and the equilibrium modulus (R2 = 0.8285, p<0.05 and 
0.9312, p<0.05, respectively). The results highlight the importance of surface charge and 
size in the design of NP agents for targeting and imaging articular cartilage. Further, 
nanoparticle CECT offers visualization of both cartilage and bone, unlike plain 
radiography, the standard for imaging bone in musculoskeletal diseases, and, as first 





2.2 Introduction  
Plain radiography remains the most accessible tool and the current standard of care 
to visualize musculoskeletal diseases and injuries. This is especially true for the diagnosis 
of osteoarthritis (OA). OA, a degenerative disease affecting synovial joint structure and 
function, afflicts 80% of people over the age of 65 worldwide.1 While X-ray plain 
radiographs are accessible and inexpensive, they cannot directly visualize soft tissues or 
cartilage, and diagnoses are based solely on boney changes such as joint space narrowing, 
osteophytes, sclerosis, joint incongruity and malalignment,2,3 which occur in the later 
stages of the disease.  
Of the imaging modalities for soft tissue, contrast-enhanced computed tomography 
(CECT) is of particular interest as it has the potential to provide real time quantitative 
assessment of soft tissues, e.g., cartilage, using a readily accessible and cost-effective 
technique. Additionally, CT imaging, over MRI, affords the ability to assess bony changes. 
Subchondral bone sclerosis is commonly associated with articular cartilage degradation 
and plays an integral role in the initiation, as well as progression of OA. Anionic iodinated 
contrast agents are the mainstay in CECT, however nanoparticular agents offer a number 
of potential advantages. Due to their composition, small diameter, high surface area and 
confined electronic structure, nanoparticles (NPs) possess distinctive properties apart from 
individual atoms, small molecules, or bulk materials.4 To date, NPs are being investigated 
for use as biosensors,5,6 reagents for diagnostic assays,7,8 as both gene and drug delivery 
vehicles,9–11 and as imaging contrast media for MRI, fluorescence, PET and X-Ray.12,13 




contrast agents for contrast enhanced computed tomography (CECT) of lymph nodes,17 
vasculature,18–23 and cartilage.24–26 Tantalum is an ideal NP material for CT imaging as it 
possesses a higher k-edge (67.4 keV) than conventional iodinated contrast agents and as 
such, absorbs a larger amount of X-rays produced at clinical scanning voltages (80-140 
keV),27 as well as lessens beam hardening artifacts. However quantitative biochemical or 
biomechanical assessment of tissue using nanoparticles and contrast enhanced CT imaging 
(be it cartilage or any other tissue) is lacking as prior studies involved only visualization of 
the tissue.   
Our objective is to develop a contrast agent that enables both qualitative 
visualization of the tissue and quantitative assessment of physiological state or tissue 
function. Herein we synthesize cationic and neutral tantalum oxide nanoparticles (Ta2O5 
NPs) for use in CECT and determine the effectiveness to distinguish both biochemical 
changes and alterations in tissue mechanical integrity associated with early-stage OA, 
along with the assessment of bony changes. OA disease pathology simultaneously involves 
changes in articular cartilage and the subchondral bone network, therefore tangential 
investigation of changes in the bone and cartilage is required to most accurately diagnose 
disease state. With a mindset towards translation in conjunction with the complexities of 
imaging both cartilage and bone in early disease, we selected ex vivo human, cadaveric 
metacarpal phalangeal joints (MCPJs) as our model. OA commonly occurs in human 
fingers,28 and is associated with overuse from activities such as typing and texting, as well 
as with injury and age.29 MCPJs contain intact, hemispherical, nearly axisymmetric 




mechanical testing. Additionally, the underlying subchondral bone provides a suitable size 
for high resolution imaging. We hypothesize that tetra-ammonium functionalized cationic 
Ta2O5 NPs (NP1) will accumulate in direct proportion to the tissue glycosaminoglycan 
(GAG) content, an established biomarker of early OA, via electrostatic interactions with 
negatively charged GAGs. The resulting X-ray attenuation of the cationic NPs will 
positively correlate with GAG content and tissue stiffness while the CT signal obtained 
with neutral NPs (NP2) will be inversely correlated and of a smaller magnitude in 
attenuation change, while strongly correlating with tissue stiffness as it reflects the porosity 
of the tissue.    
2.3 Methods 
2.3.1 Preparation and Characterization of Ta2O5 Nanoparticles 
We prepared core-shell tantalum oxide (Ta2O5) NPs possessing cationic or neutral 
silane ligands surrounding the radiopaque Ta2O5 core (Figure 2.1). Building off of the 
publications from Hyeon,17 Kulkami,18 and others,22 we performed the controlled 
hydrolysis of tantalum (V) ethoxide, Ta(OEt)5, in the presence of isobutryric acid to form 
the Ta2O5 NPs. NP diameter was altered by varying the molar ratio of isobutryric acid to 
tantalum oxide. After the Ta2O5 NP solution stirred for 16 hours, we added a solution of n-
propanol, 2- [methoxy(polyethyleneoxy)6-9propyl]trimethoxysilane and N-
trimethoxysilylpropyl-N,N,N-trimethylammonium chloride (1:1, mass ratio) to the 
reaction mixture and refluxed for an additional 2 hours in air to prepare the cationic NP1. 
Alternatively, we added a solution of n-propanol, 2- [methoxy(polyethyleneoxy)6-




to room temperature, we neutralized the pH of the reaction mixture, and purified the NPs 
by dialysis (see SI for complete synthetic details). We subsequently lyophilized the sample 
to obtain the NPs as a white powder.  
2.3.2 Specimen Preparation 
The 2nd and 3rd MCPJ were dissected from 12 human cadaver hands (10 donors, no 
reported hand pathology, 70% male, mean age: 68 yrs, purchased from Medcure, Inc, 
Portland, OR). For each joint, all surrounding soft tissue was removed and the joint 
disarticulated. Surfaces were rinsed in a 400mOsm saline solution including GIBCO Anti-
Anti stock solution (Invitrogen, Grand Island, NY), 5mM of EDTA (Sigma, St. Louis, 
MO), and benzamidine HCl (Sigma B6506, St. Louis, MO) to prevent cartilage 
degradation. In order to facilitate manipulation in mechanical testing and imaging, the 
metacarpal diaphysis was embedded in polymethylmethacrylate (PMMA) bone cement.  
2.3.3 Nanoparticle Diffusion Kinetics 
2nd and 3rd MCPJs from 6 cadaveric hands were disarticulated, all the surrounding 
soft tissue removed, submerged in saline to remove excess synovial fluid, and separated 
into two groups (n = 5). The MCPJ surfaces were immersed in 1 mL of either NP1 or NP2 
(80 mg NP/mL 400 mOsm, ionic strength of synovial fluid, pH 7.4) at room temperature. 
Samples were removed from their respective NP solution, gently blotted to remove excess 
contrast agent and individually positioned in an airtight holder. Samples were serially 
imaged after being immersed for: 0, 30, 60, 120, 240, 480, 720, 1440, 2880 minutes. 




at an isotropic voxel resolution of 36 um, 70-kVp tube voltage, 113-uAmp current, and 
300-ms integration time. Scans were converted to DICOM format using proprietary 
software from Scano Medical AG followed by import for post processing analysis into 
AnalyzeTM (AnalyzeDirect, Overland Park, KS). and articular cartilage volumetric maps 
were created using a semi-automatic threshold-based algorithm, which were manually 
reviewed and adjusted if necessary. The attenuation values for all transaxial µCT slices 
were combined, averaged, and normalized by the 0-min time point attenuation.  
2.3.4 Mechanical Testing 
Initial µCT baseline scans of all MCPJs were conducted to measure mean cartilage 
thickness at the apex of the hemispherical cartilage surface. The samples were scanned at 
an isotropic voxel resolution of 36 um, 70-kVp, 113-uAmp, 300 ms integration time 
(μCT40, Scanco Medical AG). µCT data was converted into DICOM format and imported 
into Analyze for post-processing analysis as previously described. The mean cartilage 
thickness at the apex was determined by a custom code (MATLAB version). The 
equilibrium modulus (E) of each sample was evaluated using a standard indentation 
procedure. Each MCPJ was potted in PMMA and clamped into a mechanical testing 
apparatus (Enduratec3230, BOSE, Eden Prairie, MN). The MCPJ apex (a locally flat 
surface) was aligned perpendicular to a 1-mm diameter, flat-ended, stainless steel indenter 
tip. Samples were submerged in 400-mOsm saline followed by a 2N pre-load. Each sample 
was compressed using a 4-step stress relaxation protocol consisting of four 5% strain steps 
with a displacement rate of 0.005 mm/s followed by a 300s relaxation period. A linear 




equilibrium compressive modulus. 
2.3.5 CECT Imaging and Analyses 
Following mechanical testing, MCPJ samples were immersed in 2mL of 80 mg 
NP/mL for 24 hrs at room temperature. Prior to imaging, samples were gently blotted dry 
and imaged in air as previously described. Cartilage surfaces were segmented from the 
subchondral bone using the same software and threshold-based algorithm as previously 
mentioned. The mean CECT attenuation was obtained by averaging the X-ray attenuation 
over all transaxial µCT slices containing cartilage tissue. Effects from biological variations 
alongside trace residual contrast agents was negated by normalizing CECT attenuation 
values by baseline CT attenuation. The subchondral trabecular network was assessed from 
the µCT baseline scan and bone was segmented using a fixed threshold of 500 mgHA/cm3. 
Structural model index (SMI), bone volume fraction (%BV/TV), trabecular number (Tb.N, 
1/mm), trabecular thickness (Tb.Th/mm), trabecular spacing (Tb.Sp,mm), and connectivity 
density (1/mm3) are reported.   
2.3.6 Determination of Cartilage Glycosaminoglycan Content 
Samples were equilibrated overnight in saline (40mL, room temperature), to 
remove residual NPs. The cartilage surface was removed, and GAG content was assessed 
using the standard 1,9-dimethylmethylene blue (DMMB) colorimetric assay.9    
2.3.7 Cytotoxicity 
NIH3T3 murine fibroblast cells were maintained in Dulbecco’s Modified Eagle 




maintained in a humidified atmosphere at 37 °C and 5% CO2. Sub-confluent cells were 
harvested and seeded on 96 well plates at 3,000 cells/well for use in in vitro cytotoxicity 
studies. After 24-hours, the cells were treated with nanoparticles suspended in nanopure 
water, starting at 120 mg/mL and serially diluted by 1/3 until a final concentration of 0.002 
mg/mL. After a 24-hour exposure, cell viability was tested using a colorimetric MTS [3-
(4,5-dimethylthiazol-2-yl)-5-(3- carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-
tetrazolium] cell proliferation assay (Sigma, St. Louis, MO) and absorbance read at 490 
nm on a Biotek Synergy HT Plate Reader (Winooski, VT). Cell viability in each well was 
calculated as the percentage of the positive control absorbance. 
2.3.8 Statistical Analysis 
Univariate linear regression analysis (GraphPad) was applied to examine 
relationships between E, CECT attenuations, and GAG content. The coefficient of 
determination (R2) was used to assess the strength of correlations, and significance was 
defined as two-tailed t-test, P-value <0.05. 
2.4 Results  
2.4.1 NP Characterization 
FTIR and 1 H NMR showed the characteristic peaks and confirmed the silane 
coating on the particle (Figure 2.2). As shown in Table 2.1, the hydrodynamic size of the 
NP1s and NP2s are 5.6 ± 1.2 and 4.4 ± 1.3, respectively, by dynamic light scattering (DLS). 
NP1 possess an overall positive charge of 13.22 ± 2.44 mV as measured using Brookhaven 




neutrality (0.10 ± 0.13 mV).  TEM images of both NP formulations reveal a diameter of 
3.78 ± 0.8, for the cationic NP1, and 3.45 ± 1.2, for the neutral NP2 (measure 200+ nps 
from the image), and in agreement with the DLS data. 
2.4.2 Cytotoxicity 
The nanoparticle concentration response curves for both NP1 and NP2 were fit with 
a dose response curve in order to obtain an IC50 value. IC50 value for the NP1 is 24.29 
mg/mL. IC50 for the NP2 is 20.07 mg/mL (Figure 2.3).  
2.4.3 Diffusion Kinetics 
The diffusion kinetics of the Ta2O5 NPs into MCPJ cartilage were measured as a 
function of time and of both the entirety of the cartilage (Figure 2.4 and 2.5) and by 
cartilage layer (surface, middle and deep) (Figure 2.6). We chose a concentration of 40 mg 
NP/mL based on a prior study24 and that this concentration afforded sufficient attenuation 
for cartilage imaging and we balanced the osmolality to 400 mOsm; the ionic strength of 
synovial fluid. The diffusion kinetics for NP1 and NP2 were fit with an exponential 
function for the average of the entire depth of the MCPJ cartilage (Figure 2.4 and 2.5, 
respectively) and for each cartilage layer (Figure 2.6). Both NP formulations disseminate 
throughout all layers of the articular cartilage, increasing attenuation of the tissue and 
allowing clear visualization of the cartilage and delineation between the cartilage and 
subchondral bone. Figure 2.4 and 2.5 establish the diffusion kinetics of both NP1 and NP2, 
respectively, for average of all the cartilage layers (Y = 0.9618 + (0.1453 – 0.9618)e0.002094X 




score of tissue used for diffusion study ranged from II – IV.    
NP1 fully diffuses throughout all three cartilage layers (surface, middle, deep) after 
24 hours, providing the highest attenuation values in the surface zone (Figure 2.6). NP2 
fully diffuses throughout the surface layer but continues to accumulate in the middle and 
deep zones after 48 hours (Figure 2.6).  
2.4.4 Visualization of MCPJ cartilage using CECT with NPs  
Color maps generated from NP1 and NP2 enhanced CT scans reflect GAG 
distribution within the three layers of articular cartilage, and the thickness and gross 
morphology can be easily visualized. The cartilage appears vague and without distinction 
of layers without contrast agent (Figure 2.7).  
2.4.5 Relationship between CECT Attenuation with NP1, GAG Content and Equilibrium 
Modulus 
The cationic NP1 enhanced CT attenuation significantly and positively correlates 
with GAG content, with coefficients of variation greater than or equal to 0.89 (p<0.05) 
(Figure 2.8). As shown in Figure 2.8, a positive correlation exists between equilibrium 
compressive modulus and attenuation with NP1 (R2 ≥0.82, p<0.05). The strong, positive 
correlation between cationic NPs and GAG content and tissue stiffness indicate the 
electrostatic attraction between the two.    
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2.4.6 Relationship between CECT Attenuation with NP2, GAG Content and Equilibrium 
Modulus 
The neutral NP2 enhanced CT attenuation was negatively and significantly 
correlated with the equilibrium modulus, with coefficients of variation greater than or equal 
to 0.93 (p<0.05) (Figure 2.8). Following the same trend, attenuation values were linearly 
and inversely correlated with the cartilage GAG content, accounting for 70% of the 
variation in cartilage GAG concentration (p<0.05) (Figure 2.8). 
2.4.7 Relationships between Cartilage and the Subchondral Trabecular Network 
The correlations between both cartilage and nanoparticle enhanced attenuation and 
the subchondral trabecular network are presented in Figure 2.9 for both NP formulations. 
Trabecular structural indices examined included trabecular number (Tb.N), trabecular 
spacing (Tb.sp), trabecular thickness (Tb.Th), bone volume/total volume (BV/TV), and 
SMI. Strong positive correlations were observed between equilibrium modulus and 
trabecular number (R2 = 0.9264, p<0.05) for NP2 enhanced CT attenuation (Figure 2.10). 
Additionally, a strong negative correlation was noted between NP2 enhanced attenuation 
and trabecular number (R2 = 0.9782, p<0.05) (Figure 2.10). There were no significant 
correlations noted between NP1 and trabecular structural indices.  
2.5 Discussion  
Osteoarthritis is a disease of the whole joint afflicting 80% of people over the age 
of 65.30,31 Integral to OA pathology is the loss of cartilage function and structure, as 
cartilage serves as a smooth, lubricated surface for articulation and transmit loads to 
underlying subchondral bone. The biomechanical behavior of articular cartilage is best 
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described as a biphasic medium, its unique properties a result of the poroelastic collagen 
fibril network, which provides structure and tensile strength, complemented by the GAG 
matrix of anionic polysaccharides covalently attached to a proteoglycan backbone. The 
solid phase consists of the 3D poroelastic collagen network, while the fluid phase consists 
primarily of water, up to 80% of cartilage wet weight.32,33 GAGs maintain the hydrated 
state of articular cartilage by conferring a fixed negative charge by way of their heavily 
carboxylated and sulfated side chains.32,33 The pressurization of fluid within the solid 
collagen matrix in conjunction with the frictional resistance to water flow through the 
cartilage forms the mechanisms by which articular cartilage derives its ability to withstand 
significant load, frequently upwards of multiple times bodyweight.33–36 Upon loading, 
water becomes pressurized within the pores of cartilage. It will slowly efflux out of the 
tissue, but is faced with significant frictional drag forces, this interstitial fluid pressure 
allows cartilage to support large loads, up to 20MPa on a repeated basis, without wearing 
away.35,36 The ability of cartilage to withstand physiologic loads and shear forces depends 
on both the composition and structural integrity of the extracellular matrix. During early-
stage OA the composition and structural integrity of the extracellular matrix is perturb via 
a decrease in GAG content coupled with collagen degradation.33 Together these 
perturbations lead to an increase in cartilage permeability and a decrease in tissue stiffness. 
Higher permeability of the tissue causes rapid exudation of interstitial fluid upon tissue 
loading resulting in the solid collagen matrix bearing more of the load and leaving cartilage 
vulnerable to further mechanical damage and propagating a positive feedback loop of 
pathological changes. This feedback cycle of cartilage degradation continues throughout 
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disease progression, exacerbated by other factors such as the increased production of 
inflammatory cytokines and matrix metalloproteinases. As such, loss of GAGs (i.e., the 
anionic polysaccharides) is an early sign of disease1 and an established biomarker.37,38 
In conjunction with biochemical and biomechanical changes in the cartilage, OA 
disease pathology encompasses changes in the subchondral bone and trabecular network 
morphometry. Techniques to assess both cartilage and bone simultaneously are of 
significant interest to gather comprehensive information regarding disease state. Herein, 
the use of the human metacarpal enables the study of the relationship between cartilage 
and bone properties, specifically using contrast-enhanced CT. OA commonly occurs in 
human fingers,28 and specifically the metacarpal phalangeal joint (MCPJ) (the knuckle) 
presents an intact, hemispherical, nearly axisymmetric cartilage surfaces that is ideal for 
high-resolution imaging, biochemical evaluation, and mechanical testing. Using MCPJs 
obviates damaging the bone and cartilage through sample extraction methods such as 
coring, while providing an ideal geometry for testing and imaging. Additionally, use of 
MCPJs alleviates the need to artificially degrade cartilage to create an OA model for study 
and naturally provides a range of cartilage health as the extent of OA increases in each 
MCPJ along the hand (with the pointer finger having highest degree and OA prevalence 
decreasing towards the last finger).39,40    
The two nanoparticle formulations described herein, cationic NP1 and neutral NP2, 
diffuse throughout the entirety of MCPJ cartilage. Macroscopically, articular cartilage is 
divided into three layers – surface, middle and deep. Upon analyzing these different layers 




throughout all layers (Figure 2.6). On the other hand, results clearly indicate that NP2 had 
not fully diffused through the middle and deep layers (Figure 2.6). Despite not having 
diffused throughout the entirety of all cartilage layers, the NP2 still provide significant 
correlations between both CT attenuation and GAG content and CT attenuation and 
equilibrium modulus. This suggests that if allowed to diffuse longer those correlations may 
improve even further in strength, and that if there is a significant correlation with GAG and 
E before the NP2 has reached full diffusion equilibrium, that a full 24 hours may not be 
needed to achieve significant correlations. This is important from a clinical perspective as 
a 1 – 2-hour incubation time would be more appropriate. Further studies are warranted to 
examine if significant correlations can be achieved with GAG and E using a short diffusion 
time.  
The results presented in Figure 2.8 show strong significant correlations between 
both NP1 and NP2 enhanced CT attenuation and GAG content. The neutral NP2 enhanced 
CT attenuation accounts for 70% of the variation in GAG content, while the positively 
charged NP1 enhanced CT attenuation accounts for 89% of the variation in GAG content 
and is a stronger correlation. Similarly, strong significant correlations between both NP 
formulations and equilibrium modulus are present.  The neutral NP2 enhanced CT 
attenuation accounts for 98% of the variation in equilibrium modulus and the positively 
charged NP enhanced CT attenuation accounts for 83% of the variation in equilibrium 
modulus. The positively charged Ta2O5 NP2 more closely reflect the local fixed charge 
density of the cartilage as a whole – i.e., GAG, due to the favorable electrostatic 
interactions between the cationic NPs and the anionic GAGs. Additionally, in healthy 
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cartilage with simultaneously high GAG content and high tissue stiffness, the electrostatic 
attraction between the positively charged NP1 and negatively charged GAGs resulted in 
higher overall tissue uptake of the NP1 compared to NP2. The positively charged NP1 
exhibit a 1.33-fold greater CT attenuation dynamic range (linear attenuation ranging from 
2453 to 3636.71) compared to the neutral NP2s (linear attenuation ranging from 1154 to 
2044) (Figure 2.11). 
In contrast, the neutral NPs have no electrostatic interaction with the ECM and 
diffuse into the tissue in direct reflection of the structural integrity and stiffness of the 
ECM, an indirect reflection of GAG content. The structural integrity of the solid collagen 
network of cartilage, presents a key component of cartilage mechanical function and tissue 
health, with the solid collagen matrix giving rise to the compressive and tensile strength of 
the tissue. Coupled with a high GAG content, a high equilibrium modulus is an indicator 
of healthier tissue, where healthy human cartilage typically has GAG content in the range 
of 5-10% wet weight and an equilibrium modulus of 0.5-1 MPa.33,41 The porosity of 
cartilage arises as a result of the interaction between GAGs, collagen fibrils and interstitial 
fluid.33,42 The solid collagen matrix alone has pore sizes ranging from 50 to 200 nm, and is 
densely packed with aggrecan molecules, with anywhere from 4.5 to 15 nm between GAG 
side chains.42 This results in an overall pore size of 6 – 11nm for the ECM.42 The concurrent 
loss of anionic GAGs and decrease in steric hindrance (due to increasing tissue porosity) 
during OA pathogenesis, decreases the fixed charge density of the tissue and results in 
more porous, softer tissue, thereby allowing for a higher partitioning of the neutral NP2 




cartilage, the neutral NP2 was largely excluded from healthy cartilage, resulting in a 
slightly weaker correlation between NP2 enhanced attenuation and GAG content compared 
to the cationic NP1. 
Our depth wise analysis of the diffusion kinetics of NP1 and NP2 indicate the 
diffusion of both contrast agents is non-uniform throughout the three layers cartilage. For 
the cationic NP1, the time constant increases from surface to deep zones, with the deep 
zone failing to reach equilibrium In contrast, the neutral NP2, fails to reach equilibrium at 
48 hours in any of the zones of cartilage, so far as to present a linear diffusion curve in the 
deep zone. Degraded articular cartilage possesses higher tissue porosity due to a 
degradation of the solid collagen network, increasing tissue permeability and in turn 
facilitating diffusion. Concurrent with degradation of the solid collagen matrix, the GAG 
content decreases with cartilage degradation, lowering the fixed negative charge density, 
which we surmise slows the diffusion of the cationic NP1 but aids to increase the passive 
diffusion of NP1. These simultaneous, but opposite effects make the interpretation of 
diffusion kinetic results complicated. How exactly NP1 and NP2 diffusion relates to 
variation in the depth wise organization of the cartilage constituents requires further 
experimentation in combination with finite element modeling. 
 Contrast enhanced CT (CECT) allows for analysis of both cartilage and bone. OA 
causes concurrent changes in cartilage and subchondral bone; an ideal model would allow 
characterization of both. With the MCPJ model, NP2 contrast enhanced CT attenuation 
negatively correlates between trabecular morphological indices, specifically trabecular 
number, and both CECT attenuation and equilibrium modulus (Figure 2.10). Increased 
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CECT attenuation with NP2 signifies decreasing trabecular number. This result is 
corroborated by the positive correlation between trabecular number and equilibrium 
modulus, where a higher equilibrium modulus (e.g., healthier tissue) significantly 
correlates with a larger trabecular number. Trabecular number, a component of the bone 
volume fraction, along with trabecular thickness and trabecular spacing, is one 
morphometric to measure boney changes in the subchondral trabecular network, of which 
deterioration is indicated during OA pathogenesis.43,44 These correlations described 
between decreases in the trabecular morphological indices with OA disease progression, 
are corroborated by results from studies using early-stage osteoarthritic mice45 and rats,46 
concomitant with studies of beginning-stage OA in humans.47  Correlations were not all 
significant, although trends were noted between attenuation and both bone mineral density 
and bone structural model index (a measure of the shape of the trabeculae) (Figure 2.9). 
Cartilage degeneration with age is a natural occurrence resulting from accumulation of 
advanced glycation end products and senescent chondrocytes. One short coming of this 
study is that there was not a truly normal, healthy population, with all donors being above 
55 years of age and naturally having some degree of cartilage degradation. Additionally, 
the MCPJ is not a heavy load bearing joint, and therefore changes in trabecular 
morphometrics may be diffuse compared to those changes in load bearing joints such as 
the knee and hip. CECT using tantalum oxide nanoparticles enables simultaneous 
evaluation of both cartilage biochemical and mechanical healthy in addition to bone 
properties of the human metacarpal.  




to diagnose OA. While it is accessible and inexpensive, it cannot directly visualize soft 
tissues or cartilage, and diagnoses are based solely on boney changes such as joint space 
narrowing, osteophytes, sclerosis, joint incongruity and malalignment,48,49 which typically 
occur in the later stages of the disease. Other imaging modalities include MRI, which is 
able to visualize soft tissues and cartilage directly. Specifically, gadolinium enhanced MRI 
(dGEMRIC) which uses gadopentetate as a mobile anionic probe to measure cartilage 
composition and structure.49–51 Yet this is not a perfect scenario, dGEMRIC is hindered by 
nephrotoxicity concerns associated with the IV injection, specifically for elderly and 
diabetic patients.52,53 Additionally, deeper joints such as the hip cannot be imaged with 
standard coils and require high field strength magnets and specialized coils.54 MRI is also 
costly, and research has shown non-unanimous results between studies.55 Detecting early 
changes in the biochemical composition of cartilage is key in order to implement 
therapeutics at a point when the cartilage may be salvaged to prolong the lifespan of the 
joint or joints in question. Therefore, minimally invasive techniques, specifically targeted 
contrast agents, that quantitatively assess changes in cartilage are of great interest, as 
cartilage thickness, morphology and GAG content correlate with tissue health and disease 
state. As such CT is a key imaging modality for musculoskeletal diseases and injuries and 
when combined with contrast agents offers the potential to both visualize and quantify 
tissue composition and properties. 
 Advances in the synthesis of nanoparticles are yielding various types of 
nanoparticles for medical imaging. Although up to now, their use as has been restricted to 
non-quantitative imaging of soft tissues.56–58 With regards to detection and treatment 
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monitoring, nanotechnology offers significant potential through new diagnostic 
capabilities. Herein we demonstrate the use of Ta2O5 NPs for CECT imaging and 
quantitative assessment of cartilage biochemical and mechanical health, as well as a 3D 
spatial determination of cartilage and bone. Ta2O5 NPs, regardless of charge, offer an 
alternative to dGEMRIC MRI and iodinated contrast agents for measuring articular 
cartilage functional properties non-invasively. Contrast agents for CT imaging are of 
immediate interest for use in diagnosing subtle changes correlated with early-stage 
osteoarthritis. Early intervention via detection is key to prolonging the lifespan of existing 
cartilage and preventing further degradation and irreversible damage of the tissue. 
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Table 2.1. Nanoparticle diameter measured via DLS and TEM 
Nanoparticle 
Type 




Zeta Potential in 
D.I. H2O (mV) 
Cationic (NP1) 5.6 ± 1.2 3.78 ± 0.8 13.22 ± 2.44 






Figure 2.1. Synthesis schematic of both cationic (A) and neutral (B) nanoparticle 
synthesis. C) Cartoon representation of cationic charged nanoparticles attracted to the 
negatively charged GAGs within cartilage. D) Cartoon representation of the neutral 








Figure 2.2. TEM images of synthesized nanoparticles. A) TEM of positively charged 
particles NP1, B) TEM of neutral nanoparticles NP2, C) higher magnification TEM of 
positively charged particles where bonds between chemical groups are visualized. D) H1 






Figure 2.3. IC50 for tantalum oxide nanoparticles A) cationic NP1 and B) neutral NP2 
particles. Determined by measuring cell viability of NIH 3T3 fibroblasts after 24 hours of 










Figure 2.4. Representative, single CT slices at A) T = 0 hours and B) T = 24 hours. C) 
Diffusion kinetics of cationic NP1 into the cartilage of three MCPJs. Data are plotted as 
the normalized CECT attenuation. By fitting the data for each sample with an exponential 
decay equation, tau values can be calculated for each sample. Mean tau value 477.7 min. 







Figure 2.5. Representative, single CT slices at A) T = 0 hours and B) T = 24 hours. C) 
Diffusion kinetics of cationic NP1 into the cartilage of three MCPJs. Data are plotted as 
the normalized CECT attenuation. By fitting the data for each sample with an exponential 
decay equation, tau values can be calculated for each sample. Mean tau value 395.0 min. 






Figure 2.6. A) Diffusion kinetics of cationic NP1 through the surface, middle and deep 
zones of articular cartilage. N = 3 replicates, exponential decay analysis. B) Diffusion 
kinetics of neutral NP2 through the surface, middle and deep zones of articular cartilage. 






Figure 2.7. Representative color maps and corresponding contrast enhanced CT slice of 
coronal slices of MCPJs using cationic NP1 or neutral NP2 for healthy and naturally 







Figure 2.8. Correlation between X-ray attenuation (A) and equilibrium modulus (B) for 
NP1. Correlations were statistically significant at P = 0.0041 and P = 0.0318, 
respectively. N = 3 replicates, linear regression analysis, dashed lines indicate 95% 
confidence bands of best fit line. Correlation between X-ray attenuation (C) and 
equilibrium modulus (D) for NP2. Correlations were statistically significant at P = 
0.00750 and P = 0.0011, respectively. N = 3 replicates, linear regression analysis, dashed 

















Figure 2.10. Representative coronal µCT slices of MCPJs reflecting the Trabecular 
number vs Attenuation relationship for a sample with A) late-stage OA and B) early-
stage OA. C) Significant negative correlation between subchondral trabecular number 
and contrast enhanced attenuation. D) Significant positive correlation between Trabecular 
number vs Equilibrium modulus. Linear regression analysis, dashed lines indicate 95% 
confidence bands of best fit line. 
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CHAPTER THREE: Nanotechnology and Osteoarthritis: Opportunities for 
Advanced Devices and Therapeutics 
3.1 Abstract 
Osteoarthritis (OA) is a multifactorial disease of the entire joint which afflicts 140 
million individuals worldwide regardless of economic or social status. Current clinical 
treatments for OA primarily center on reducing pain and increasing mobility, and there are 
limited therapeutic interventions to restore degraded cartilage or slow disease 
pathogenesis. This review focuses first on current surgical and non-surgical treatments for 
OA and then summarizes recent advancements in nanotechnology-based treatments. We 
review nano delivery systems for small molecule drugs, nucleic acids, and proteins 
followed by nano-based scaffolds for neocartilage formation and osteochondral 
regeneration, and lastly nanoparticle lubricants. We conclude by identifying opportunities 





3.2.1 Medical Management 
To date, initial treatments for patients suffering from OA include activity 
modification, weight loss, braces, exercise, and physical therapy in conjunction with anti-
inflammatory drugs and/or intra-articular corticosteroid injections (Table 3.1). 1-6 
Analgesics only relieve symptoms. Nonsteroidal anti-inflammatory drugs (NSAIDs), while 
both analgesic and anti-inflammatory, exhibit serious side effects over extended time 
periods. Predicated on the theory that supplementing hyaluronic acid in osteoarthritic 
synovial fluid will improve its viscous lubrication, viscosupplementation is the intra-
articular injection of a cross-linked hyaluronic acid derivative into an osteoarthritic joint. 
While viscosupplements are generally safe, well tolerated by elderly patients, and 
demonstrated to provide moderate pain relief, they do no improve cartilage health and 
provide comparable outcomes to saline in several randomized controlled studies. 
Corticosteroids are recommended for short term (16-24 weeks) treatment of OA based on 
strong clinical and scientific evidence that glucocorticoids inhibit the expression and action 
of most cytokines.7 Dexamethasone, the most potent of these, is chondroprotective in post-
traumatic OA.8 While systemically administered corticosteroids systemically prevent toxic 
side effects in off-target tissues and organ systems, intra-articular administration minimizes 
these unintended consequences. Although effective short-term, quarterly intra-articular 
steroid injections over two years do not reduce pain and compared to intra-articular saline,9 




3.2.2 Clinical Surgical Treatments 
When medical management fails to ameliorate pain and OA progression begins to 
affect quality of life, surgical treatments are the next course of action. Surgical treatments 
are directed at correcting the inciting pathoanatomy from articular joint trauma, joint 
instability, ligamentous deficiency, skeletal malalignment or congenital deformity.  
Arthroscopy permits minimally invasive access to lavage the synovial joint, debride and/or 
repair injured structures including hyaline cartilage, menisci, and cruciate ligaments, but 
alone is ineffective at moderating the progression of OA.10,11 Arthroscopy in conjunction 
with meniscal repairs, either full or partial, improves outcomes. Whereas meniscal repairs 
have a higher reoperation rate than partial meniscectomies, meniscal repairs are associated 
with better long-term outcomes.12 A systematic review of the outcomes of meniscal repair 
>5 years postoperatively revealed similar rates (20-25%) of failure for all techniques 
investigated.13 Cohort studies after meniscal transplantation with >10-year follow-up 
suggest that symptomatic relief is good and that progression to late stage OA is lower than 
natural history studies of meniscectomized knees.14,15  
Full-thickness articular cartilage defects (Outerbridge grade III or IV)16 possess 
limited regenerative potential,  do not readily and spontaneously heal, and are associated 
with significant pain, swelling and stiffness.17,18 Restoration of a discrete cartilage lesion 
with a lubricious cartilage-like tissue, able to withstand repetitive compressive and shear 
loads without degeneration and loss of function, remains a challenge because the 
endogenous repair tissue is unable to repopulate the type II collagen and aggrecan content 




defect by micro-fracture aims to induce articular tissue reparation by allowing bone 
marrow elements (bone marrow mesenchymal stem cells) and blood products (fibrin clot) 
to fill the defect with fibrocartilaginous scar. While meta-analysis of the literature 
demonstrates clinically relevant improvement in pain and function, the cartilaginous repair 
tissue is generally fibrous (collagen I, II, III), is partly integrated with the surrounding 
hyaline cartilage, is mechanically softer, less lubricious, and deteriorates over time.19,20 
Osteochondral allograft transfer (OATS or mosaicplasty) is a procedure where a 
cylinder of bone and cartilage is transferred into the defect from a lesser weight bearing 
region of the knee. The procedure suffers from donor site morbidity and limited availability 
of suitable anatomic donor sites. Tissue modulus mismatch between donor and surrounding 
host cartilage results in non-congruous tissue deformation and interfacial shear strains that 
interfere with graft integration at the host-graft interface. Systematic reviews of patients 
with long term follow-up treated by OATS show benefit in 70-75% of patients. Increased 
age, previous surgery, large defect size and patella femoral location associate with higher 
failure rates, whereas concomitant surgical procedures to address internal derangement, 
malalignment or instability improve outcomes.21 OATS may achieve higher activity levels 
and lower failure rates compared to microfracture for cartilage lesions in the knee >3 cm2, 
although at 3-year follow-up, there was no significant difference for lesions <3 cm2.21  
Autologous chondrocyte implantation is FDA approved for the treatment of 
discreet knee cartilage defects (>3 cm2).22 Chondrocytes, harvested from cartilage biopsy 
(200,000–300,000) and expanded in cell culture (12–48 million, depending on defect size), 




the proximal tibia, or a synthetic collagen membrane.22 Chondrocytes attach to the 
subchondral bone and produce cartilage matrix, filling the defect with hyaline-like 
cartilage. Successful transplantation depends on technique, rehabilitation protocol and 
anatomic site; complications include symptomatic hypertrophy, disturbed fusion, 
delamination, and graft failure  
Finally, total joint arthroplasty is the most cost-effective and reliable intervention 
for improving quality of life, alleviating pain, and restoring function in articular joints 
compromised by end-stage OA.23 Overall failure rates for total hip and knee replacement 
(most common total joint arthroplasty) are low at 1%/year. Risk of failure is higher in 
younger and more active patients as well as patients with medical co-morbidities. While 
short term failures tend to be related to imperfect surgical technique, longer term implant 
failures are a result of symptomatic loosening due to infection or polyethylene wear debris 
induced osteolysis,24,25 an inflammatory foreign body reaction resulting in osteoclast 
mediated bone loss.26 Improved surgical technique, aided by robotic assisted surgery, better 
implant designs that allow more functional joint kinematics, advanced materials that reduce 
wear and implant surface coatings that are antimicrobial and/or osteoinductive may 
enhance outcomes and decrease total joint arthroplasty failure rates.27  
3.3 Drug Delivery Systems 
Today, to treat arthritic conditions, therapeutics typically are administered 
systemically which entails high risk for systemic toxicity and minimally effective doses 
reaching the target joints.28 As OA is a local joint disease, intra-articular (IA) 




transportation, and decreases off target effects and risk for systemic toxicity. Rapid 
clearance from the synovial space and inadequate penetration throughout the cartilage 
layers hamper this strategy. Synovial fluid is constantly undergoing turnover thus requiring 
frequent IA injections to deliver sufficient drug, increasing patient discomfort, risk for 
infection, and doctor’s office visits. Given the drawbacks and less than ideal clinical 
outcomes, significant research is devoted to drug delivery systems.28,29 
Successes in cancer treatments using nanomedicines provide motivation to employ 
these technologies to address OA clinical challenges (Figure 3.1). Nanoparticles (NPs) are 
typically spherical in shape and between 10–1000nm in diameter. NP drug delivery 
systems improve pharmacologic characteristics of agents, enabling controlled delivery of 
poorly-water soluble agents and water-soluble small molecules, proteins, or nucleic acids. 
NP composition dictates what agent(s) can be encapsulated, the release profile, target tissue 
accumulation, and cellular mechanism of uptake. Additionally, NPs can penetrate the ECM 
and/or cell barriers, allowing for either extracellular or intracellular drug delivery, 
respectively.30 NP drug delivery systems commonly contain an agent encapsulated within 
or chemically conjugated to the NP and a hydrophilic charged surface coating for aqueous 
colloidal stability. NP compositions range from solid core materials composed of polymers 
to water filled vessels surrounded by lipids. NP accumulation in target tissue employs 
either passive or active targeting. Passive targeting capitalizes on physicochemical 
properties and allows for non-specific localization in the negatively charged ECM, Coll II, 
or chondrocytes.31 While, active targeting employs specific biochemical moieties such as 




3.3.1 Polymeric NPs  
For NPs, natural polymers are attractive materials due to their biodegradability and 
biocompatibility. Their drawbacks include ill-defined composition, batch-batch 
nonuniformity and impurities from harvest and isolation procedures. Chitosan, a prime 
example of a natural polymer, has positively charged amine groups lending itself useful for 
adherence to the anionic surfaces of cellular membranes, electrostatic complexation with 
anionic DNA or RNA, and chemical modification. Chitosan itself enhances 
chondrogenesis and shares structural similarities to GAG. Kartogenin is a small molecule 
that induces chondrogenesis by regulating the nuclear localization of Core Binding Factor 
-β. When conjugated to chitosan nanoparticles (150nm) or microparticles (1.8um) 
kartogenin is released over 7 weeks in vitro, and when administered intra-articularly 
affords less degenerative changes compared to untreated controls in a surgically induced 
rat OA model (Figure 3.2).32 Similarly, genipin cross-linked chitosan microspheres 
containing flurbipofen, a commonly utilized NSAID with a very short in vivo half-life of 4 
hours, release the agent for over 108 hours.33  
Synthetic polymeric NPs offer defined chemical composition, reproducible 
synthetic procedures, lack of immunogenicity, and tunability. Aliphatic polyesters such as 
polylactide (PLA), polyglycolide (PGA), and their co-polymers are biocompatible, 
biodegradable, and widely used to engineer NPs. Degradation products of these polymers 
are lactic acid and glycolic acid, two metabolites of the citric acid cycle, i.e., the Krebs 
cycle. Additionally, these polymers are components of a number of regulatory approved 




Constaâ for schizophrenia and bipolar disorder.34, 35 Notably, one such PLGA (poly(lactic-
co-glycolic acid)) microspheres affords  sustained release of a steroid, and this 
microtechnology is in phase 3 trials for patients with severe OA pain.36  
Active and passive targeting techniques enhance specificity and retention in the 
joint space. For example, hyaluronate binds the CD44 surface receptor on chondrocytes t. 
Chondrocytes readily internalize nanoparticles functionalized with hyaluronate.37 Self 
assembled amphiphilic block copolymer NPs, 300nm in diameter, tethered with a natural 
protein inhibitor of IL-1 (IL-Ra) reduce IL-1 mediated inflammation.44 These NPs retain 
bioactivity in vitro and target synoviocytes, blocking the IL-1 signaling pathway, and 
remain in rat stifle joints over 14 days providing an extended  IL-Ra half-life (3X) 
compared to soluble IL1-Ra (Figure 3.2).38 Peptide ligands also enhance targeting 
specificity and lead to greater accumulation in target cells and higher retention in the ECM 
compared to non-targeted particles.39 A cartilage  affinity peptide, identified via phage 
display biopanning, when conjugated to polyethylenimine nanoparticles, caring DNA, 
exhibits a 9-fold higher transfection efficiency in-vivo in rabbits compared to scrambled 
peptide polyethylenimine /DNA complexes.39  
Passive targeting techniques use both size and charge to increase accumulation of 
nanoparticles in the ECM and joint space. For example, 70nm PLGA and Eudaragit RL (a 
co-polymer of ethyl acrylate and methyl methacrylate) cationic NPs when injected in the 
joint space form micrometer sized clusters with hyaluronic acid, increasing localization of 
NPs to the cartilage surface. These cationic NPs reside in mice stifle joints for over 4 weeks 




ionically cross-linked hydrogel following IA injection with increased in vivo retention 
times.41 Apart from charge, NP size increases retention times. Singh et al. demonstrate size 
dependent prolonged retention of self-assembled nanoparticles. 900nm Nanoparticles 
composed of polyhydroxyethylmethacrylate), functionalized with bovine serum albumin 
and pyridine particles show sustained retention (~30% at 14d) in a rat stifle joint and a 
significantly longer retention than 500nm particles.42 
3.3.2 Stimuli Responsive Nanoparticles  
Stimuli responsive nanoparticles release their agent only when the appropriate 
environment conditions or triggers are present. Triggers include disease related changes in 
local environmental conditions such as temperature, pH or oxidative stress, enzyme 
activity, or external stimuli such as near infrared light.  
To address the challenge of loading multiple drugs with independent release 
profiles, Kang et al. report a dual drug loaded thermo-responsive nanocapsule system 
composed of a chitosan modified pluronic. The hydrophobic small molecule drug 
kartogenin, which promotes chondrogenic differentiation of mesenchymal stem cells and 
induces regeneration of cartilage in OA, covalently links to the amine groups of chitosan, 
while the anti-inflammatory small molecule drug diclofenac, is contained within the core.43 
Drug release depends on temperature with an initial burst release of diclofenac after cold 
shock treatment, followed by sustained release of kartogenin. The nanocapsule system 
suppresses lipopolysaccharide-induced inflammation in chondrocytes and induces 
chondrogenesis in MSCs, enhanced via a cold shock treatment.43 In a rat model, treatment 




expression. The outcomes improve with a cold treatment.43 Other strategies use 
temperature to directly control formation of nanoparticles. Hyaluronic acid conjugated to 
the thermoresponsive polymer, poly(N-isopropylacrylamide) (pNiPAM), described by 
Maudens et al., only forms NPs (247nm diameter) above the lower critical solution 
temperature, due to aggregation of hydrophobic polymer side chains, while below the 
lower critical solution temperature it is soluble. A hyaluronic acid-pNiPAM solution, 
which exhibits a lower critical solution temperature around body temperature. injected 
intra-articularly in an OA murine model, curtails pro-inflammatory cytokines and produces 
biocompatibility with prolonged (up to 2 months) intra-articular residence time.44   
Reactive oxygen and reactive nitrogen species normally exist at low levels in 
chondrocytes but are upregulated during OA as a result of dysregulation of antioxidant 
mechanisms. In an in-vivo rodent OA model, administration of 112nm diameter melanin 
nanoparticles slow cartilage degradation, reduces reactive oxygen and reactive nitrogen 
species levels in cartilage, and enhances autophagy.45 
Near infrared (NIR) light, which penetrates tissue with low tissue absorption, 
reduced scattering, and minimal autofluorescence, is an external stimuli of wide-spread 
interests.46 Chitosan modified molybdenum disulfide nanosheets, as reported by Zhao et 
al., are NIR photo-responsive carriers of the dexamethasone.46 Dexamethasone releases in 
response to NIR light via photothermal conversion, enabling remote control over drug 
release by adjusting the NIR light dose.46 In a mouse model of OA, dexamethasone loaded 
chitosan modified molybdenum disulfide nanosheets remain within mice stifle joints (48h), 




inflammatory factors (IL-1β, TNF-α, and IL-8) in the synovial membrane and serum. 46 
3.3.3 Micelles and Liposomes   
Micelles, structures of 20-200nm in diameter, are composed of amphiphilic 
polymers and readily self-assemble in aqueous solvents. The micelle’s core entraps 
hydrophobic drugs, while hydrophilic drugs can be tethered to the surface. Preferential 
uptake of micelles occurs via conjugation by peptides, antibodies, or other targeting 
ligands, while functionalization with poly(ethylene glycol)  shields micelles from 
phagocytosis, and is a site for further modification.35 Doxorubicin-conjugated block 
copolymer micelles are widely used in many preclinical and clinical anticancer agent 
studies.47 Examples of micellar  drug delivery systems for OA are common and include 
delivery of  hydrophobic small molecules (e.g., indomethacin, triamcinolone, and 
kartogenin) administered either locally or systemically. Indomethacin loaded poly(N-
isopropylacrylamide)-polyphosphazene micelles, functionalized with ethyl 4-
aminobenzoate, reported by Zhang et al., possess increased indomethacin loading 
efficiency compared to the non-functionalized micelles. IV administration of this micellar 
formulation in an OA rat ankle arthritis model affords prolonged indomethacin circulation 
time and reduces inflammation.48 Saadat et al. report a polymeric micelle based on 
hyaluronic acid conjugated  1,2-distearoylphosphatidyl-ethanolamine for sustained 
delivery of triamcinolone, a common corticosteroid for OA and rheumatoid arthritis that 
suppresses production of COX1 and COX2.49 In vitro release profiles of the micellar 
system show a small burst release during the first four hours with sustained release for the 




revealed by real time NIR fluorescence imaging with cy-7.5 labeled micelles.49 Self-
assembling micelles constructed from amphiphilic polyurethane with pendant amino 
groups and covalently bound kartogenin, reported by Fan et al., reduce cartilage 
degradation in an anterior cruciate ligament transection  rat model of OA.50 Cartilage 
surfaces are intact with only mild superficial fibrillation, confirmed via histological 
staining, while immunohistochemistry reveal polyurethane-kartogenin treated groups 
increase Coll II production.50 Kang et al. report self-assembled PEGylated kartogenin  
micelles covalently integrated into hyaluronic acid  hydrogels.51 In vitro, hydrogels with 
PEGylated kartogenin  micelles show an initial burst release over 12 hours, followed by 
sustained release over 5 days, resulting in a cumulative drug loss of 32.4%, compared to 
PEGylated kartogenin  micelles alone.51 In an anterior cruciate ligament transection  OA 
rat model, treatment with the hydrogel PEGylated kartogenin  micelle system suppresses 
progression of OA compared to free-HA hydrogels via OARSI and Mankin scores.51 Apart 
from drug delivery systems, micelles may contain vectors for gene therapy. Delivery of 
recombinant adeno-associated virus vectors (rAAV) via poly(ethylene oxide)-co-
poly(propylene oxide) polymeric micelles, developed by Rey-Rico et al., to human 
chondrocytes increases TGF-β expression and cell proliferation.52 Treatment to human 
osteochondral defect cultures in situ with rAAV-micelles increases TGF-β production and 
cell density in regions adjacent to defects, and enhances production of proteoglycan rich 
ECM.52 
Like micelles, liposomes are self-assembled structures but possess an aqueous core 




Liposomes vary from 50–5000nm depending on composition and formulation and are 
routinely used to deliver anti-cancer agents. Doxorubicin loaded liposomes are already 
used in the clinic with several additional clinical trials underway including PEGylated 
liposomal doxorubicin (Doxil/Caelyx), non-PEGylated liposomal doxorubicin (Myocet), 
liposomal daunorubicin (DaunoXome), and liposomal cytarabine (Depocyte).53 Liposomes 
with a positive surface charge target the negatively charged ECM via electrostatic 
interaction. Bio-adhesive, multilamellar liposomes developed by Elron-Gross et al., 
encapsulate dexamethasone, diclofenac, or both.54 Liposomes, surface functionalized with 
either hyaluronan or collagen, exhibit increased affinity for the ECM and CD44 membrane 
receptors on chondrocytes. In a monosodium iodoacetate induced OA rat model, these 
liposomes reduce inflammation volume compared to untreated animals.54 The best 
performing liposome, one functionalized with hyaluronan co-encapsulating diclofenac and 
dexamethasone, reduces inflammation volume by 12.9% at 17 days post single injection.54 
Near infrared immuno-liposomes of 200nm, conjugated with type II collagen antibody, 
bind to exposed type II collagen in the ECM and enable quantitative analysis of cartilage 
damage. In a guinea pig spontaneous model of OA, the immune-liposome conjugates bind 
to the damaged cartilage and the fluorescence intensity corresponds to the extent of 
cartilage damage.55   
3.3.4 Dendrimers 
Dendrimers, repetitively branched molecules, are nano-scale carriers for small 
molecules, imaging agents, therapeutic proteins, peptides, and nucleic acids.56-60 Their size 




allows for attaching target ligands or peptides to increase retention times and accumulation. 
Recently, Geiger et al. describe a PEGylated polyamidoamine dendrimer to deliver insulin-
like growth factor1 directly to chondrocytes within cartilage.61 In a rat anterior cruciate 
ligament transection model of OA, dendrimers remain in the joint for 30 days and reduce 
cartilage degeneration by 60% relative to untreated rats at 4 weeks post-surgery.61 
Similarly, Hu et al. report a PEGylated polyamidoamine dendrimer for the cytoplasmic 
delivery of kartogenin, either conjugated to the surface or to the terminal end group of 
polyethylene glycol, to induce chondrogenesis of mesenchymal stem cells.62 Kartogenin 
conjugated to PEG exhibits the highest expression of chondrogenic markers (Coll II, 
aggrecan and SOX9). IA injection of this formulation, in an in vivo model of papain 
induced OA, affords improved chondrogenic differentiation efficacy and remains in the 
joint for 21 days.62  
3.4 Nanoparticle Gene Delivery Systems  
Gene delivery, the transfer of exogenous nucleic acids from the extra-cellular 
environment to intracellular compartments i.e., the nucleus for pDNA or cytoplasm for 
siRNA or miRNA, is an attractive technology for OA treatment as it targets specific disease 
related mechanisms, treating causes rather than symptoms. For successful gene therapy, an 
efficient and safe delivery system is required. Most gene therapy products in clinical trials 
use viral vectors due to their high transfection efficiency, but drawbacks include 
immunogenicity, complicated production, oncogenic effects,63-71 and risks of potential 
pathogenicity and lethality. Recent advances have yielded promising non-viral delivery 




include for example PEG-polyethylenimine based systems for ovarian and lipid-based 
siRNA nanoparticle systems for treatment of advanced cancers to fibrosis.72,73 
3.4.1 Cationic polymers for gene delivery  
Chitosan’s potential as a DNA delivery vehicle was discovered in 1998 by 
MacLaughlin et al.,74 and reflects its biocompatibility,75 biodegradability,75 and non-
toxicity75 although is hampered by low transfection efficiency.76 To identify an optimal NP 
formulation, Zhao et al. report transfection efficiency for chitosan-pEGFP nanoparticles as 
a function of NP size (100-300nm), zeta potential (+1 to +23 mV), culture media pH, 
chitosan molecular weight, and plasmid dosage.77 Chitosan-pEGFP nanoparticles (N/P 
ratio of 3.8) prepared  at pH 7 with 85 kDa chitosan and 8 µg/mL plasmid afford greater 
than 50% EGFP expression in primary chondrocytes.77 Combining chitosan with cationic 
or anionic biopolymers further increases transfection efficiency. Lu et al. report a 
hybridized chitosan-hyaluronic acid system containing plasmid DNA.78 Treatment of 
chondrocytes with the nanoparticles increases transfection efficiency compared to plasmid 
nanoparticles of purely chitosan/DNA, with an average cell viability of transfected cells 
over 90%.78 More recently, a chitosan-graft-polyethylenimine/DNA nanoparticle with a 
chitosan-graft-polyethylenimine:DNA ratio of 8:1, carries pDNA to both chondrocytes and 
synoviocytes with improved transfection efficiency and lower cytotoxicity compared to 
chondroitin sulfate/DNA nanoparticles, polyethylenimine /DNA nanoparticles, or naked 
pDNA (Figure 3.3).79 The polyethylenimine protects DNA from nuclease degradation, 
facilitates endosomal escape, and increase transfection efficiency, despite 




Peptide ligands specific to cell surface receptors enhance target specificity and 
reduce off target responses when conjugated to non-viral delivery vectors. Chemical 
conjugation of a chondrocyte affinity peptide (CAP) to polyethylenimine /DNA particles 
increases transfection efficiency and affords higher NP concentrations in rabbit stifle 
cartilage following IA injection (Figure 3.3).80 This same CAP- polyethylenimine 
nanoparticle system efficiently delivers siRNA to chondrocytes silencing HIF-2a 
expression, a transcription factor upregulated during OA that directly induces chondrocyte 
production of catabolic factors such as MMPs.80 In an OA mouse model, IA administration 
of CAP- polyethylenimine particles decreases IL-1β concentration, synovial membrane 
inflammation, and expression of Hif-2a compared to control groups.80 Yan et al., report a 
second method for siRNA delivery using the amphipathic, cationic, cell-penetrating 
peptide, melittin, targeting the p65 subunit of NF-kB to suppress inflammatory cytokine 
expression.81 In a collagen induced arthritis mouse model, these peptide-nanoparticle 
complexes localize to inflamed joints after intraperitoneal injection, and suppress NF-kB 
expression.81 Recently, IA administration of this siRNA loaded peptidic nanoparticle in a 
stifle-joint impact injury mouse model reduces chondrocyte apoptosis, injury length, and 
synovitis.82 As a proof of concept for clinical translatability, human cartilage explants 
treated with the peptide-siRNA NPs penetrate the explants and persistence in chondrocyte 
lacunae for at least 2 weeks.82 
PLGA based nanoparticles are also being explored for gene delivery. Crawford et 
al., report  PLGA nanoparticles, complexed with polyethylenimine and a PLGA scaffold, 




model with the scaffold, seeded with BMP-4 transfected adipose derived stem cell, 
significantly improves in vivo chondrogenesis.84 In a rabbit model of a critical size 
auricular cartilage defect, implantation of chondrocytes, transfected with a plasmid-
encoding BMP using the non-viral Turbofect vector embedded within a gelatin-oxidized 
dextran scaffold, improve healing compared to non-transfected chondrocyte or control 
groups.85  
3.4.2 Lipid based delivery systems for gene delivery  
Lipid-based nanoparticle delivery systems, a relatively new class of delivery 
systems for siRNA and DNA, have only recently been investigated for the treatment of 
cartilage diseases.86 Wang et al., report a novel lipid-based nanoparticle  for siRNA, 
composed of dipalmitoyl phosphatidylcholine, cholesterol and c16 ceramide-mPEG2000, 
which efficiently transfects 100% of chondrocytes.86 Intra-articular injection of lipid-based 
nanoparticle beacon into mouse stifle joint affords a positive signal by fluorescence 
molecular tomography up to 72 hours compared to IA administration of free beacon.86 In 
a rat anterior cruciate ligament transection  OA model, treatment with lipid-based 
nanoparticle-siRNA complexes correlates with stronger safranin-O staining, and increased 
cellularity.86 A second lipid-based nanoparticle system uses the transfection reagent 
GenePORTE 2 to deliver an endostatin plasmid to mesenchymal stem cells via a collagen 
scaffold, overexpression of endostatin promotes cartilage repair.87 Mesenchymal stem 
cells, seeded onto collagen scaffolds produce greater endostatin, monitored via ELISA, 




3.5 Scaffolds for Osteochondral Regeneration  
Generating well-integrated, stable cartilage and bone compartments presents a 
major challenge to tissue engineering. Not only are mechanical properties vastly different 
between native cartilage and bone, the cellular and biochemical content are distinct as well. 
Scaffolds play a key role in directing cells to appropriate lineage and location. The 
following are various approaches to the use of scaffolds in OA treatment: incorporation of 
nanoparticles within traditional scaffolds or hydrogels; modifying traditional scaffolds to 
generate nanoscale features; and direct fabrication of nanofibrous scaffolds.  
3.5.1 Nano-scale bone scaffolds 
Significant research focuses on incorporating osteogenic or mineral inducing 
nanoparticles, such as nano-hydroxyapatite , into scaffolds to induce mineralization and/or 
bone formation.88 Nano-hydroxyapatite in conjunction with mesenchymal stem cells and 
other progenitor cells enhances mineralization, and is fabricated via a wide range of 
processing techniques including thermally induced phase separation,89 3D printing,90 
selective laser sintering,91 and bioprinting.92 Other nano-scale additives, such as 
mesoporous bioglass, increase osteogenic differentiation of mesenchymal stem cells, act 
as efficient drug carrier and release systems, and elicit a greater effect than non-
mesoporous bioglass.63,94   
Mineral inducing nanoparticles aid to the improvement total joint arthroplasty 
outcomes, which are often plagued by symptomatic loosening due to infection or 
polyethylene wear debris induced osteolysis. Modification of titanium, ceramics and 




incidence of revisions.95-98 Additionally, nanomodification of joint replacement surfaces 
reduces bacterial adherence, biofilm formation and disrupts bacterial cell homeostasis.96 
3.5.2 Nano-scale scaffolds for cartilage repair 
Nano- and micro-scale scaffolds, akin to osteogenic approaches, guide and enhance 
cartilage repair. Cell pellet culture systems, widely used in the study of mesenchymal stem 
cell chondrogenesis, are inherently disadvantageous with small sizes and weak mechanical 
properties, making the system impractical for cartilage defect repair. Early studies by Tuan 
et al., describe scaffolds of randomly oriented nanofibrous poly(e-caprolactone) which aid 
mesenchymal stem cell chondrogenesis, via the Wnt signaling pathway, when coupled with 
the chondrogenic growth factor TGF-β1.99 Chondrogenesis levels are on par with levels 
observed in a cell pellet culture system, with the additional benefit of improved mechanical 
properties. These scaffolds possess limited porosity, reducing cell migration and nutrient 
transport. A low-density random nanofiber approach overcomes this issue by incorporating 
chondroitin sulfate into nanofibers, to promote chondrogenesis in vitro and in vivo in a rat 
osteochondral defect model. Although this repair tissue remains biomechanically inferior 
to native cartilage and produces significantly less proteoglycan and collagen II. Increased 
density of nanofibers further reinforces the hydrogels and improves mechanical properties, 
as well as MSC chondrogenesis of the resulting construct.100,101 More recently, melt 
electrowriting affords nano-fiber scaffolds (down to <1 µm)102 with precisely controlled 
pore sizes and geometries.103 When combined with a hydrogel and cells, the dynamic 
mechanical properties more closely match native tissue and the cells maintain their 




property gradients to mimic zonal properties of articular cartilage.105 When cells are 
embedded in these constructs, mechanical properties further improve over time.106  
There is a technological shift from melting or gluing together of bone and cartilage 
scaffold components, towards additive manufacturing technologies. Improvement in the 
latter, combined with knowledge from individual cartilage and bone studies, enables 
production of seamless composite osteochondral constructs which are a better anatomical 
match. Kon et al., describe a gradient scaffold with varying collagen I and nanoscale 
magnesium-hydroxyapatite formed in situ in separate layers. Scaffolds implanted into 
sheep femoral condyle osteochondral lesions aid bone regeneration and direct bone and 
hyaline-like cartilage regeneration.107 In a pilot human clinical trial, these osteochondral 
scaffolds improve functional  scores over 2 years as determined using the Magnetic 
Resonance Observation of Cartilage Repair Tissue scoring system.108 Positive treatment 
outcomes remain consistent over 5 years post-surgery, while some abnormalities persisted 
in the repair tissues.109 Ultimately, it will be critical to determine which scaffold-based 
strategies result in better functionality in vivo both in humans and in large animal studies, 
which are instrumental in evaluating promising approaches prior to clinical trials. 
3.6 Nanoparticle-Based Lubricants  
Nanoparticles aid lubrication by altering the tribology of contacting surfaces via 
small-gap infiltration to provide a protective layer and to act as interposed ball bearings 
between surfaces.110,111 Adding nanoparticles to conventional oils results in a colloidal 
suspension, a nanolubricant, reducing coefficient of friction  values up to 50%.110 Addition 




al., improves boundary mode lubrication by reducing the coefficient of friction between 
cartilage articulating surfaces.112  Anilkumar et al. describe a new nanoparticulate lubricant 
composed of soft, nanometer sized single hyperbranched glycerol polymers of millions of 
molecular weight (megaHPGs). These mega-polymers possess high water solubility, 
compact morphologies, low intrinsic viscosities, and exist as single polymer particles.113 
megaHPGs act as interposed ball-bearings when between both hard (e.g., stainless steel) 
and soft (cartilage) surfaces to lower the coefficient of friction. 
3.7 Conclusions and Perspectives  
Nanotechnology offers significant potential to enhance current OA management 
through targeted therapeutics, smart scaffolds, and novel viscosupplements. As discussed 
above, several new technologies and materials are in pre-clinical development to address 
OA. With regards to drug delivery systems, nanoparticles composed of polymers, metals, 
lipids, etc., are enabling selective, targeted delivery of disease modifying OA drugs, nucleic 
acids, and growth factors. These approaches provide delayed, sustained, or triggered drug 
release, increased joint retention after administration, as well as reduced off-target side 
effects. Scaffolds incorporating nano-designs and structural features recapitulate cartilage, 
augment biochemical constituents, and enhance biomechanical properties. Strategies to 
repair early-stage disease with the use of lubricants and late-stage disease utilizing tissue 
engineered scaffolds, are also being pursued. Although nanotechnology in orthopaedics is 
still in its infancy, new research opportunities exists including: 1) stimuli-responsive drug 
delivery systems which deliver their payload in response to a biological cue or under 




treatments as opposed to just pain management; 3) long-term non-metal implants that 
integrate with host tissue, including the nervous system, to functional as artificial tissues; 
and, 4) nanomaterials to augment or control the immune system. 
Clinically, nanotechnology is not a dream but a reality for OA patients. Nano-
coatings for orthopaedic implants are already available and in clinical development to 
reduce or eliminate infection and biofilm formation and/or promote host bone integration. 
For example, silver nanoparticle surface modifications reduce prosthetic joint infection, 
with its antimicrobial properties and strong anti-biofilm potential.114 To date, no 
orthopaedic implants that possess a silver nanotreatment are available for general use, but 
two manufacturers produce total joint arthroplasty implants treated by a galvanic 
deposition of elementary silver upon request (Implantcast GmbH–Medizintechnik, 
Buxtehude, Germany; Stanmore Implants, Borehamwood, UK) and clinical experiences 
are promising.115  This approach is promising given the precedence of regulatory approved 
silver nanoparticle coated medical catheters (Silverline® and ON-Q Soaker™).116 Other 
nano-based coatings include patented technology based on functionalized titanium dioxide 
to promote osteointegration and minimize bacterial infections.117 While these examples are 
all in the bone space, they set a precedent for future developments in cartilage repair.   
Nanotechnology has and will continue to unveil new fundamental material 
properties and activities, and these findings will catalyze advancements in patient care 
through collaborative efforts between engineers, scientists, and clinicians. We encourage 
all to collaborate, to form multidisciplinary teams, to perform mechanistically driven in 
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Table 3.1. Medical Management strategies for OA. 
Therapy Description and Benefits Disadvantages 
Analgesics An analgesic is any member of 




tramadol, salicylates, and 
capsaicin. 
Can effectively relieve mild to 
moderate pain short-term. 
Many available over-the counter 
(acetaminophen, etc.)  
Does not relieve inflammation or 
swelling. 
Can cause liver damage with 
chronic use and overdosing. 
Typically, not used long-term. 
Opioids have the devastating 






NSAIDs are prescribed to reduce 
inflammation and swelling as 
well as aid in pain relief for 
patients who have moderate-to-
severe pain and signs of 
inflammation. 
NSAIDs usually work well 
initially. 
NSAIDs are non-narcotic.  
Increased or chronic use often 
leads to gastrointestinal and renal 
problems such as gastric ulcers, 
gastrointestinal bleeding and 
rarely death. 
10-20% of NSAID patients 
experience dyspepsia; upper 
gastrointestinal adverse events 
estimated to result in 103,000 
hospitalizations and 16,500 
deaths per year in US (43% drug-
related emergency visits). 
NSAIDs decrease in effectiveness 
over time until they no longer 




NSAID that directly targets 
COX-2, an enzyme responsible 
for inflammation and pain. 
Selectivity for COX-2 reduces 
risk of peptic ulceration, and is 
the main feature of celecoxib, 
rofecoxib and other members of 
this drug class.  
COX-2-selectivity does not 
reduce other adverse-effects of 
NSAIDs - most notably an 
increased risk of renal failure and 
potentially an increase in the risk 
for heart attack, thrombosis, and 
stroke. 
Several COx-2 inhibitors have 
been withdrawn from the market 
or have alerts by the FDA due to 






Steroids injected intra-articularly 
for targeted pain relief.  
Alternative therapy for moderate-
to-severe knee pain and signs of 
inflammation not mitigated by 
acetaminophen or NSAIDs.  
Strong clinical and scientific 
evidence that glucocorticoids 
inhibit expression and action of 
pro-inflammatory cytokines, 
stimulate matrix remodeling and 
synthesis.7,8  
Must repeat intra-articular 
injections 3-4x/year. 
Corticosteroids associated with 
toxic side effects off-target 
tissues and organs 
Long term use may not reduce 





Hyaluronic acid, or hyaluronan, 
is a gel-like polysaccharide 
substance  
Intra-articular 
viscosupplementation is a 
treatment in which hyaluronic 
acid is injected directly into the 
joint space to supplement the 
viscous properties of the synovial 
fluid.   
Only pain relief, no clinical 
demonstration of 
chondroprotection  
Randomized, prospective clinical 
trials demonstrate no difference 
from saline for pain relief.  
No evidence that HA products 
improves viscous lubrication or 
ameliorates cartilage degradation. 





Figure 3.1. Facets of nanotechnology investigated for a multitude of applications for 
osteoarthritis, from nano-based drug delivery and gene delivery systems, along with 






Figure 3.2. Whole joint retention profiles across different drug delivery nanoparticle 
systems, with a variety of structures, compositions, sizes, and shapes. Retention presented 
as fluorescence intensity. Joint retention prolonged by nanomaterials up to 14 days A) 
Chitosan nanoparticles (CHI-KGN NPs) or microparticles (CHI-KGN MPs) conjugated 







Figure 3.3. A) Basic mechanism of non-viral gene delivery via polymer (polyplex) or lipid 
based (lipoplex) delivery system. DNA condensed via interaction with cationic polymer or 
lipid and encapsulated to for a polyplex or lipoplex. B) Images of chondrocytes (a) or 
synoviocytes (b) transfected with CP/DNA nanoparticles, naked pDNA, CS/DNA 
nanoparticles, PEI (25 kDa)/DNA nanoparticles, and Lipofectamine™ 2000 as observed 
under fluorescence microscope or inverted phase contrast microscope.79 C) Rabbit 
cartilage chondrocytes transfected by either chondrocyte affinity peptide/DNA 
(CAP/DNA) or scrambled peptide/DNA (SP/DNA), visualized under a confocal 
microscope. Blue: nuclear count-stained by Hoechst 33258; Green: GFP protein. Much 
higher GFP express level was observed inside the cartilage tissues transfected by CAP-PEI 






PART II: NANOPARTICULATE LUBRICANTS FOR ARTICULAR 




CHAPTER IV: Strategies to Augment the Rheological and Tribological Properties 
of Synovial Fluid for the Treatment of Osteoarthritis  
4.1 Abstract 
Undergoing millions of articulations throughout an average lifetime, synovial joints 
require effective lubrication to provide a low coefficient of friction and prevent wear at the 
cartilage surface. Prolonged use or trauma results in osteoarthritis, a degenerative disease 
whose pathology is predominantly characterized by the breakdown of articular cartilage, 
concomitant with the degradation of synovial fluid biomacromolecules, hyaluronic acid 
and lubricin. This degradation decreases both the fluid and boundary lubricating capacity 
of synovial fluid, exacerbating tissue wear and disease progression. Viscosupplementation 
replaces degraded synovial fluid with a highly viscous supplement aimed at reestablishing 
rheological homeostasis to osteoarthritic joints. Current clinically approved 
viscosupplements provide minimal chondroprotection paired with ineffective joint 
residence times providing limited relief from disease progression. Thus, significant 
activities are ongoing to design and evaluate novel biolubricants to reduce the friction of 
articulating joints to prolong if not restore synovial joint function. This review highlights 
existing viscosupplements along with naturally occurring, partially, or fully synthetic 
biolubricant formulations and their relationship to cartilage theory of lubrication.  
4.2 Introduction 
4.2.1 Articular Cartilage Lubrication and Osteoarthritis 
Articular cartilage is the primary bearing biomaterial of the body, lining the ends 




organized, porous, and anisotropic structure of cartilage exists both a fluid and a solid 
phase. The fluid phase consists of interstitial water and dissolved ions, while the solid phase 
comprises primarily of collagen fibrils endowing cartilage with tensile strength, 
complemented by a matrix of negatively charged glycosaminoglycan (GAGs). The 
synergistic interactions between the solid and fluid phases grant cartilage a viscoelastic 
response to loading and highly specialized lubricating abilities. Being a porous structure, 
loading of cartilage leads to the entrapment of interstitial fluid within the pores of the solid 
collagen matrix and effectively supports >90% of applied joint load (i.e., interstitial fluid 
load support, IFLS).1 Applied deformations induce efflux of fluid from the solid matrix to 
form an interposed fluid film that decreases the coefficient of friction (COF) and protects 
articulating joint surfaces from mechanical wear.1 
Classically, for engineered systems such as bearings, Stribeck curves are used to 
describe how altering parameters of viscosity, velocity and load affect the COF and in turn 
the COF values are indicative of modes of lubrication – boundary, mixed and 
hydrodynamic. Boundary lubrication is characterized by a high COF and direct asperity 
contact between the two opposing surfaces with a molecularly thin layer of biomolecules 
separating opposing surfaces, accompanied by a high load and low speed, with the COF 
dictated based on surface characteristics of roughness, chemistry, and lubricant additives. 
It is during boundary lubrication where the COF values are the greatest, and material wear 
occurs by way of direct asperity-asperity contact of opposing surfaces and friction forces. 
Mixed mode lubrication occurs by means of slightly higher speeds or lower loads and is 




the fluid is greater than the asperities thereby separating the articulating surfaces entirely. 
Lastly, a thick film of fluid separates the articulating surfaces in hydrodynamic lubrication 
and occurs at low loads or high speeds.  
While the Stribeck curve concisely places the three lubrication modes within well 
characterized boxes, lubrication modes of articular cartilage are more complex and not as 
easily defined. Unlike impermeable, non-derformable materials, boundary mode articular 
cartilage lubrication is also predicated on complex factors such as porosity and interstitial 
fluid. Other deviations from the classically ascribed Stribeck curve include the 
elastoviscous transition between boundary and hydrodynamic lubrication when the 
pressure in the self-generated hydrodynamic fluid film causes elastic deformation of the 
articulating surfaces. Furthermore, interstitial fluid pressurization enhances hydrodynamic 
lubrication. It is generally accepted that synovial joints operate under a combination and 
coexistence of boundary, mixed and elastohydrodynamic lubrication mechanisms.1  
Synovial fluid (SF) is the naturally occurring lubricant in synovial joints, whose 
primary function is to provide shock absorption and lubrication which facilitates smooth, 
pain free ambulation and articulation. SF primarily consists of lubricin and hyaluronic acid, 
which act as boundary and fluid lubricants between opposing joint surfaces.2,3 Hyaluronic 
acid (HA) is an anionic, non-sulfated, high molecular weight (MW 6 MDa) 
glycosaminoglycan, with repeating units of D-glucuronic acid and N-acetyl-D-
glucosamine linked by a glucuronidic β (1->3) bond and contributes to viscosity and by 
extension, hydrodynamic lubrication (Figure 4.1). Lubricin, on the other hand, is a surface-




the cartilage surface, lubricin contains a central bottle brush like domain, coupled with 
somatomedin B and hemopexin like peptides.4 Disulfide bridges between the somatomedin 
B domains allow lubricin multimerization, while the hemopexin domain facilitates 
hydrophobic interactions and promotes its binding to the articular cartilage surface. For 
these biomacromolecules of synovial fluid, function follows form. Synovial joint 
lubrication relies on the synergistic action of these components, none of which is solely 
responsible for the extremely low COF of articular cartilage. Recent studies indicate the 
entanglement and hydrophobic interaction of lubricin and HA contribute to mixed mode 
lubrication and shock absorption.5–7 Although, the entanglement of HA and lubricin alone 
cannot account for the low COF of articular cartilage at high applied loads. Klein et al 
suggest a three-component system, where in conjunction with lubricin-immobilized-HA at 
the articular surface, HA complexes with phosphatidylcholine lipids exposing their charge 
groups at the cartilage interface8,9 (8, 34) and allowing for "hydration lubrication", whereby 
lubrication occurs via hydration shells forming around the charged phosphatidyl choline 
molecules.8  
Osteoarthritis (OA), a painful, chronic, condition, damages synovial joint function, 
and affects both the mechanical integrity and rheological behavior of synovial fluid. While 
the etiology of OA is multi-factorial, it is typically induced by mechanical injury as a 
consequence of trauma, joint instability, ligamentous deficiency, skeletal malalignment, 
obesity or anatomic deformity. Early-stage OA is characterized by the depletion of GAGS 
and subsequent collagen network degradation, instigating increased hydraulic permeability 




the biochemical composition of SF that cause deterioration of its rheological properties, 
resulting in increased cartilage wear. Specifically, HA decreases in molecular weight and 
viscosity, with degradation of lubricin occurring in parallel, decreasing the boundary 
lubricating capabilities of SF,3,10 which is associated with early signs of articular cartilage 
wear.11–13  
4.2.2 Viscosupplementation 
To date, the two most common non-surgical treatment options for OA are non-
steroidal-anti-inflammatory drugs and viscosupplementation. Viscosupplementation refers 
to the concept of augmenting osteoarthritic synovial fluid with solutions aimed to 
recapitulate the lubricating abilities of healthy SF. Current viscosupplementation targets 
HA concentration restoration, increasing viscosity, improving lubricity, and enhancing 
cushioning properties of the SF, while on the macroscopic scale providing pain relief and 
improved ambulation.   
There are a handful of commercially available HA viscosupplements which vary 
with respect to molecular weight, crosslinking, zero shear rate viscosity, shear thinning 
ratio and cross over frequency. Made commercially available in 1986, Hyalgan and Artz 
are two of the oldest and lowest molecular weight supplements (Table 4.1). The efficacy 
of currently available viscosupplements is variable at best and significant debate exists 
surrounding the use of intra-articular (IA) HA injections, so much so that the guidelines of 
the American Academy of Orthopedic Surgeons do not recommend the use of HA 
injections to treat knee OA.14 




studies that indicate improvements in pain and joint function as a result of IA HA 
injections.15–18 Miltner et al describe improvements in knee function following HA 
injections (2 mL Hyalart), as demonstrated by pain relief, and improved functional 
performance.19 Similarly, following a single injection of Hylan G-F20 or a placebo in 
patients with symptomatic primary OA of the knee, patients who received the HA injection 
report significant improvements in WOMAC pain scores compared to the placebo up to 26 
weeks post injection.20 Likewise, in a comparison of functionality of IA HA injections and 
a placebo, it was found that while there was no appreciable difference in gait velocity, 
patients treated with the IA HA injections had improvements in WOMAC pain scores. 
Following 5 weekly injections of Hyalgan in patients with symptomatic knee OA, 
statistically significant improvements in knee joint function and maximum walking time 
for up to 12 months were observed, demonstrating long term efficacy for IA HA.21 
A prime example of the tenuous link between IA HA injection and pain relief is the 
systematic review and meta-analysis by Rutjes et al., initially indicating no clinically 
significant reduction in pain following HA injections for OA, but a sub-analysis only 
including those studies using high molecular weight HA shows a statistically and clinically 
significant reduction in pain. The efficacy of varying HA molecular weight has been further 
investigated in a study of 1187 late-stage OA patients. Those injected with high molecular 
weight HA delayed, by an average of 2 years, total knee arthroplasty.22 In a comparison of 
two differing molecular weight HA preparations, an intermediate (800-1500 kDa, GO-ON) 
and low (500-730 kDa, Hyalgan), Berenbaum et al. illustrate superior knee pain relief of 




Hyalgan) when administered to patients with primary knee OA.23 Apart from pain 
reduction, studies indicate high molecular weight HA has a positive impact on cartilage 
biochemistry.23 Following high molecular weight HA viscosupplementation, results from 
Shah et al show increased proteoglycan content at both 6 weeks and 3 months, concomitant 
with improvements in pain scores as measured by WOMAC.24 
In contrast to studies indicating the positive effects of HA viscosupplementation 
several studies report none to minimal differences in measurable efficacy between IA HA 
injections and placebos or between varying MW of HA supplements. Weekly intra-
articular injections for four weeks of sodium hyaluronate (Hyalgan) in comparison to IA 
injection of physiological saline, demonstrate no statistical difference between groups.25 
While a comparison of high and low molecular weight HA in symptomatic knee OA 
patients showed improvements in pain and WOMAC scores for both groups but not 
between groups, indicating similar efficacy regardless of MW.26 These results are 
supported by a randomized control trial of IA HA injection of high molecular weight HA 
and a placebo, with no statistical difference in cartilage preservation observed between 
groups.27 In tandem, a double blind randomized controlled trial comparing high molecular 
weight HA and saline found no improvements or differences in WOMAC pain scores in 
mild to moderate knee osteoarthritis.28 Concomitantly, a study comparing 3 weekly 
injections of HA (MW 1.5 million Da) or a saline placebo indicate no significant difference 
between function and symptoms with respect to the saline placebo injection,29 and a similar 
study consisting of 5 weekly IA injections of HA, illustrate no significant improvement in 




evidence to the nebulous efficacy of viscosupplementation, IA administration of high 
molecular weight HA (Artzal®), or crosslinked HA (Synvisc-One®) show no clinical 
benefit compared to a placebo.31  
The contrasting results reflect the existing debate between clinical efficacy of 
viscosupplementation with hyaluronic acid. While there are studies indicating 
improvements in patients’ pain, a similar number of studies conclude no differences 
between treatment with HA and saline. It is no surprise that given the polarizing 
conclusions on efficacy, the American Association of Orthopedic Surgeons guidelines do 
not recommend the use of HA injections to treat knee OA, and further studies concomitant 
with exploration of other lubricant materials apart from hyaluronic acid are warranted and 
explored in this review. 
4.3 Naturally Occurring Lubricants for Tribosupplementation 
4.3.1 Lubricin 
Lubricin, a mucinous glycoprotein found in synovial fluid, protrudes from the 
cartilage surface, functioning as a boundary lubricant, while also acting to entangle and 
bind HA near the cartilage surface. These physical and chemical entanglements form a 
lubricious film on the surface of cartilage which contributes to cushioning applied forces 
and reducing the COF of articulating cartilage surfaces during mixed mode lubrication. 
Lubricin mimetic HA-binding peptides offer one approach to mimic lubricin’s ability to 
bind HA and lubricate the cartilage surface. The HA-binding peptide, HABpep, covalently 
binds the cartilage surface upon reaction with free amines, or non-covalently binds to the 




time of HA 12-fold compared to an untreated control. Cartilage-on-cartilage friction testing 
reveals that healthy cartilage treated with HABpep submerged in a solution of HA, 
significantly decreases the static and kinetic COFs compared to untreated cartilage, 
demonstrating the HA-binding peptide does not need HA to be continuously present for it 
to lubricate a surface (Figure 4.2). Similarly, mLub15, a lubricin-mimetic consisting of a 
chondroitin sulfate backbon e with type II collagen- and HA- binding peptides, 
demonstrates cartilage surface localization and when used to lubricate trypsin degraded 
cartilage-on-glass, restores the static and kinetic COF to values equal to non-degraded 
cartilage and comparable to the commercially available viscosupplement Synvisc-One® 
(Figure 4.2).33 Notably, following IA injection of mLub15 into the patellar tendon of a 
spontaneous model of OA using Dunkin Hartley guinea pigs, mLub15 resides at the 
cartilage surface 6 hours post injection and is replaced by native lubricin 1- to 2-weeks post 
injection.33  
Apart from mimicking the structure and function of lubricin, efforts are ongoing to 
develop recombinant lubricin for use in viscosupplementation.34–37 Recombinant human 
lubricin (rhLub) shares 70% of its amino acid sequence with rat lubricin and reduces the 
COF of cartilage in a dose dependent manner up to ~50 µg/mL.35,36 At this concentration, 
cartilage treated with rhLub affords an equilibrium coefficient of friction (0.093 ±0.011), 
significantly lower than PBS (0.281± 0.014), but not significantly different from equine 
synovial fluid (0.115±0.013).36 Administration of rhLub in an OA rat medial collateral 
ligament and meniscus transection model, 1 or 3 times a week, decreases cartilage 




fluorescence in situ hybridization show that rhLub, increases native lubricin content and 
mRNA production, demonstrating lubricin administration during OA progression may 
have benefits beyond its lubricating abilities. Although in an OA rat anterior cruciate 
ligament transection (ACLT) model of OA, rhLub does not significantly improve Mankin 
scores when compared to cell culture derived lubricin and patient derived lubricin.37 
Other lubricin related endeavors include modification of the naturally occurring 
molecule itself, offering a means to localize lubricin to the cartilage surface. One such 
modification is the addition of a reactive aldehyde to lubricin which then reacts with free 
amines on the cartilage surface to form a shift-base bond.38,39 The aldehyde 
functionalization of lubricin, termed PRG4-CHO, does not significantly impact its function 
as a boundary lubricant and serves to increase the concentration of lubricin at the cartilage 
surface. Cartilage-on-cartilage friction tests show the static and kinetic COFs of PRG4-
CHO are significantly lower than PBS and significantly higher than SF, however, were not 
significantly different from unmodified or sham modified lubricin.38 Nevertheless, the 
aldehyde modification increases lubricin localization at the cartilage surface, with PRG4-
CHO found at a 2- and 5-fold higher concentration at the cartilage surface compared to 
native lubricin and SDS treated cartilage samples, respectively.39   
4.3.2 Micelles and Liposomes 
Surface active phospholipids also play a role in synovial joint lubrication serving 
as boundary lubricants and with their highly hydrated headgroups reduce friction via 
hydration lubrication.40–42 Phospholipid liposomes, derived from hydrogenated soy 




diameter between 65 and 75 nm and when absorbed onto mica surfaces, produce COF 
values as low as 0.00002 and 0.0006, in pure water and a salt solution, respectively.40,41 
The polar headgroups on the outer surface of the liposomes coordinate water molecules 
and form hydration layers, leading to the low COFs observed, while the salt ions present 
in the physiological solution compete with the polar headgroups of the liposomes for water 
interactions, leading to an increase in COF of liposomes in the salt containing solution.41 
Similarly, Sivan et al. describe five different phospholipid-based liposomes and their 
ability to reduce friction in a cartilage-on-cartilage set up, with those composed of 1,2-
dimyristoyl-sn-glycero-3-phosphocholine (DMPC) producing the lowest static and kinetic 
COFs across all loads tested.42 Likewise, DMPC forms large multilamellar vesicles 
(MLVs), with an average diameter greater than 800 nm, as well as SUVs, with an average 
diameter less than 100 nm. When compared, the DMPC-MLVs yields lower static and 
kinetic COFs than DMPC-SUVs when dispersed in the same buffer, and distillate at higher 
concentration at the cartilage surface, a result of DMPC-SUVs penetrating and diffusing 
throughout the layers of the cartilage.42  
Akin to phospholipid liposomes, surfactant-based micelles are being explored, 
albeit to a lesser degree, for their lubricating capabilities in aqueous solutions. Kampf et 
al., report micelles of tri(dodecyldimethylammonioacetoxy) diethyltriamine trichloride 
(DTAD), a trimeric surfactant, adsorbed onto mica surfaces. At low pressures, the DTAD-
micelle functionalized surface achieves an average coefficient of friction of 0.00013, 
whereas increasing the pressure above 26 atms causes the average COF to increase to 0.01. 




phospholipid liposomes, they produce significantly higher coefficients of friction on the 
same articulating mica-on-mica surface, suggesting that phospholipid liposomes are a more 
promising viscosupplement.  
4.3.3 Chitosan 
Chitosan, a naturally occurring polymer with positively charged amine groups 
useful for adherence to anionic surfaces, enhances chondrogenesis, shares structural 
similarities to glycosaminoglycans (GAGs), and offers potential as a viscosupplement.43–
45 Scognamiglio et al. chronicle several sterilizable microgels based on lactose-modified 
chitosan. Rheological testing demonstrates the deleterious mechanical effects of 
autoclaving and tunability of the materials based on the chitosan to boric acid ratio. The 
lactose-modified chitosan hydrogels display a high resistance to degradation and at mildly 
higher pH the hydrogels exhibit an increase in elastic modulus in contrast to HA-hydrogels 
which degrade.45 Of the hydrogels synthesized, those of 3 w/v% lactose-modified chitosan 
and 2 mM boric acid have storage (27.12±0.21 Pa) and loss (19.44±0.88 Pa) moduli akin 
to both commercially available viscosupplements (Synvisc-One®) and healthy SF.45 In a 
rat bilateral medial partial meniscectomy model of OA, treatment with a thermo-responsive 
self-forming chitosan-hyaluronate hydrogel reduces pain as measured by increased load 
bearing of the joint.43 This is coupled with histological evaluation indicating treated knees 
maintain thicker cartilage (170 ±8 µm) compared to control knees (108 ±10 µm) and 
prevent the formation of cysts. Similarly, IA injection of HA associated with lactose 
modified chitosan (Arty-Duo®) in a rat medial meniscotibial ligament transection model of 




injected knees show a decrease in the amount of matrixmetalloproteinase-3, 
matrixmetalloproteinase-13, Galectin-1 and Galectin-3 staining and increased Coll-II 
staining, compared to the saline control, demonstrating Arty-Duo’s® ability to 
downregulate cartilage degrading proteins and promote cartilage regeneration during OA 
progression.44  
4.3.4 Platelet Rich Plasma 
Platelet rich plasma (PRP) offers a novel and effective treatment strategy for OA 
due to its high concentration of growth factors, which may promote chondrocyte 
differentiation and proliferation, and slow the progression of OA. The potential of PRP has 
led to several clinical studies comparing intraarticular injections of PRP to HA or saline.46–
51 Sakata et al., report both thrombin-activated and non-activated PRP produce COF values 
statistically significantly lower than those from saline and high-molecular weight HA.52 
Correspondingly, Russo et al. elucidate the rheological properties of HA solutions and HA 
solutions containing PRP. A frequency sweep conducted on the test solutions demonstrate 
that addition of PRP causes the storage and loss moduli of HA solutions to decrease, while 
increasing the crossover points.53 However, similar trends are observed with addition of 
PBS to HA solutions, suggesting that the change in rheological properties are not due to 
the components of the PRP interfering with the lubricating ability of HA, but rather a 
change in the concentration of HA.53 These preliminary studies hint that administration of 




4.4 Synthetic Lubricants for Tribosupplementation 
Synthetic biolubricants may overcome some of the disadvantages of naturally 
derived biolubricants such high compositional heterogeneity and undesirable physical 
properties related to poor oxidation stability, low temperature properties, and viscosity 
indexes. Despite the potential for naturally derived biolubricants, they are not widely 
commercialized due to high heterogeneity and undesirable physical properties related to 
poor oxidation stability, low temperature properties, and viscosity indexes.54 The 
advantages of partially and fully synthetic lubricants include their ability to restore 
cartilage lubrication in conjunction with resistance to enzymatic degradation, superior 
stability, increased longer residence time, and ability to control tribological properties.55  
With inspiration from hyaluronic acid and lubricin, researchers are developing both 
semi and fully synthetic biomimetic lubricants using two major approaches: either 
mimicking the 1) architecture or 2) chemistry (charge, functional groups, etc.) of biological 
macromolecules found in synovial fluid.  
4.4.1 Proteoglycan Mimetics 
The brush-like design of lubricin plays a vital role in lubrication. Following this 
lead, several groups are synthesizing and optimized brush-like diblock copolymers that 
bind and localize at the cartilage surface, reducing the COF during boundary mode 
lubrication to values comparable to native cartilage. Putnam et al., report an AB diblock 
copolymer consisting of a cationic cartilage-binding domain and a brush like lubricating 
domain that reduce the COF of cartilage in boundary mode conditions to naturally 




exhibits a cartilage-binding time constant comparable to purified human and recombinant 
lubricin.56 As in lubricin, the composition is key to successful performance as the same 
polymer as a random copolymer or the individual polymer blocks fails to lubricate the 
articular surface. A second study of this AB diblock copolymer, further demonstrates the 
interdependence of form and function by altering the block lengths of the polymer.57 The 
cartilage-binding block length influences degree of lubrication under boundary mode 
conditions, with twenty-four cartilage binding groups providing the lowest COF. Whereas 
the length of the actual lubricating block does not affect the degree of lubrication, providing 
key quantitative values for future designs of synthetic lubricants. With the same aim of 
designing and fabricating a biomimetic lubricant, Morgese et al., describe graft copolymers 
of a polyglutamic acid backbone onto which poly(2-methyl-2-oxazoline) (PMOXA) and 
hydroxybenzaldehyde are alternatively grafted.58 The graft copolymers bind to bovine 
articular cartilage surfaces and cartilage-on-cartilage tribology experiments show a 
statistically significant reduction in friction using the graft copolymers, with COF values 
reaching those of native cartilage. The lubricity of the graft copolymer improves with 
higher concentrations of PMOXA side chains and by replacing the linear PMOXA side 
chains with cyclic side chains.59  
Water absorption and coordination within synovial fluid plays a major role during 
boundary mode lubrication. As such, water-coordinating polyelectrolytes are a promising 
class of viscosupplementation material. For example, grafting surfaces with poly(2-
methacryloyloxyethyl phosphorylcholine) (pMPC) reduces COF and provides 




brushes onto surfaces maintain the COF as low as 0.0004 at pressures as high as 8 MPa.60,62 
These results suggest the low COF arises due to formation of the hydration shells 
surrounding the phosphocholine monomers, thus providing lubricity via hydration 
lubrication. Likewise, physisorbed pMPC bottlebrush structures with positively charged 
terminal domains on charged mica surfaces afford COF values lower than naturally 
occurring lubricin over a wide range of applied loads and speeds. Tangentially, bottlebrush 
like polymers using polyacrylic acid-graft poly(ethylene glycol) and a thiol terminating 
backbone onto lubricin depleted cartilage surfaces, lower the COF, though not to values 
found within native cartilage.   
This brush like strategy also applies to nanoparticles or microparticles as lubricants. 
For example, a microgel possessing a polyelectrolyte shell composed of polymer brushes 
grafted onto hollow silica nanoparticles, functions both as a lubricant and a drug delivery 
vehicle. The system, composed of poly(N-isopropylacrylamide) (PNIPAAm) microgels 
functionalized with a poly(3-sulfopropyl methacrylate potassium salt) shell, yield COF 
values akin to native cartilage when used to lubricate PDMS vs. silcon wafer.63 On top of 
their lubricating capabilities, the microgels carry a drug payload which releases at different 
rates by way of the thermoresponsive properties of the PNIPAAm core.63 Along this same 
vein, pMPC grafted mesoporous silica nanospheres synthesized via photopolymerization, 
encapsulate diclofenac sodium (DS), a commonly used anti-inflammatory for osteoarthritis 
pain relief, and lubricate the cartilage surface. In an in vivo medial meniscectomy rat model 
of OA, the pMPC grafted nanospheres loaded with DS preserve joint space, decrease 




Concomitantly, hyaluronic acid-mimetic polymers synthesized to increase joint 
residence times and reintroduce anionic charged species to synovial fluid, outperform 
lubricin during boundary mode lubrication.66 To increase the hyaluronic acid residence 
time in knee joints, the tribological properties of crosslinked or chemically modified 
hyaluronic acid microgels of vinyl sulfone-modified HA are crosslinked via dithiol-
terminated poly(ethylene glycol) (HA-VS/SH-2-pEG).67 The microgels increase viscosity 
and decrease COF compared to unmodified HA, while maintaining drug loading 
capabilities.67 A second approach to modification of HA is via chemical modification. 
Zheng et al., describe grafting 2-methacryloyloxyethyl phosphorylcholine (MPC) onto HA, 
reducing the COF by 60% compared to endogenous HA, which is mechanistically 
attributed to hydration lubrication between water and the zwitterionic MPC.68  
Along those same lines, Wathier et al., describe a (poly(7-oxanorbornene-2-carboxylate) 
polymer to highlight the importance of the hydrophilicity and negatively charged 
moieties of HA on lubrication.69 The polymers resist enzymatic degradation in vivo, 
display similar non-Newtonian behaviors to healthy synovial fluid, and demonstrate 
superior tribological, wear-preventative, and chondroprotection compared to native HA.69 
4.4.2 Hydrogels 
As osteoarthritis progresses, the viscoelastic and rheological properties of synovial 
fluid, crucial to maintaining the fluid barrier between articulating surfaces, deteriorate as 
HA and lubricin degrade. With many desirable properties such as localized drug delivery, 
tunable mechanical properties, biocompatibility, and environmentally responsive 




organization of hydrogel nanofibers with an inner core of cationic peptide amphiphiles 
surrounded by anionic high molecular weight HA entrap endogenous HA.70 Tissue staining 
demonstrate that this scaffold approach was effective at maintaining cartilage tissue, 
increasing cellularity, enhancing cartilage specific GAG deposition, and increasing 
collagen II abundance.70 Along those same lines, hydrogels synthesized via simple click 
chemistry, covalently bond HA to divinyl sulfone with thiol-terminated PEG.67 Using 
various weight ratios of HA, the hydrogels demonstrate tunable viscoelasticity and 
controllable degradation rates, coupled with resistance to hyaluronidase and sustained 
release of the disease modified OA drug, triamcinolone acetonide.67 When intra-articularly 
injected in an ACLT rabbit model of osteoarthritis the hydrogel decreases macroscopic 
scores of OA paired with decreased Mankin scores.67 An HA-based hydrogel with 
covalently bound micelles of PEG and kartogenin (KGN), a small molecule that promotes 
chondrocyte differentiation of mesenchymal stem cells, sustains release of KGN and when 
intra-articularly injected into an ACLT and medial meniscectomy rat model of OA 
significantly suppresses disease progression.71  
The use of naturally occurring polysaccharides as hydrogels is not limited to HA.72–
76 Analogous to previously mentioned endeavors to combine naturally occurring lubricants 
with chitosan, groups are using this naturally occurring polysaccharide to synthesize 
chitosan-based hydrogels and synthetic polymers for lubrication. Faivre et al., describe a 
hydrogel of chitosan coupled with HA and a bottle brush polymethylmethacrylate polymer, 
which substantially resists wear induced degradation following articulation and increases 




composite gelling system of a chitosan gel loaded with poly(caprolactone) microparticles 
for use as a viscosupplement and an intra-articular drug delivery depot of the COX-2 
inhibitor Etoricoxib, which poses severe cardiovascular toxicity when administered 
orally.73 The microparticle-hydrogel system demonstrates similar viscoelastic properties to 
HA, and in vivo fluorescence imaging reveal improved joint residence times, compared to 
bare chitosan gels or microparticles alone, and allow for sustained release of Etoricoxib.73 
Apart from chitosan, other polysaccharide-based hydrogel systems include one of gellan 
gum, a linear, anionic extracellular polysaccharide, coated with crosslinked polyvinyl 
alcohol, shows resistance to degradation when sterilized and elastic and viscous moduli 
values higher than the commercially available Synvisc indicating improvements in 
resistance to shear and compression.77 Similarly, a hydrogel based on the naturally 
occurring polysaccharide guar gum, described by Cunha et al., demonstrates shear thinning 
behavior and viscosity on par with commercially available Hylan G-F 20.78 
4.5 Conclusion  
In OA, the capacity for SF to effect elastohydrodynamic cartilage lubrication is 
altered by decreases in the Mw of HA that deplete the viscoelastic properties of SF, along 
with deprivation of lubricin that reduces boundary lubrication. As a result, articular 
cartilage exhibits a higher COF, increasing mechanical wear, coupled with elevated 
cytokine levels, which stimulate matrix metalloproteinase production, further propagating 
degradation of the cartilage ECM.  
FDA approved intra-articular injection of HA for viscosupplementation as a device 




SF viscosity and rejuvenate the elastohydrodynamic lubrication properties of SF. However, 
the safety and efficacy of viscosupplements as a “device” was established on attaining 
analgesia equivalent to non-steroidal anti-inflammatory drugs administered enterally, 
rather than proof of chondroprotective or chondroregenerative effectiveness. As such, the 
efficacy of currently available viscosupplements is variable, limited by failure of these 
treatments to modify OA cartilage pathology as a consequence of short intra-articular 
residence time due to enzymatic degradation by hyaluronidase⁠, and persistence of elevated 
cytokine levels in OA SF.  
Currently, no device or pharmacological treatment has been demonstrated to impart 
chondroprotection after the induction of OA. Therefore, to address these deficits, 
researchers are developing bio-lubricants that reduce friction between articulating joint 
surfaces and cartilage wear by recapitulating the non-Newtonian, tribological properties of 
healthy SF and imparting boundary lubrication. As a general strategy, these biolubricants 
use bio-inspired polymer networks based on HA and/or lubricin, incorporating the 
hydrophilic phosphorylcholine headgroup, exploiting its ability to attract and coordinate 
water molecules to induce hydration lubrication. Chemical or physical alterations to HA 
so as to resist enzymatic degradation in the hostile environment of an OA afflicted synovial 
joint include vinyl sulfone-modified HA crosslinked via dithiol-terminated poly(ethylene 
glycol) (HA-VS/SH-2-pEG),67 or grafting the zwitterionic monomer 2-
methacryloyloxyethyl phosphorylcholine onto HA.68 Efforts to create boundary lubricants 
range from transforming naturally occurring lubricin, by attaching an HA-binding peptide, 




cartilage surface localization. Research involving naturally occurring polysaccharides, 
such as chitosan,73 gellan gum,77 and guar gum,78 are being explored for use as fluid film 
lubricants. While boundary lubricants are a final defensive guard against cartilage wear, 
this treatment will not repair degraded cartilage ECM. Therefore, multifunctional SF 
supplements are being developed that not only augment SF viscoelasticity and resist 
enzymatic degradation, but incorporate nanoparticles, micelles and/or hydrogels that are 
depots for the sustained release of disease modifying OA drugs and/or small therapeutic 
molecules. However, the challenge to the clinical efficacy of recuperating 
elastohydrodynamic lubrication in diseased joints with synovial fluid supplements is 
diagnosing OA at a stage where chondroprotective biolubricants are capable of mitigating 
cartilage destruction before irreversible damage has transpired. Imaging methods to 
identify early-stage biochemical and structural changes indicative of OA pathology, before 
pathoanatomy is apparent must be developed in tandem with the tribosupplementation 
endeavors described herein. 
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Table 4.1. FDA Approved, clinically used viscosupplements. 
Name Injections per week Molecular Weight (kDa) 
Euflexxa 3 2400 - 3600 
Synvisc 3 6000 - 7000 
Synvisc-One 1 6000 - 7000 
Gel-One 1 Crosslinked, infinite MW 
Synojoynt 3 2500 
Monovisc 1 1000 - 2900 
Gel-Syn 3 1100 
Orthovisc 3 to 4 1000 - 2900 
Supartz 3 to 4 620 - 1170 
Durolane 1 1000 
Ostenil 3 1000 - 2000 
Visco-3 3 620 - 1170 
Suplasyn 1 500 - 730 
Hyalgan 5 500 - 730 
Hymovis 2 500 - 730  
Triluron 3 500 - 730 







Figure 4.1. Macromolecules of synovial fluid and their synergistic interactions at the 
cartilage surface. The lubrication mode which this organized surface layer of 








Figure 4.2. A) Schematic of mLub15 binding to the articular surface and HA in the 
synovial fluid. B) Reaction schematic for the synthesis of mLub15 with the addition of HA 
and type II collagen binding peptides to a chondroitin sulfate backbone. C) Calculated 
static and kinetic coefficient of friction values of each treatment group (n ≥ 9). In static 
COF, there is statistical difference (p < 0.05) between the trypsin treated plug and the WT, 
mLub15 + Synvisc, and mLub15 + HA treatments. In kinetic friction, there is statistical 
difference (p < 0.05) between the mLub15 + Synvisc treatment and the trypsin, Synvisc, 
and mlub10 + Synvisc treatments. Standard error bars are shown.33 D) Schematic of a 
cartilage surface modified with a HABpep designed to interact with and bind HA in 
surrounding fluid. E) HA-recruiting molecules able to reduce the COF of healthy OA 















Figure 4.3. A) Schematic representations of the bottle-brush polymer mimicking LUB. B) 
Experimental data showing that the friction coefficient μ is independent of the applied load. 
C) PGA-α-PMOXA(x)-β-HBA synthesis via cationic ring-opening polymerization of 2-
methyl-2-oxazoline D) Degraded cartilage slices were coated with PGA-PMOXA-HBA 
graft-copolymers, and the COF values were measured sliding them against each other using 
a bovine synovial fluid solution of the corresponding graft-copolymer at 5 mm/s (a–b–c), 
the recorded values of COF are reported for the different copolymer grafting densities (α) 
and a fixed side-chain length: x = 30 for (a), x = 100 for (b), x = 120 for (c). Native cartilage 
(NC) and digested cartilage (DC) were chosen as positive and negative controls, 
respectively. E) Fabrication of PSPMA-g-HSNPs, and drug loading. F) Friction curves for 
steel–steel contacts lubricated by pure water and PSPMA-g-HSNP suspension with 
different solid contents (0.1, 0.3, and 0.5 wt %). DOI: (10.1021/jp500074g). All figures 
















CHAPTER V: Mega-Macromolecules as Single Molecule Lubricants for Hard and 
Soft Surfaces 
5.1 Abstract 
 A longstanding goal in science and engineering is to mimic the size, structure, and 
functionality present in biology with synthetic analogs. Today, synthetic globular polymers 
of several million molecular weight are unknown, and, yet these structures are expected to 
exhibit unanticipated properties due to their size, compactness, and low inter-chain 
interactions. Here we report the gram-scale synthesis of dendritic polymers, mega 
hyperbranched polyglycerols (mega HPGs), in million daltons. The mega HPGs are highly 
water soluble, soft, nanometer-scale single polymer particles that exhibit low intrinsic 
viscosities. Further, the mega HPGs are lubricants acting as interposed single molecule ball 
bearings to reduce the coefficient of friction between both hard and soft natural surfaces in 
a size dependent manner. We attribute this result to their globular and single particle nature 
together with its exceptional hydration. Collectively, these results set the stage for new 
opportunities in the design, synthesis, and evaluation of mega polymers. 
5.2 Introduction 
 As our mastery of polymerization reactions advances, macromolecules of 
increasing complexity and size are readily synthesized. Dendrimers clearly showcase this 
advancement; specific structural or compositional features are introduced at defined 
locations within a 3D globular structure.1-6 Linear polymers of a few million Dalton 
molecular weight also exhibit interesting properties and are prepared via judicious choice 




deactivation radical polymerization7, atom transfer radical polymerization,8 reversible 
addition-fragmentation chain transfer9, ring-opening metathesis10 and Lewis pair 
polymerizations.11 Synthesizing globular polymers of several million molecular weight has 
not been previously achieved and will, similarly, afford unexpected properties as one single 
polymer itself occupies a size of tens of nanometers owing to its compact structure. A path 
to such mega-macromolecules of several million Dalton molecular weight represents a 
significant synthetic challenge. During a polymerization reaction, the viscosity of the 
polymerization medium increases, which leads to quenching of propagation species, poor 
control of molecular weight, polydispersity, and branching.  
Herein, we report the synthesis and characterization of semi-dendritic 
hyperbranched polyglycerols of 1, 3, and 9 million Dalton (MDa) (i.e., mega HPGs), and 
their performance as single molecule soft ball bearing lubricants on hard and soft surfaces. 
The mega HPGs reduce the coefficient of friction between both hard and soft surfaces and 
exhibit rheological properties similar to a fluid lubricant. The high-water solubility, low 
intrinsic viscosity, compactness, nearly molecular weight independent intrinsic viscosity, 
and hydration of the mega HPGs are responsible for their performance as single molecule 
ball bearings.  
5.3 Methods 
5.3.1 Materials 
All solvents and reagents were purchased from Sigma-Aldrich, Canada, unless 
otherwise mentioned. Glycidol was vacuum distilled over CaH2 at 40-50 °C and stored 




without further purification.  Deuterated solvent (D2O, 99.8%D) was purchased from 
Cambridge Isotope Laboratories, Inc. Standard regenerated cellulose (RC) membranes 
(MWCO-50 and 10 kDa) were purchased from Spectrum, Inc., USA. NMR spectra (1H, 
13C, and 13C inverse-gated (IG)) were recorded on a Bruker Avance 300 and 400 MHz 
NMR spectroameters. Degree of branching of polymers was measured in deuterated water 
(D2O) with a relaxation delay of 6 s, and it, and it was calculated as per the reported 
procedure from the equation, DB = 2D/(2D + L), where D and L represent the intensities 
of the signals corresponding to the dendritic and linear units respectively).12,13 The absolute 
molecular weights of the polymers were determined by gel permeation chromatography 
(GPC) on a Waters 2695 separation module fitted with a DAWN HELEOS II multi angle 
laser light scattering detector coupled with Optilab T-rEX refractive index detector, both 
from Wyatt Technology, Inc., Santa Barbara, CA. GPC analysis was performed using 
Waters ultrahydrogel columns (guard, linear and 120) and 0.1 N NaNO3 buffer (pH = 7.0) 
was used a mobile phase, and dn/dc value for mega HPG used was  0.12 mL/g. The dn/dc 
values of the mega HPGs were determined independently; there was no molecular weight 
dependence. The hydrodynamic radii (Rh) of the polymers were obtained by quasi elastic 
light scattering (QELS) detector using a Wyatt Internal QELS instrument (angle of 
measurement, 99.9°, laser λ = 620 nm). The intrinsic viscosity measurements were 
performed on viscometer-II from Wyatt technologies in which 0.1 N NaNO3 buffer (pH = 
7.0) was used a mobile phase. Hydration of the polymers was determined using differential 
scanning calorimetry (DSC) (TA instruments, New Castle, DE, USA.14 Cryo-scanning 




Ion Company) Helios NanoLab 650 SEM with a focused ion beam (SEM-FIB) facility at 
4D LABS, Simon Fraser University, Burnaby, Canada. Tc28a2 juvenile chondrocytes were 
purchased from EMD Millipore. MTT cell proliferation assay was purchased from ATCC. 
Absorbance readings for cell viability studies were measured at 570 nm on a SpectraMax 
190 microplate reader from Molecular Devices.  
5.3.2 Synthesis of high molecular weight HPG macro-initiator15 
Trimethylolpropane (TMP) (120 mg, 0.894 mmol) was added to a flame dried three 
neck flask and dried under melting conditions (60 °C) and vacuum for 5 h. The dried TMP 
was partially deprotonated (33% of the total OH groups of TMP) with potassium methylate 
(25% MeOH, 70 µL, 0.237 mmol) under argon, and stirred for 30 min at room temperature.  
Methanol was evaporated at 70 °C for 4 h under vacuum. The flask was connected to an 
overhead stirrer and dry dioxane (24 mL) was added followed by slow addition of glycidol 
(12 mL, flow rate of 0.5 mL/hr) with a syringe pump under argon. After the addition of 
glycidol, the reaction mixture was stirred (rpm-150) for an additional 5 h. The reaction 
mixture was quenched with 0.5 mL of methanol after cooling it to RT. After decanting the 
supernatant (dioxane), the polymer was dissolved in 60 mL of methanol and precipitated 
from acetone (240 mL). The precipitation process was repeated twice (Caution: Make sure 
that a homogenous solution of the polymer in methanol was obtained before proceeding to 
precipitation with acetone. If it is taking long time for the dissolution of macro-initiator in 
methanol, the volume of methanol can be increased, however, same ratio of methanol and 
acetone should be maintained). The precipitated polymer was dissolved in deionized water 




against water in a cellulose membrane (MWCO-10 kDa) for 2 days (with water 
replacement every 4-5 h). The polymer was freeze-dried and characterized by NMR (1H 
and 13C NMR; Figure 5.1) and GPC-MALS analyses (conversion of monomer-100%, 
yield-70%; Mw-840 kDa, Đ-1.2, Figure 5.1). 
5.3.3 Synthesis of mega HPG-1 
All the mega HPGs were synthesized by a modified macro-initiator approach.16 The 
HPG macroinitiator (Mw-840 kDa, Đ-1.2) (2.5 g, 0.034
 mols of OH groups) was dissolved 
in MeOH (5.0 mL) in a flame dried three neck flask and a polymer film was made on the 
walls of the flask by slowly evaporating the solution under vacuum. The flask containing 
the polymer film was further dried under vacuum at 100 °C for overnight to completely 
remove traces water and methanol. Thermogravimetric analysis was used to make sure that 
the polymer film was completely dried. The dried polymer was dissolved in dry DMF (35 
mL) under Ar and KH suspension in oil (30 %) (80 mg, 270 µL, 1 eq) was added. The flask 
was heated to 95 °C and stirred for 50 min to ensure that all the polymer was completely 
dissolved and turned into a yellow-colored solution. The reaction flask was connected to 
an overhead stirrer under argon and the stirring speed was set at 150 rpm. To this 
homogenous solution, dried glycidol (8 mL) was added slowly (0.5 mL/h). After 
completion of glycidol addition, reaction was continued for 10 more hours, then cooled it 
to RT. The solution was turned into a clear pale red colored solution. The conversion of 
the monomer was almost 100%, confirmed by 1H NMR spectroscopy. The polymer was 
dissolved in methanol (70-100 mL, make sure that no precipitate was found on the bottom 




two more times to remove the small molecular weight fractions. The obtained precipitate 
was dissolved in water (100 mL), neutralized (pH-7) by dropwise addition of 0.1 M HCl 
and was further purified by dialysis (regenerated cellulose dialysis membrane, MWCO-
50,000 Da) against water for 5 days (water replacements every 8 h). The polymer was 
stored as aqueous solution at 4 °C (yield-80 %). The experiment was repeated at least three 
times to determine the reproducibility (yield-81±3.6%). The polymer was characterized by 
NMR, GPC-MALS, viscosity measurements, and quasielastic light scattering 
measurements (Table 5.1 and 5.2). Caution: For the deprotonation of macroinitiator, the 
base, KH (in oil), is highly recommended. The KH solution should be homogenous before 
adding to the macroinitiator solution. Considering the pKa of the reagents involved in this 
deprotonation process, usage of either base KOMe or KH would be appropriate. However, 
if KOMe (25% in methanol) is used, the trace amounts of methanol can influence the 
polymer growth process resulting a bimodal distribution of HPG formed.  
5.3.4 Synthesis of mega HPG-2 
The HPG macroinitiator (Mw-840 kDa, Đ-1.2) (2.5 g, 0.034
 mols of OH groups) 
was dissolved in MeOH (5.0 mL) in a flame dried three neck flask and a polymer film was 
made on the walls of the flask by slowly evaporating the solution under vacuum. The flask 
containing the polymer film was further dried under vacuum at 95 °C for 24 h to completely 
remove the traces water and methanol. Thermogravimetric analysis was used to make sure 
that the polymer film was completely dried. The dried polymer was dissolved in dry DMF 
(35 mL) under Ar and KH (30% suspension in oil, 80 mg, 270 µL) was added. The flask 




dissolved. The reaction flask was connected to an overhead stirrer under argon and the 
stirring speed was set up at 150 rpm. The solution color was turned to yellow. To this 
homogenous solution, dried glycidol (24 mL) was added slowly (1.4 mL/h). After 
completion of glycidol addition, reaction was continued for 10 more hours, then cooled to 
RT. The color of the solution was turned into pale red. The conversion of the monomer 
was almost 100% confirmed by 1H NMR spectroscopy. Methanol (100 mL) was added to 
dissolve the polymer. A small amount of the precipitate was not soluble. 10 mL of DMF 
was added to completely to dissolve the polymer (make sure that no precipitate was found 
on the bottom of the flask). The polymer was precipitated from acetone (500 mL). The 
precipitation process was repeated two more times to remove the small molecular weight 
fractions. The obtained polymer was dissolved in water (100 mL), neutralized by dropwise 
addition of 0.1M HCl and was further purified by dialysis (regenerated cellulose dialysis 
membrane, MWCO-50,000 Da) against water for 5 days (water replacements every 8 h). 
The polymer was stored as aqueous solution at 4 °C (yield-85 %). The experiment was 
repeated at least three times to determine the reproducibility (yield-78 ± 6.5%). The 
polymer was characterized by NMR, GPC-MALS, solubility, viscosity measurements, and 
quasi elastic light scattering measurements (Table 5.1, 5.2, 5.3).  
5.3.5 Synthesis of mega HPG-3 
The HPG macroinitiator (Mw-840 kDa, Đ-1.2) (2.5 g, 0.034
 mols of OH groups) 
was dissolved in MeOH (5.0 mL) in a flame dried three neck flask and a polymer film was 
made on the walls of the flask by slowly evaporating the solution under vacuum. The flask 




remove the traces of water and methanol. Thermogravimetric analysis was used to make 
sure that the polymer film was completely dried. The dried polymer was dissolved in dry 
DMF (35 mL) under Ar and KH suspension in oil (30 %) (~80 mg, 270 µL) was added. 
The flask was heated to 95 °C and stirred for 30 min to ensure that all the polymer was 
completely dissolved. The reaction flask was connected to an overhead stirrer under argon 
and the stirring speed was set up at 200 rpm. To this homogenous solution, dried glycidol 
(50 mL) was added slowly (1.4 mL/h). After completion of glycidol addition, reaction was 
continued for 10 more hours, then cooled it to RT. The conversion of the monomer was 
almost 100% confirmed by 1H NMR spectroscopy. Methanol (100 mL) was added to 
dissolve the polymer. A small amount of the precipitate was not soluble. 10-20 mL of DMF 
was added to completely to dissolve the polymer (make sure that no precipitate was found 
on the bottom of the flask). The polymer was precipitated from acetone (500 mL). The 
precipitation process was repeated two more times, dissolved in water (100 mL), 
neutralized (pH-7) by dropwise addition of 0.1M HCl and was further purified by dialysis 
(regenerated cellulose dialysis membrane, MWCO-50,000 Da) against water for 5 days 
(water replacements every 8 h). The polymer was stored as aqueous solution at 4 °C (yield-
74 %). The experiment was repeated at least three times to determine the reproducibility 
of the synthesis of mega-HPG-3 (yield-74 ± 0.21%). The polymer was characterized by 
NMR, GPC-MALS, solubility, viscosity measurements, and quasi elastic light scattering 




5.3.6 Solubility measurements 
The solubility of mega HPGs in water was measured and compared with other 
linear polymers (polyethylene oxide, polyvinyl alcohol purchased from Sigma-Aldrich, 
ON). The mega HPGs were initially dissolved in water (100 mg in 1 mL) using vortex 
mixing. Additional amount of mega HPGs were added until the solution reached saturation 
(Table 5.2). The solution was equilibrated overnight to measure consistency. The similar 
protocol was repeated for the other linear polymers until the solution become a stable gel.     
5.3.7 Determination of hydration of mega HPG 
Hydration of the polymers was determined using differential scanning calorimetry 
(DSC).17 The mega-HPG solution was prepared in water (10% W/W). 20 μL of the solution 
was loaded into a Tzero aluminum hermetic sample pan and closed with appropriate lids. 
The sample pan was cooled down to −20 °C and warmed to −5 °C at the rate of 2 °C/min. 
Heating of the sample was further continued from −5 °C to +5 °C at the rate of 0.2 °C/min 
and to +20 °C at the rate of 2 °C/min. The enthalpy of fusion of polymer solution or pure 
water was determined by integrating the area under the respective peak on DSC trace 
(Table 5.3). An empty pan was used as a reference. The number of water molecules bound 
per polymer was calculated using the following equation.  
                       [Nbw] = [ΔHfo (Wtw − Wt p) −ΔHfps × Wtps] / [ΔHfo ×MWH2O × Np] 
Nbw   = number of water molecules bound per polymer 
ΔHfps , ΔHfo = fusion enthalpy of polymer solution and pure water respectively  





Np = number of moles of polymer taken. 
5.3.8 Cryo-scanning electron microscopy (cryo-SEM) measurements 
The morphology of the mega HPGs were visualized using cryo-SEM assembled 
with a focused ion beam SEM-FIB equipped with Quorum PP3010T cryo sample 
preparation system. A small volume of sample (10 µL) solution was loaded onto the sample 
carrier and immersed in slush liquid nitrogen for rapid freezing. The carrier with the frozen 
solution pellet is quickly vacuum transferred to the sample preparation stage cooled at -
140 °C for fracturing the pellet. The fractured pellet was further transferred to the SEM 
stage cooled also at -140 °C for imaging the fractured surface, with an electron beam of 1 
keV and 13 pA. The optimal concentration of the mega HPGs in Millipore water was 0.1 
mg/mL. The average size of the mega HPGs were calculated from the 10 images with 
approximately 500 particles.   
5.3.9 Cell viability measurements 
Cell viability was assessed in Tc28a2 juvenile human chondrocytes and 3T3 murine 
fibroblast cells using the (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) 
tetrazolium reduction (MTT) assay as per previously reported protocol.10 Cells were seeded 
at 10,000 cells/well and allowed to settle and adhere for 24 hours before addition of mega 
HPG or control samples. Mega HPG samples (10 µL) were prepared in regular growth 
media (DMEM) for (90 µL) to obtain a final polymer concentration of 1.25 mg/mL. Cells 
were incubated with the mega HPG samples for 48 h at 37 ºC. Wells containing 50% 




volumes to the polymer samples were used as normal controls. After incubation, cells were 
washed with PBS 3 times followed by the addition of 100 µL of fresh media and 10 µL of 
12 mM MTT reagent (from ATCC). After 4 h, 100 µL of sodium dodecyl sulphate (SDS)-
HCl was added to solubilize the generated formazan. After solubilization for 2–24 hours, 
absorbance at 570 nm was read on a SpectraMax 190 microplate reader (Molecular 
Devices) and compared to saline controls. Three technical replicates were conducted per 
sample, and each study was independently repeated in triplicate. Average values and 
standard deviation are reported.  
5.3.10 Lubrication measurements 
Viscosity measurements were performed on a TA Instrument AR2000 rheometer 
using a 2° aluminum cone and a 47 µm gap at 25°C. Viscosity was then averaged across 
shear rates from 10 to 100 s-1. Stribeck curves were constructed on a DHR-2 rheometer 
(TA instruments) with a stainless-steel ring on plate tribology geometry attachment. 300 
µL of each lubricant were applied to the stainless-steel surface and a 5N load was applied, 
radial velocity increased from 0.001 rad/s to 50 rad/s while the load was held constant. This 
test was replicated three times for each lubricant, using fresh lubricant for all 
measurements. Average COF values and Hersey numbers, along with standard deviation 
were used to construct Stribeck curves for all formulations of mega HPG along with 
Synvisc One and BSF as controls. The values of 7 and 23% for mega HPGs were chosen 
as to ensure a 3X difference in amounts to better observe potential differences. Cartilage 
on cartilage coefficient of friction measurements, using 7 mm diameter bovine 




cored from skeletally mature bovine knees using a diamond tipped drill bit. Plugs were 
incubated in 0.5 mL of lubricant at room temperature overnight prior to testing. An 8 N 
(200 kPa) creep load was applied to paired osteochondral plugs. After 3 hours of 
compression to equilibrate the tissue in creep, equilibrium friction measurement was made. 
Friction measurements used an angular velocity of 360°/s (effective velocity = 14.7 mm/s) 
for 120 seconds. Coefficient of friction (μ) was calculated from μ = (3/2)·(τ/Nr), where: τ 
= torque, N = load, r = plug radius.17 Sampling frequency was 10 Hz.   
5.3.11 AFM measurements 
Atomic force microscopy (AFM) was performed using an MFP-3D microscope 
(Asylum Research; Santa Barbara, CA). The contact mode was applied using a silicon 
nitride tip with a nominal spring constant of 40 pN/nm. mega HPG-3 was chemically 
adhered to the surface of epoxide functionalized glass slides. 5 mg of mega HPG-3 was 
diluted in 50 mL of dimethylformamide. Stoichiometric amount of sodium hydride was 
then added. Ten microliters of this solution at concentration of (0.1 mg/mL) was dropped 
on the surface of the epoxide glass slide and kept at 60 °C overnight. The glass surface was 
rehydrated in PBS just before experimentation. The tip was slowly lowered to the surface 
to confirm contact without damage. Tip calibration was done on the bare glass surface, 
which acts as an infinitely hard surface, to set both a baseline deflection and virtual 
deflection correction. This determines the cantilever’s inverse optical lever sensitivity 
(InvOLS; unit: m/V). The spring constant was verified via thermal tuning and was always 
within the range dictated by Bruker (within 30 pN/nm). After calibration, an area scan was 




polymer. Clumps of polymer were chosen for indentation based on shape and size. Force 
spectroscopy was then obtained over a 2 m extension length and a 1000 nm/s approaching 
and retreating velocity. The tip was triggered at a set-point of 0.75 V of deflection. Once 
an indentation was performed, the raw distance of the tip along the z-direction was 
converted into an indentation depth using the InvOLS. 
5.4 Results  
5.4.1 Synthesis and structural characterization of mega HPGs 
To overcome the challenges and prepare a large globular polymer, we used a 
homogenous polymerization method along with a macroinitiator to obtain ultra large 
dendritic polymers possessing a globular shape. As our interests lie in the polymers of 
potential use for environmentally responsible high-performance and biomedical 
applications, the selection of building blocks that are degradable, green, biocompatible, or 
natural metabolites is an additional key design criterion.18,19 Polymers possessing a 
glycerol backbone are of significant interest for biomedical and environmental-green 
applications due to their chemical tuneability, degradability, and biocompatibility.20-27 We 
synthesized the mega HPGs, in the million Dalton range (up to 10 million Dalton), via ring 
opening multibranching polymerization (ROMBP) in a single pot using a combined macro-
initiator as and solvent based solution polymerization approach (Figure 5.2).16 
Specifically, we used the partially deprotonated (10%) high molecular weight HPG (KH in 
DMF, Mw - 840 kDa, Đ - 1.2) as the macroinitiator (Figure 5.1). The high solubility of the 
deprotonated macroinitiator in the polymerization medium, dry conditions and the use of 




macroinitiator. The slow addition of the monomer glycidol at 95 °C produced 
predetermined molecular weights of mega HPGs in a controlled manner in good yields 
(Fig. 5a, Table 5.1). We synthesized three different molecular weight mega HPGs (mega 
HPG-1 (Mw - 1.3 MDa, Đ - 1.2), mega HPG-2 (Mw - 2.9 MDa, Đ - 1.2), and mega HPG-3 
(Mw - 9.3 MDa, Đ - 1.4)) by changing the glycidol to macroinitiator ratio (Table 5.1). The 
mega HPGs exhibit a monomodal distribution as demonstrated using gel permeation 
chromatography with multi angle light scattering (GPC-MALS) (Figure 5.2d, 5.3, Table 
5.1). Homogeneous polymerization conditions in dry solvent and the maintenance of 
uniform stirring using an overhead stir are important determinants in synthesizing mega 
HPGs with low polydispersity in good yield (~74 to 85%). For example, the current 
protocol affords ~42 g of isolated mega HPG-3 in a single batch. We repeated all of the 
reactions at least twice and obtained similar results (for example, average Mw for mega 
HPG-3 from three different batches was 9.3 ± 0.03 MDa and the yield was 74 ± 0.21%). 
This is significant, considering the difficulty in synthesizing semidendritic/hyperbranched 
polymers of such high molecular weights in large quantities using anionic ring opening 
polymerization. 
We further characterized the mega HPGs by nuclear magnetic resonance (NMR) 
analysis for structure and branching density (Figure 5.2 and Figure 5.4). A representative  
NMR spectra of mega HPG-3 shows the characteristic peaks of the polyglycerol backbone 
(Figure 5.2b and 5.2c).28 The degree of branching of mega HPGs, determined by C Inverse 
gated NMR spectroscopy, is between 53 and 57%, and similar to HPGs reported previously 




achieved are the highest reported for dendritic polymers and as such these polymers display 
unique characteristics. For example, mega HPG-3 possesses >87000 hydroxyl groups per 
polymer on average influencing properties and amenable to modification. The mega HPGs 
are highly hydrated, as determined by differential scanning calorimetry; mega HPG-3 
possesses ~389,300 bound water molecules per polymer (Figure 5.5 and Table 5.2). As 
suspected, the mega HPGs are highly water soluble (> 380 mg/mL) in contrast to similarly 
sized linear polymers (e.g., polyethylene oxide, polyvinyl alcohol) which form gels at high 
concentrations (Table 5.3).29  
Mega HPGs are highly compact nanostructures as demonstrated by their 
hydrodynamic diameters (determined by dynamic light scattering) which range from 21 
nm for the 1.3 MDa to 43 nm for the 9.3 MDa polymer (Table 5.1). We further investigated 
the size of mega HPGs using cryogenic scanning electron microscopy (cryo-SEM). A 
representative cryo-SEM of mega HPG-3 shows the spherical and single particle nature of 
the mega HPGs (Figure 5.6). The average size of the mega HPGs are 28, 34, and 51 nm 
for mega HPG-1, 2, and 3, respectively, and slightly higher than the data obtained from 
DLS likely due to the frozen hydrated shell of the mega HPG in the cryo-SEM preparations 
(Figure 5.6). Importantly, individual mega HPGs are nanometer-scale singular polymer 
particles and easily visualized. The low hydrodynamic sizes of mega HPGs confirms their 
stability in water without aggregation,30, 31 and the size does not scale with molecular 
weight as with linear polymers32 and low molecular weight HPG (Figure 5.7a and Table 
5.2). The size of the mega HPGs lies between linear polymers (e.g., PEG) and dendrimers 




than linear polymers and less compact in comparison to dendrimers, and this might be 
advantageous in terms of offering more ‘interior room’ between branching units.  
The mega HPGs possess exceptionally low intrinsic viscosity in comparison to 
other polymeric systems. The intrinsic viscosity, [η], of the mega HPGs does not change 
considerably with molecular weight (Table 5.1); this small change in intrinsic viscosity of 
mega HPGs also does not follow the Mark-Houwink-Sakurada equation and instead falls 
in line with the Einstein viscosity theory’s prediction of almost minimal change in [η] with 
molecular weight for “hard” globular shaped polymers.31 This result is in striking contrast 
to dendrimers (PAMAM, generation G1-G10), which show an unusual bell shape 
dependence of [ƞ] with increasing molecular weight (Fig. 5.7b).33 Published simulation and 
experimental studies validate that the PAMAM dendrimer has almost zero asphericity with 
increasing generation number (G1→9) which indicates substantial back folding of terminal 
groups into the interior core of the dendrimer structure.34 This conformational change may 
be occurring with mega HPGs to some degree as evident from their nearly molecular 
weight independent intrinsic viscosity, however, additional studies are needed to confirm 
this notion. Interestingly, the intrinsic viscosities of the mega HPGs  are slightly increased 
with molecular weight compared to their lower molecular counterparts; the increase in size 
of the mega HPGs might be attributing to this rise.35 The intrinsic viscosity values of mega 
HPGs are significantly lower than linear water-soluble polymers of similar molecular 
weight (e.g., polyethylene oxide, hyaluronic acid, and dextran sulfate),29, 36-39 and this 
observation further confirms the compact nature of the mega HPGs. For example, the mega 




the globular proteins in aqueous solutions,40-42 whereas a linear PEG (Mw-11 MDa) has a 
value of 2600 mL/g.32 Thus, mega HPGs show a unique combination of ultra-high 
molecular weight, compact size, and very low intrinsic viscosity almost independent of 
molecular weight.    
5.4.2 Lubrication properties 
To take advantage of the unique solution properties of mega HPGs (high solubility, 
compactness, and low intrinsic viscosity), we investigated the lubrication properties of 
mega HPGs on hard synthetic and soft natural surfaces. Considering the globular and single 
particle nature of the mega HPGs, we anticipated that the rheological properties of mega 
HPGs will be quite different from their linear counter parts. We first determined the 
performance and lubrication characteristics of mega HPGs on stainless steel by generating 
Stribeck curves. Stribeck curves describe the coefficient of friction (COF) of a system 
across different lubrication modes: boundary, mixed, and hydrodynamic lubrication. 
Generally, boundary lubrication exists under conditions of low speed, high load and is 
characterized by a high COF while conversely hydrodynamic lubrication occurs under 
conditions of high speed and low load and is characterized by a low COF. Using a DHR-2 
Rheometer (TA Instruments), we applied a 5N load and held it constant, while the radial 
velocity increased from 0.001 rads-1 to 50 rads-1. Stribeck curves for all six mega HPGs 
formulations along with three controls, Pennzoil 80W-90 motor oil, Synvisc One, and 
bovine synovial fluid, were constructed by plotting COF against the Hersey number 
(velocity*viscosity/load) (Figure 5.8). Synvisc One and bovine synovial fluid (BSF) were 




polymer of hyaluronic acid of high viscosity versus a low viscous, natural lubricating 
solution) and relevance to the soft natural surface next investigated. Pennzoil was chosen 
in order to verify our method of Stribeck curve construction.43 Additionally, Synvisc One 
and BSF lubricate via different mechanisms, BSF aids in mixed mode lubrication within 
joints, while Synvisc One is a fluid lubricant. The mega HPGs-1, -2, and -3, at both 7 and 
23 w/v%, possess viscosities on the order of BSF and display boundary mode lubrication. 
The higher weight percent mega HPGs exhibit boundary mode lubrication at a consistently 
higher velocity with a molecular weight and concentration dependence. At 23 w/v%, the 
mega HPGs transition into mixed mode lubrication from boundary mode at increasing 
Hersey number with increasing molecular weight and with COFs equal to but speeds 
greater than BSF, despite their similarities in viscosities to BSF (Figure 5.8a and 5.8b). 
Consequently, mega HPGs demonstrate Stribeck curves similar to the hyaluronic acid 
solution, Synvisc, except that the mega HPGs are 100X less viscous. 
For the natural soft surface, we selected articular cartilage for evaluation of the 
mega HPGs as lubrication of this surface is key for bodily movement, protection from 
wear, and prevention of osteoarthritis.10, 44-48 Previously, linear10, 49 and brush polymers44, 
50,51 have been explored for lubricating cartilage as these materials present controlled 
electrostatic interactions and hydration. Additionally with the brush structures, the tilting 
and/or the physical thinning of the polymer chains improves the lubricant properties.52,53 
Cartilage is a hydrated porous elasto-hydrodynamic material,12,13 where upon initial 
loading interstitial aqueous fluid supports most of the applied load by creating an 




of the interstitial fluid has extruded, the deformed cartilage is softer and weeping 
lubrication is depleted. We conducted mechanical friction tests (BOSE Electroforce 3200) 
on harvested mated bovine osteochondral plug pairs (7 mm diameter, N = 6 pairs) in 
unconfined geometry (Figure 5.9).10 After incubating the samples in the test groups (saline, 
healthy bovine synovial fluid, human osteoarthritic synovial fluid, and 1, 3, and 9 MDa 
mega HPGs at 7 and 23 w/v%), the opposing cartilage surfaces were pressed against each 
other (200 kPa creep load) for three hours while submerged in the test solutions. Then, 
while under load, rotation was applied for 120s at an angular speed of 360°/s and the 
equilibrium COF was determined.  
All of the mega HPGs lubricate the cartilage surface. The COF values for the mega 
HPGs are statistically equivalent to healthy bovine synovial fluid (positive control) and, 
importantly, significantly lower than the COF value obtained with human osteoarthritic 
synovial fluid (Fig. 4, p<0.0001, one-way ANOVA). Between the different molecular 
weights of the mega HPGs, the 9 MDa mega HPG-3 exhibits a slightly lower COF, albeit 
not statistically significant. The performance of the mega HPG-3 is more consistent than 
the smaller mega HPG-1 and -2 lubricants as evident by the lower standard deviation bars. 
With regards to the relative COF performance of the 9 MDa mega HPG-3 to other 
lubricants, it is challenging to compare as the extracted absolute values depends on the 
measurement geometry and protocol, as well as tissue type. Given the above caveats, the 
COF values of the mega HPGs are roughly an order of magnitude lower than the values 
reported for some bottle-brush copolymer lubricants between cartilage and glass 




cartilage surfaces.55 (Comparative study results presented in Table 5.4). Analysis of the 
flow data reveals only the solution of mega HPG-1 (1 MDa) at 23% shear thins mimicking 
that of Synvisc, although with a smaller change in viscosity as a function of shear rate 
(Figure 5.10). We surmise that the mega HPG-2 and 3 (3 and 9 MDa polymers) are denser 
than the mega HPG-1. The hydrodynamic diameter of the mega HPG-3, for example, is 
only twice the size of the mega HPG-1 polymer, and therefore is less likely to entangle 
with itself. The mega HPG-1 extends into solution, shear thins, and is a non- Newtonian 
fluid. The mega HPG-3 maintains a constant viscosity across shear rate and acts as a 
Newtonian fluid. A Newtonian fluid lubricant is advantageous over a non-Newtonian one 
because the viscosity of the non-Newtonian lubricant reduces as a function of shear, 
displacing it from the surface and increasing the contact area between the surfaces. The 
mega HPGs exhibit viscosities similar to natural healthy synovial fluid, which are markedly 
lower than Synvisc (1226 mPas). Practically, this is advantageous as an 18G needle is used 
to intra-articularly administer Synvisc while mega HPGs easily flow through a 25 G needle. 
Finally, the cell compatibility of the mega HPGs against human chondrocytes and 
fibroblasts was evaluated at 48 hours. The different molecular weight mega HPGs show 
close to 80% cell viability demonstrating high cytocompatibility of these ultra-high 
molecular weight dendritic polymers with results similar to the saline control (Figure 
5.11).   
The mega HPGs acted as additive for enhanced liquid lubrication and join a class 
of tribological altering nanomaterials applied in lubrication engineering. The mechanism 




colloidal effect, protective film, and third body material transfer.56,57 The mega HPGs are 
20-40 nm in diameter and in the size range of most metal nanoparticle additives, albeit they 
are softer materials and more compressible with a Young’s Modulus of 7.9 kPa determined 
by atomic force microscopy measurements (Figure 5.12).57 No correlation is seen between 
COF and viscosity values suggesting that mega HPGs lubricate via a different mechanism 
than the extremely viscous Synvisc One. We propose that the mega HPGs, specifically the 
3 and 9 MDa Newtonian fluid lubricants, function as interposed molecular ball-bearings in 
water to reduce the COF between the stainless-steel surfaces. We hypothesize a few modes 
of lubrication may be in effect during lubrication of cartilage with mega HPGs, particularly 
hydration shell lubrication described by Klein et al.,58-60 where our highly hydrated, water 
dense structures of the mega HPGs maintain a molecular water film at the cartilage surface, 
supporting heavy loads without being squeezed out while simultaneously rapidly 
relaxing.61 Additionally, we suspect the 9 MDa mega HPG-3 is better retained on the tissue 
surface and does not get washed off, providing constant and lower COF compared to PBS, 
or other lubricants. This proposal is supported by experiments that show no shear thinning 
with the mega HPG-3 as it is a Newtonian lubricant and follows the scenario in which 
Greene suggests62 that a mechanical trapping mechanism maintains a layer of immobilized 
HA between surfaces. This is similar to the ‘ultra-filtration’ hypothesis from Walker et 
al.,63 where water preferentially flows into the articular surface through the ~10 nm bovine 
cartilage pores,64 leaving larger molecules, such as the 20 – 40 nm diameter mega HPGs to 
aggregate at the leading edge of contact. How these proposed mechanisms relate to the 





In summary, we report the synthesis of ultra large dendritic polymers in the million 
Dalton range with high degrees of branching. The polymers are single molecule nanoscale 
objects with unique properties. The synthetic route affords control over the molecular 
weight and provides grams of material for study. The high-water solubility, low intrinsic 
viscosity, compactness, nearly molecular weight independent intrinsic viscosity, hydration 
and cell compatibility are important characteristics justifying investigation of these new 
polymers. The mega HPGs, we propose, are new nanoparticulate lubricants acting as 
interposed ball-bearings to reduce the COF between both hard and soft surfaces and 
demonstrate rheological properties similar to a fluid lubricant. This unexpected result arises 
from the unique size and structure of the polymers. Size, structure, and composition dictate 
function and this is highlighted in the largest known protein, titin, at 3.7 MDa which 
exhibits elastic properties and functions in muscle contraction.65 Advances in synthetic 
polymer chemistry are providing routes to unique polymers and polymer architectures of 
unprecedented size and properties. These advances will propel our capability to prepare 
large single entity molecular structures as well as to conceive of self-assembled higher 
order complexes and to study the interactions of these materials with synthetic and natural 
substrates.  
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Table 5.1. Physical characteristics of mega HPGs. Absolute molecular weight (Mw) and 
distribution (Đ) of mega HPGs was confirmed size exclusion chromatography coupled with 
light scattering detector (MALS). Degree of branching (DOB- 53-57%) supports the semi 
dendritic nature of the polymers and it was determined by 13C IG NMR spectroscopy.  
Mega HPGs are compact in size and have low intrinsic viscosity [ƞ], determined by quasi 
elastic light scattering (QELS) detector and viscometer-II detector respectively which are 
coupled to a gel permeation chromatography system.  
  
Polymer Mw (Da) Đ DOB Size (nm) [ƞ] (mL/g) 
mega 
HPG-1 
1.3 × 106 1.2 0.57 21.2 ± 0.4 4.67 
mega 
HPG-2 
2.9 × 106 1.2 0.54 30.6 ± 0.6 5.26 
mega 
HPG-3 




Table 5.2. Hydrodynamic diameters, degree of branching, and hydration of the mega HPGs 
and comparison with low molecular weight analogues.  






of water molecules 
per polymer)c 
HPG-1 120 kDa (1.15) 0.56 9.203 - 
HPG-2 491 kDa (1.40) 0.57 12.604 - 















0.53 43.0 ± 0.4 389300 
 
aDetermined by quasi-elastic light scattering (QELS) analysis. bMeasured by 13C inverse 





Table 5.3. Comparison of solubility of mega HPGs with other linear synthetic polymers 
Sample (Mn) Solubility (mg/mL) 
mega HPG-2 (2.5 MDa) 380 
PEO (8 MDa) 20  
PEO (4 MDa) 25  
PVA (0.205 MDa) 200  






Table 5.4. COF for other biomimetic lubricants. 
Lubricant System specifics COF 
Lubricin Bovine cartilage on glass; 40% 
compressive strain imposed on each plug 
to ensure boundary mode, and 60min 
allowed for hydrostatic pressure to 
equilibrate 
0.093 
Inflamed SF 24oC Human cartilage on cartilage; 30N load, 
1 mm/s speed 
0.109 (static)/ 
0.089 (dynamic) 
Inflamed SF 37oC Human cartilage on cartilage; 30N load, 
1 mm/s speed 
0.06 (static)/ 
0.055 (dynamic)  
Water Human cartilage on cartilage; 30N load, 
1 mm/s speed 
0.059 (static)/ 
0.05 (dynamic) 
NaCl 15mM Human cartilage on cartilage; 30N load, 
1 mm/s speed 
0.07 (static)/ 
0.06 (dynamic) 
NaCl 150mM Human cartilage on cartilage; 30N load, 
1 mm/s speed 
0.089 (static)/ 
0.067 (dynamic) 
PBS Early OA human cartilage on cartilage, 
6.27 N load, 1 mm/s sliding speed, 900s 
test duration 
0.134 +/- 0.034 
PBS Late OA human cartilage on cartilage, 
6.27 N load, 1 mm/s sliding speed, 900s 
test duration 
0.106 +/- 0.053 
Human SF Early OA human cartilage on cartilage, 
6.27 N load, 1 mm/s sliding speed, 900s 
test duration 
0.04 +/- 0.018 
Human SF Late OA human cartilage on cartilage, 
6.27 N load, 1 mm/s sliding speed, 900s 
test duration 
0.042 +/- 0.015 
PBS Early OA human cartilage on glass, 6.27 
N load, 1 mm/s sliding speed, 3600s test 
duration 
0.026 +/- 0.009 
PBS Late OA human cartilage on glass, 6.27 
N load, 1 mm/s sliding speed, 3600s test 
duration 
0.024 +/- 0.009 
Human SF Early OA human cartilage on glass, 6.27 
N load, 1 mm/s sliding speed, 3600s test 
duration 




Human SF Late OA human cartilage on glass, 6.27 
N load, 1 mm/s sliding speed, 3600s test 
duration 
0.19 +/- 0.001 
Poly-oxanorbornane 
carboxylate 
Bovine cartilage on cartilage; torsional 
friction for 10,080 rotations at 22 mm/s, 
0.78 MPa compressive strain 





Bovine cartilage on cartilage; torsional 
friction for 10,080 rotations at 22 mm/s, 
0.78 MPa compressive strain 
0.0316 ± 0.0005 
High-molecular-weight 
lubricious polymer with 
poly(2-methyl-2-
oxazoline) side chains 
Immature bovine cartilage mounted on a 
ball-on-disc microtribometer; 5 mm/s 
speed; 0.5, 0.7 and 0.9 MPa pressure for 
10 minutes each 
0.02 - 0.1 
Lubricin mimetic - 
chondroitin sulfate 
backbone with type II 
collagen and HA 
binding peptides  
Trypsin treated cartilage on glass with 
lubricin mimetic AND purified, 
commercially available HA; 0.0873 
rad/sec sliding speed; 2 min test duration 
0.1 - 0.3 
pAA:PEG lubricant 
library with varying 
backbone lengths and 
ratios of the two 
polymers 
Bovine cartilage on XX; 40% 
compressive strain imposed on each plug 
to ensure boundary mode, and 60min 
allowed for hydrostatic pressure to 
equilibrate 




Cartilage on cartilage equilibrated for 60 
min and then subjected to a relative 
rotation of +2 revolutions (720°) at 5 







Figure 5.1. A) 1H NMR spectrum (D2O, 400 MHz) of the HPG macroinitiator. B) 
13C 
NMR spectrum (D2O, 100 MHz) of the HPG macroinitiator. C) GPC-MALS 












Figure 5.2. Synthesis and characterization of mega HPGs. A) Schematic representation of 
synthesis of mega HPGs (Mw: 1.3-9.3 million Dalton) by a macroinitiator approach in 
combination with solvent based ring opening multibranching polymerization. B) 1H NMR 
and C) 13C inverse gated (IG) NMR characterization confirmed the structural features of 
the mega HPG-3. D) Gel permeation chromatography analysis shows the monomodal 
distribution of mega HPG-3.  E) Formation of single particles and globular shape of mega 
















Figure 5.3. A) GPC-MALS chromatogram (0.1 M NaNO3 buffer, pH 7.4) of the mega 
HPG-1 (Mw-1.3 MDa). B) GPC-MALS chromatogram (0.1 M NaNO3 buffer, pH 7.4) of 






Figure 5.4. A) 1H NMR spectrum (D2O, 400 MHz) of the mega HPG-1 (Mw-1.3 MDa). B) 
1H NMR spectrum (D2O, 400 MHz) of the mega HPG-2 (Mw-2.9 MDa). C) 
13C NMR 
spectrum (D2O, 100 MHz) of the mega HPG-1 (Mw-1.3 MDa). D) 
13C NMR spectrum 






















Figure 5.7. Comparison of solution properties of mega HPGs with PEG and PAMAM 
dendrimers. A) Variation of hydrodynamic size of the polymer with molecular weight. 
mega HPGs and their low molecular weight counterparts (first four data points), and 
PAMAM dendrimers are compact in size compared to PEG polymers. The values for high 
molecular weight HPGs (76.5, 307, and 771 kDa) are obtained from literature.12 For PEGs, 
the size of PEG-4 (11 million Dalton) was derived from Rg and simulation studies.
13 B) 
Dependence of intrinsic viscosity of the polymers with molecular weight (arrow shows the 
representative Y-axis). Mega HPGs showed similar intrinsic viscosity behavior as that of 
PAMAM dendrimers, however, slight increment with molecular weight might was 










Figure 5.8. Lubrication characteristics of mega HPGs. A) Graph of the Hersey number at 
which each group transitions from boundary mode to mixed mode lubrication (left y-axis 
and green bars). The COF at the time each lubricant transition from boundary to mixed 
mode lubrication. Error bars represent standard deviation, N = 3 replicates; one-way 
ANOVA used to compare groups, statistical differences indicated by asterisk where p<0.05 
=*, p<0.01=**, p<0.0001 =****. For full list of statistical results see SI. b.  Stribeck curves 
for best preforming mega HPG (mega HPG-3) at both 7 and 23 w/v% as well as two 
controls, BSF and Synvisc One (right y-axis, black symbols). Error bars represent standard 
deviation, N = 3 replicates. B) Stribeck curves for best preforming mega HPG (mega HPG-
3) at both 7 and 23 w/v%, as well as two controls, BSF and Synvisc One. Error bars 








Figure 5.9. Determination of coefficient of friction of mega HPGs. Coefficient of friction 
values for cartilage on cartilage with each lubricant after equilibrating in creep, as shown 
with box-and-whiskers plot. Whiskers represent (min to max), bounds of box represent 
lower (25th percentile) and upper quartile (75th percentile), and center line represents 
median. Error bars represent standard deviation, N = 3 or greater replicates; one-way 
ANOVA used to compare groups, statistical differences indicated by asterisk where p<0.05 






Figure 5.10. The viscosity-shear rate behavior of mega HPGs at two different 
concentrations (7 and 23 wt%) and compared with Synvisc One (Synvisc), osteoarthritic 







Figure 5.11. Cell viability of mega HPGs-1, 2, and 3 (1.25 mg/ml) towards Tc28a2 
juvenile human chondrocytes (A) and 3T3 murine fibroblast cells (B). Cells were incubated 
with either mega HPGs, saline, or DMSO for 48 h at 37 °C. After washings, the metabolic 
activity of the cells was assessed by MTT assay.5 Six replicates were performed and each 
study was repeated in quadruplicates. Average values and standard deviation are reported. 
Cell viability of mega HPGs (≥80%) irrespective of the cell line confirmed the high cell 






Figure 5.12. AFM image of mega HPG-3 chemically adhered to the surface of an 





CHAPTER VI: A Biocompatible Nanolubricant 
6.1 Abstract 
Osteoarthritis is a degenerative disease whose pathology is predominantly 
characterized by the breakdown of articular cartilage, concomitant with the degradation of 
synovial fluid macromolecules, hyaluronic acid and lubricin. Macromolecule degradation 
decreases both the fluid and boundary lubricating capacity of synovial fluid, exacerbating 
tissue wear and disease progression. The chemical and physical nature of both the lubricant 
and articulating surfaces are important determinants of wear. Classically, the mode of 
lubrication (i.e., boundary, mixed or fluid film) for rigid articulating surfaces is determined 
from the Stribeck curve: a plot of the non-dimensional Hersey number [(angular velocity 
of a rotating bearing x viscosity of lubricating fluid) / applied stress per unit length] vs. 
COF. Boundary lubrication, characterized by high load and low speed, is defined as that 
where apposing articulating surfaces are separated by a very thin film of lubricant 
molecules absorbed onto the bearing surfaces. It is particularly relevant during “stiction”, 
the friction threshold that must be overcome to enable sliding between articulating surfaces 
after prolonged static contact; during this regime the COF is greatest. Nanoparticles (NPs) 
aid in boundary mode lubrication by altering the tribology of the contacting surfaces via 
introduction of a rolling ball element and infiltration of small gaps between bearing 
surfaces to provide a protective layer. By adding biocompatible tantalum oxide NPs to 
bovine synovial fluid (BSF), we propose a biocompatible nanolubricant that improves 
boundary mode lubrication by reducing the COF between articulating surfaces comprised 





Nanoparticles dispersed within a base fluid result in a colloidal suspension termed 
a nanolubricant.1 Adding nanoparticles to conventional oils enhances performance by 
reducing the COF up to 50%, while purely introducing a rolling element between two 
surfaces in contact decreases the friction, producing frictional forces 102 – 103 times lower 
than those from sliding alone.1–3 Lubricants play an integral role in the operation of several 
technologies, including internal combustion engines, vehicles, gear systems, compressors, 
turbines, and the bearings of the body, synovial joints, whose main function is to reduce 
friction and material wear of hyaline cartilage.  
In healthy synovial joints, hyaline cartilage supports mechanical loads and provides 
a smooth, nearly frictionless gliding surface with a coefficient of friction (COF) 20% that 
of ice on ice.4 Hyaline cartilage is comprised of a collagen fibril network that provides 
structure and tensile strength, complemented by a glycosaminoglycan (GAG) matrix of 
negatively charged polysaccharides that regulate interstitial fluid transport such that >90% 
of applied joint load is supported by pressurization of entrapped interstitial fluid (i.e. 
interstitial fluid load support, IFLS).5 Applied deformations induce efflux of fluid from the 
hyaline cartilage to form an interposed fluid film that decreases the COF and protects 
articulating joint surfaces from mechanical wear.5–7 Synovial fluid (SF) contains polymers 
(e.g., hyaluronic acid and lubricin) that act as boundary lubricants between opposing joint 
surfaces.8,9 Hyaluronan within synovial fluid contribute to viscosity and fluid lubrication, 
while surface zone proteins such as lubricin aid in boundary lubrication.9 




of cartilage GAG and subsequent collagen network degradation that increase hydraulic 
permeability and decrease cartilage stiffness.10 Integral to OA pathology are concomitant 
changes in the biochemical composition of SF that result in deterioration of its rheological 
and lubricious properties, which contribute to increased cartilage wear - hyaluronan 
decrease in molecular weight, decreasing viscosity, and surface zone proteins are degraded, 
decreasing boundary lubricating abilities.9,10 Early signs of articular cartilage are associated 
with loss of the boundary lubrication function of synovial fluid.11–13  
Lubrication is classically divided into three modes for non-deformable materials: 
boundary, mixed and hydrodynamic. Lubrication in the presence of an incompressible fluid 
lubricant is characterized and displayed on a Stribeck curve.14 A Stribeck plots the non-
dimensional Hersey number [(angular velocity of a rotating bearing x viscosity of 
lubricating fluid) / applied stress per unit length] vs. COF and displays three distinct modes 
of lubrication.14 The COF within boundary and mixed is particularly high, causing wear 
and debridement. Lubricant additives, such as nanoparticles, are particularly relevant 
during “stiction”, the friction threshold that must be overcome to enable sliding between 
articulating surfaces after prolonged static contact and in turn boundary lubrication. To 
date, a large number of nanomaterials are used as additives for lubricating oils such as 
carbon materials, carbon nanotubes, graphene eoxide, boron nitrides, and silicon oxide.3 
The mechanisms of action for nanoparticle lubrication are: 1) formation of tribo-films or 
adsorption films that change the surface properties and separate the two friction surfaces15; 




3) NPs are compacted on the wear track due to heat and pressure generated during the 
friction process, called sintering or the repair effect.15  
By adding biocompatible tantalum oxide NPs to bovine synovial fluid (BSF), we 
propose a biocompatible nanolubricant. The goal of this study is to elucidate the 
effectiveness of a novel synthetic nanolubricant compared to saline, BSF and hyaluronic 
viscosupplement (Synvisc One) to reduce wear along of articulating surfaces comprised of 
poroelastic materials and improve boundary and hydration lubrication (and by extension, 
provide chondroprotection). 
6.3 Methods 
6.3.1 Nanoparticle Synthesis and Characterization 
Tantalum oxide (Ta2O5) nanoparticles were synthesized by adding tantalum 
ethoxide (1.20 mL) dropwise at 0.2 mL/min to a stirring solution of n-propanol (34 mL), 
isobutyric acid (0.440 mL), and deuterium oxide (0.500 mL).  This solution was stirred for 
48 hours at room temperature after which, solutions of n-propanol (20 mL), N-
trimethoxysilylpropyl-N,N,N-trimethylammonium chloride (2.343 mL), and 2-
[methoxy(polyethyleneoxy)6-9propyl]trimethoxysilane (2.5 mL) were subsequently added 
to the reaction vessel at 1 mL/min. The reaction was refluxed for 2 hours at 103C, and 
cooled to room temperature. 0.1 M NH4OH (0.250 mL) was added to the vessel and stirred 
for 18 hours. At 1 mL/min, deionized water (40 mL) and 1.2 M hydrochloric acid (10 mL) 
were added to the solution and stirred at 50C for 48 hours. The reaction was then cooled 
to room temperature, adjusted to a pH of 7 using Na2CO3, and filtered using a 0.22 um 




changes, followed by lyophilization to yield a white powder. 1H NMR (500 MHz, D2O): δ 
= 0.10 (br s), 1.15 (br s), 1.37 (br s), 2.5–3.3 (br m). FTIR (cm−1): 2871 (strong), 1647 
(medium), 1479 (medium). 
Nanoparticle size was evaluated using dynamic light scattering (DLS) and 
transmission electron microscopy (TEM). DLS size characterization was conducted using 
the Brookhaven Nanobrook Omni Particle Sizer (Brookhaven Instruments, Holstville, 
NY). Samples were prepared by suspending nanoparticles in either deionized water or 
bovine synovial fluid, and the hydrodynamic size of the nanoparticles was subsequently 
measured at room temperature. Samples for TEM were prepared by depositing 0.010 mL 
droplet of 0.1 mg/mL nanoparticles solution to dry on a glassy C-coated Cu TEM grid. 
Imaging was performed using a Hitachi 780 TEM at 80 kV. 
Zeta potential of the nanoparticles was measured Brookhaven Nanobrook Omni 
Particle Sizer (Brookhaven Instruments, Holstville, NY), using the samples prepared with 
deionized water used for DLS size characterization.  Zeta potential was recorded for each 
sample after three runs of ten cycles. Ta2O5 NPs were suspended in deuterium oxide and 
NMR spectra were obtained using the Agilent 500 MHz VNMRS spectrometer with a 
Varian ultra-shielded magnet. FTIR spectra were obtained on dried Ta2O5 NPs samples, 
using Thermo-Nicolet Nexus 670 FTIR E.S.P. instrument, equipped with Miracle ZnSe 
ATR prism (Thermo Sci., Billerica, MA).  
6.3.2 Cytotoxicity 
NIH3T3 murine fibroblast cells were maintained in Dulbecco’s Modified Eagle 




maintained in a humidified atmosphere at 37 °C and 5% CO2. Sub-confluent cells were 
harvested and seeded on 96 well plates at 3,000 cells/well for use in in vitro cytotoxicity 
studies. After 24-hours, the cells were treated with nanoparticles suspended in nanopure 
water, starting at 120 mg/mL and serially diluted by 1/3 until a final concentration of 0.002 
mg/mL. After a 24-hour exposure, cell viability was tested using a colorimetric MTS [3-
(4,5-dimethylthiazol-2-yl)-5-(3- carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-
tetrazolium] cell proliferation assay (Sigma, St. Louis, MO) and absorbance read at 490 
nm on a Biotek Synergy HT Plate Reader (Winooski, VT). Cell viability in each well was 
calculated as the percentage of the positive control absorbance. 
6.3.3 Classical Tribological Testing 
Viscosity measurements were performed on a TA Instrument AR2000 rheometer 
using a 2° aluminum cone and a 47 µm gap at 25 °C. Viscosity was then averaged across 
shear rates from 10 to 100 per s. Rigid body Stribeck curves to evaluate the modes of rigid 
body lubrication were constructed using a DHR-2 rheometer (TA instruments) with a 
stainless steel ring articulating on a stainless-steel plate, bathed in 300 µL of each lubricant:  
100 nm diameter NP in BSF were prepared at a range of concentrations 0.01, 0.1, 1, 3, 8 
and 11 wt% to first determine a dose response curve. Next stribeck curves of the 
nanolubricant at 11 wt%, Synvisc, and BSF were conducted. Tribologic testing was 
conducted in triplicate for each lubricant at a constant 5N applied compressive load and 
progressively increasing radial velocity 0.001 rad/s to 50 rad/s. Stribeck curves were 





6.3.4 Sample preparation 
Bovine osteochondral plugs (7 mm diam.; N=9) were cored from skeletally mature 
cows (Green Village packing, Green Village, NJ) using a diamond tipped drill bit and 
stored at 4°C in 400 mOsm saline supplemented with protease inhibitors and antibiotics. 
Sample degradation was performed by placing osteochondral plugs in a Trypsin solution 
containing PBS and 0.1 mg Trypsin at pH 7.5 for two hours at 37 °C.16 
6.3.5 Biotribological Testing 
Cartilage on cartilage tribology testing using paired bovine osteochondral plugs in 
unconfined compression was performed for saline, BSF and nanoparticles suspended in 
BSF at 11 wt%. A static 8N (200kPa) compressive load was applied (Bose Electroforce 
3200), followed by 3 hours of tissue creep to reach equilibrium, while submerged in the 
test solutions. Equilibrium COF was determined at an angular velocity of 360°/s (effective 
velocity = 14.7 mm/s) for 120 seconds. A second tribology test was then preformed after 
increasing the compressive load to 30N and decreasing the angular velocity to 36°/s. 
Dynamic and equilibrium COF were calculated using a custom MATLAB program.   
6.3.6 Wear Testing 
A static 30N load was held constant for 105 minutes while submerged in a bath of 
lubricant; saline BSF, or nanolubricant at a concentration 11 wt% nanoparticles. While the 
static load was applied, cartilage surfaces were articulated at 180°/s for the entire test 
duration. Cartilage wear was quantified by measuring tissue volume via microcomputed 




tomography at an isotropic voxel resolution of 36 um, 70-kVp, 113-uAmp, 300 ms 
integration time (μCT40, Scanco Medical AG). µCT data were converted into DICOM 
format and imported into Analyze for post-processing analysis as previously described. 
The mean cartilage thickness at the apex was determined by a custom MATLAB program. 
6.3.7 Animal Model 
A mouse model was utilized for this study, specifically destabilization of the 
medical meniscus (DMM) as it is an accepted model of post-traumatic osteoarthritis for 
evaluation of novel therapeutics. After medial parapatellar arthrotomy, the infrapatellar fat 
pad (IFP) was temporarily repositioned laterally, allowing access to the anterior medial 
meniscotibial ligament. This ligament was severed using a #11 blade. The IFP was 
repositioned, and the incision closed using 5-0 PDS or similar absorbable suture. Mice 
were monitored daily throughout the study period for any signs of adverse events or 
complications to evaluate pain, lameness, incisional site, and ambulatory function as well 
as general health status, any animal noted to have abnormal clinical findings during routine 
daily monitoring, a complete physical examination will be performed by a veterinarian and 
a diagnostic plan and therapeutic plan will be implemented.  All animals will receive intra-
articular injections at 14-, 28-, and 42-days post-op. For each time-point, mice received a 
single intra-articular injection (10uL of Ta nanoparticles in sterile saline) in the injured 
knee under general anesthesia. Delivery occurred via a 27-gauge syringe into the cranial 
aspect of the knee just medial to the patellar tendon. Sham treatment animals received a 
needle puncture without an intra-articular injection. For recovery, animals were returned 




cardiac puncture using a 25G needle while the animal is under general anesthesia. All blood 
samples were centrifuged at 2,000xg for 10 minutes, and the serum removed and stored at 
-20˚C. All animals were humanely euthanized by CO2 inhalation and confirmatory cervical 
dislocation, following blood collection via cardiac puncture in accordance with the 
American Veterinary Medical Association (AVMA) guidelines. All hind-limb samples 
were processed for decalcified histological analysis. Following fixation in 10% NBF, 
specimens were decalcified in 10% EDTA. Specimens were processed using standard 
techniques (Tissue-Tek VIP, Sakura, Torrance, CA), embedded in paraffin, and one (1) 
5um thin coronal section was taken from each knee joint. All sections were then be stained 
for toluidine blue and imaged under bright field light. 
6.3.8 Statistics 
Univariate linear regression (GraphPad Prism 8) was used to examine the 
relationship between boundary coefficient of friction and nanoparticle concentration. The 
coefficient of determination (R2) was used to assess the strength of correlation. Brown-
Forsythe, one-way repeated measure ANOVA, was used to examine the relationship 
between BSF, Synvisc, and nanolubricant. A dose-response curve was fit to evaluate the 
nanoparticle concentration response curve. The coefficient of determination (R2) was used 





6.4 Results  
6.4.1 Characterization 
1 H NMR showed the characteristic peaks and confirmed the silane coating on the 
particle (Figure 6.2). As shown in Table 6.1, the hydrodynamic size of the nanoparticles 
confirmed via dynamic light scattering (DLS) begin at 101.16 nm in DI water and grow in 
diameter to 285.91 nm when in bovine synovial fluid. The nanoparticles possess an overall 
positive charge of 8.9 +/- 2.1 mV as measured using Brookhaven Instruments ZetaPALS 
Zeta Potential Analyzer.  
6.4.2 Dose response curve  
Concentration is an important factor in development of a nanolubricant, 
demonstrating efficacy at concentrations below 1 wt % and above 2 wt%,3 indicative that 
there is no ideal concentration and no predictable relationship between the concentration 
and the effect of the NP additive on friction and wear. Therefore, we determined the lowest 
concentration at which the tantalum oxide nanolubricant became efficacious compared to 
BSF alone, and if efficacy increased with concentration using our non-deformable body set 
up. At the lowest concentration of nanoparticle additive, the nanolubricant demonstrated 
an average boundary coefficient of friction lower than BSF alone (0.33 and 0.40, 
respectively). The measured boundary COF varied linearly with nanoparticle concentration 
(Figure 6.4). The highest concentration, 11 wt%, produced the lowest boundary mode COF 




6.4.3 Tribological characterization 
The nanolubricant displayed a viscosity on the order of BSF (0.0114 Pa.s and 
0.0149 Pa.s, respectively), both an order of magnitude less than Synvisc (0.290 Pa.s) 
(Figure 6.6). All controls along with the nanolubricant demonstrate a shear thinning 
behavior and are therefore non-Newtonian fluids. Elastic and viscous effects for BSF 
(0.7898 and 0.4458, respectively) are slightly higher than the nanolubricant (0.5255 and 
0.3384) but not to a statistically significant amount. Storage and loss moduli at a frequency 
of 2.5Hz. Moduli averaged over 11 logarithmically spaced data points spanning stress 1-
10 Pa within linear viscoelastic region  
6.4.4 Cytotoxicity  
The nanoparticle concentration response curve was fit with a dose response curve 
in order to obtain an IC50 value. IC50 value for the tantalum oxide nanoparticle is 21.76 
mg/mL. Nanoparticles demonstrate 90% viability at 11wt%, the concentration which 
demonstrated the most efficacy in reducing the boundary COF.  
6.4.5 Rigid body Stribeck curves 
BSF demonstrated an inflection point at the highest COF (0.473) and lowest Hersey 
number (5.97*10-6). The nanolubricant demonstrated an inflection point at a Hersey 
number multiple orders of magnitude higher (2.4*10-4) and at a COF half that of BSF 
(0.24). Consequently, the nanolubricant exhibited a Stribeck curve similar to the hyaluronic 
acid solution, Synvisc, except that the nanolubricant is 100× less viscous. Boundary mode 




both Synvisc (0.30) (p = 0.001) and BSF alone (0.40) (p = 0.0038) (Figure 6.5).  
6.4.6 Deformable body COF 
Lubricant type had little to no effect on dynamic COF, with little variation between 
lubricant types. Upon instantaneous loading, fluid pressurization within the cartilage and 
exudation at the cartilage-cartilage interface governs dynamic equilibrium with an 
insensitivity to boundary lubricating and viscosity modifying entities in the lubricant. 
When fluid pressurization reaches equilibrium, the lubrication mode is sensitive to the 
operating parameters – specifically viscosity, strain, and co-planarity, and not dominated 
by tissue pressurization parameters. At equilibrium conditions at two different loads, 8N 
and 30N, the nanolubricant’s ability to modulate the COF is apparent. At the 8N load and 
0% interstitial fluid load, with a rotational speed of 360 °/second, the COF values for the 
nanolubricant (0.018) were statistically equivalent to healthy BSF (0.021)  and, 
importantly, significantly lower than the COF value obtained with saline (0.15) (p = 0.018) 
(Figure 7). With the goal of better emulating mixed mode lubrication, the load was 
increased by 375% to 30N and the speed decreased by an order of magnitude to 36°/second. 
Under these conditions at 0% interstitial fluid load support, the nanolubricant 
outperformed, BSF having a COF value of 0.135 compared to BSF at 0.039 (p = 0.0219) 
(Figure 6.X).   
6.4.7 Cartilage Wear 
Using healthy, native bovine cartilage, the nanolubricant allowed for a mere 3% 




cartilage volume was decreased by 13% and with saline by 17%.  Bovine tissue was then 
degraded with Trypsin to remove surface level phospholipids and lubricin which aid in 
boundary lubrication, in conjunction with decreasing surface zone GAG content.16 Using 
these degraded samples, the nanolubricant preserved tissue to an even greater extent, 
allowing for only 2% decrease in total cartilage volume following the supra-physiologic 
wear cycle, compared to saline and BSF which allowed for a decrease of 6.93% and 13.67% 
respectively (p = 0.0029) (Figure 6.8).  
6.5 Discussion 
Viscosupplementation is one of the most common non-surgical treatment options 
for OA, accompanied only by nonsteroidal anti-inflammatory drugs, both aimed at pain 
control and improved joint function. Current viscosupplementation endeavors aim at 
restoring concentrations of hyaluronic acid to increase viscosity, improve lubricity, and 
modulate hydrodynamic lubrication, while on the macroscopic scale provide pain relief 
and improved ambulation.  Yet, to date, viscosupplementation efficacy remains under 
scrutiny, with ample recommendations both for and against its use. Its lack of 
chondroprotection, poor lubricity and a short in vivo half-life are shortcomings.  
We describe a novel, biocompatible nanolubricant for modulating the coefficient 
of friction and wear of deformable, poroelastic, biphasic materials such as articular 
cartilage. This novel nanolubricant joins a class of tribological altering nanomaterials most 
commonly employed for lubrication of machinery (i.e., metal bearings and automotive 
applications)17,18, but now demonstrating applicability to the living bearings of the body, 




To investigate changes in tribological behavior from addition of nanoparticles to 
synovial fluid, we performed basic rheological characterization. Synvisc One and bovine 
synovial fluid (BSF) were selected as controls based on their different compositions (a 
lightly crosslinked linear polymer of hyaluronic acid of high viscosity versus a low viscous, 
natural lubricating solution) and relevance to the hard and soft natural surfaces 
investigated. Concomitantly, Synvisc One and BSF lubricate via different mechanisms, 
BSF aids in boundary and mixed mode lubrication, while Synvisc One is a fluid lubricant, 
operating during hydrodynamic lubrication.  The nanolubricant, in comparison to the base 
fluid alone, BSF, reveals no apparent changes in viscous or elastic properties. The 
nanolubricant retains the same viscosity as pure BSF, in conjunction with the same storage 
and loss moduli. Tangentially, both BSF and nanolubricant present much lower viscosity 
and storage and loss moduli in comparison to the commercially available viscosupplement, 
Synvisc-One ®.  
We first created Stribeck curves in order to determine the performance and modes 
of lubrication of the nanolubricant on non-deformable materials, specifically stainless steel. 
Stribeck curves describe the COF of a system composed of non-deformable materials 
across different lubrication modes: boundary, mixed, and hydrodynamic lubrication. 
Generally, boundary lubrication exists under conditions of low speed, high load, and is 
characterized by a high COF while conversely hydrodynamic lubrication occurs under 
conditions of high speed and low load, and is characterized by a low COF, with inflection 
points indicating thresholds for the transition from boundary to mixed mode lubrication. 




some areas of the articulating surfaces in direct contact where others are fully separated by 
a film of fluid.  
Stribeck curves are a property of the whole system. Hersey number being (velocity 
* viscosity)/load, and are created by varying only one parameter, in this case, velocity. 
Both BSF and the nanolubricant possess similar viscosities (0.0115 Pa.s and 0.0149 Pa.s, 
respectively), yet they span different regions of the Stribeck plot , with BSF spanning fewer 
Hersey numbers (10-7 – 10-4) in comparison to the nanolubricant (10-7 – 10-2), concurrent 
with much higher COF values through all modes of lubrication for BSF. While the 
nanolubricant Stribeck curve differs from that of BSF, it more closely mimics that of 
Synvisc. Syncisc-One ®, a highly crosslinked supplement of hyaluronic acid possess a 
viscosity an order of magnitude greater than the nanolubricant and BSF (0.29 Pa.s), in 
parallel with larger viscous and elastic properties. Higher viscosity values increase Hersey 
numbers, effectively shifting Stribeck curves to the right on the Y-axis. Despite its 
fractional viscosity value compared to Synvisc, the nanolubricant’s Stribeck curve spans 
similar Hersey numbers and COF values. The only parameter altered between Stribeck 
curves is the lubricant itself, with the load and velocity parameters held constant between 
groups. Thus the vastly different Stribeck footprint despite identical testing parameters to 
BSF (same viscosity, velocity and load) indicates the nanolubricant is lubricating via a 
different mechanism.  
We propose the mechanisms of action for nanolubricant reduction in the COF are 
multifaceted and include – rolling effects, mending effects, and polishing effects. Rolling 




bearings rolling into the contact zone and changing sliding friction to a combination of 
sliding and rolling.19 The mending effect is characterized by nanoparticle deposition on 
friction surfaces and mass loss compensation, filling scars and grooves to reduce 
abrasion.20 The polishing effect manifests itself when roughness of lubricating surface is 
reduced by abrasive treatment with nanoparticles. Nanoparticles fill gaps acting as 
reservoirs of solid lubricants and this artificial smoothing results in improved tribological 
characteristics owing to reduced surface roughness.21 With our current model it is 
impossible to parse out if all or only some of these mechanisms are responsible for the 
reduction in COF, and determining which mechanisms are present requires further 
investigation.  
In addition to these mechanisms of action, we hypothesize a different mode of 
lubrication to be in effect during lubrication with our nanolubricant, which involves charge 
effects and hydration shell lubrication. For the macromolecules of synovial fluid, function 
follows form; hyaluronic acid, lubricin and phosphatidylcholine lipids all playing very 
specific roles in cartilage lubrication as dictated by their form and chemical composition. 
It is the synergistic interaction of these eloquently designed macromolecules and the 
extracellular matrix, which give rise to the extremely low COF of articular cartilage. Recent 
studies indicate the entanglement and hydrophobic interaction of lubricin and HA 
contribute to mixed mode lubrication and shock absorption.22–24 Although, the 
entanglement of HA and lubricin alone do not account for the low COF of articular 
cartilage at high applied loads. Klein et al suggest a three-component system, where in 




phosphatidylcholine lipids exposing their charge groups at the cartilage interface and 
allowing for "hydration lubrication", whereby lubrication occurs via hydration shells 
forming around the charged phosphatidyl choline molecules.25–28 
We hypothesize that our hybrid tantalum oxide nanoparticles coupled with 
hyaluronic acid aggregate on the surface to maintain a lubricious, hydrated film, aiding to 
support heavy loads and decreasing the COF of articulating surfaces, able to act as both a 
fluid film or boundary lubricant, depending on the operating conditions. That tantalum 
oxide nanoparticles described herein are cationic, possessing multiple positive charges per 
nanoparticle, whereas lubricating constituents within SF, including hyaluronic acid, are 
negatively charged.29 When suspended in DI water, DLS measurements reveal the 
nanoparticles to be a size 101.16 nm in diameter, yet when suspended in BSF, the 
nanoparticle size increases to 285.91nm, supporting the hypothesis that when these cationic 
particles are suspended in BSF, the aggregation of negatively charged SF constituents 
occurs. Aggregation of SF constituents affords the nanoparticles within our nanolubricant 
a hybrid structure, a synergistic combination of a rigid internal shape and a slippery fluid-
like surface. We envision these hybrid structures function to maintain a lubricious film near 
the anionic cartilage surface during mixed mode lubrication. This proposal is supported by 
results that show when used to lubricate poroelastic, biphasic materials such as hyaline 
cartilage, the nanolubricant acts to modulate the coefficient of friction under mixed mode 
operating conditions, (higher load, lower speed), generating COF values much lower than 
BSF, but in hydrodynamic lubrication, when the COF is dominated by the viscous effects 




Being cationic, we hypothesize that during boundary mode lubrication, when other 
synovial fluid constituents have been squeezed out from between the surfaces, the cationic 
nanoparticles lubricate via hydration shell lubrication and a mechanical trapping 
mechanism. Cartilage being an anionic material, creates hydration layers of charge bound 
water molecules when exposed to a bath solution of saline at high salt concentrations, when 
ions condense over ionizable sites.30,31 These charge bound water molecules form 
hydration layers, and when there is overlap of layers, water moves freely, effectively acting 
as a low viscosity lubricant.30–32 In our scenario with the cationic nanoparticles, we 
postulate the cationic nanoparticles condense over the ionizable sites on the anionic 
cartilage, while simultaneously forming hydration shell around the particles themselves, 
thereby creating similar hydration layers and allowing water to move freely in overlapping 
regions. This entrapment of a lubricious layer of nanoparticles coated with HA and water 
molecules also follows the scenario in which Greene et al suggest a mechanical trapping 
mechanism maintains a layer of immobilized HA between articulating surfaces.33 Where 
rather than HA alone, as the nanoparticles are ionically bound to the HA, they too become 
mechanically trapped between the articulating surfaces. Purely introducing a rolling ball 
element between surfaces reduces the COF [REF], independent of the presence of 
lubricating macromolecules, suggesting a second mechanism by which the nanoparticles 
act to reduce the COF during boundary mode operating conditions. The ability of the 
nanolubricant to modulate boundary mode COF values is supported by results from the 
non-deformable materials, where the nanolubricant reduces the boundary mode COF to 




High friction causes increased shear strain, vitally important when it comes to 
articular cartilage and the disease pathogenesis of OA, as strains transmits themselves to 
the chondrocytes embedded within cartilage, causing upregulation of cartilage degrading 
enzymes via mechanotransduction.34–36 Degraded tissue is then abraded and removed by 
friction upon articulation, damaging the cartilage surface causing higher friction, 
increasing shear strain and so on in a self-reinforcing cycle.37 In a healthy joint, synovial 
fluid and its constituents aid to mitigate shear strains on the tissue, but with OA 
pathogenesis this functionality decreases, making viscosupplementation an attractive 
solution to elongating the lifespan of hyaline cartilage.38  Viscosupplementation standard 
of care utilizes solutions of highly crosslinked hyaluronic acid, which demonstrate 
nebulous efficacy, are susceptible to enzymatic degradation via hyaluronidase and possess 
minimal joint residence time.38,39 Previously, linear40,41 and brush polymers41–43 have been 
explored for lubricating cartilage as these materials present controlled electrostatic 
interactions and hydration, yet none to date have employed nanoparticles.  
In summary, we report the synthesis of cationic, tantalum oxide nanoparticles 
suspended in bovine synovial fluid as a first of its kind, biocompatible nanolubricant. The 
nanolubricant acts as interposed ball bearings to reduce the COF between both hard and 
soft surfaces, without altering the rheological properties of the base synovial fluid. It 
possesses the capacity to operate and improve the COF under both hydrodynamic and 
mixed lubrication modes. A function that arises due to the hybrid nature of the particles 
with a hard, core shell of tantalum oxide, which act as load bearing ball bearings during 




via the aggregation of negatively charged synovial fluid constituents (e.g. hyaluronic acid), 
to facilitate hydration shell lubrication. 
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Table 6.1. Zeta Potential and Nanoparticle Size in deionized water and BSF as determined 
by DLS.   
Charge Zeta Potential in 
Deionized water* 
Size in Deionized 
Water (nm) 
Size in BSF (nm) 
Positive 8.9 ± 2.1 101.16 285.91 





Figure 6.1. Mechanisms of action and Stribeck curve A) Schematic representing 
nanoparticle lubrication mechanism of action, lubricating the deformable material, hyaline 
cartilage. B) Stribeck curve representing coefficient of friction vs. hersey number depicting 








Figure 6.2. Characterization of tantalum oxide nanoparticles. A) schematic representation 
of nanoparticles synthesized. B) TEM image of synthesized nanoparticles. C) 1 H NMR 






Figure 6.3. Tantalum oxide nanoparticle concentration response curve. IC50 of tantalum 
oxide nanoparticles determined by measuring cell viability of NIH 3T3 fibroblasts after 24 








Figure 6.4. Nanolubricant Dose Response Curve. 100 nm diameter NP in BSF were 
prepared at a range of concentrations 0.01, 0.1, 1, 3, 8 and 11 wt%. The measured boundary 
COF varied linearly with nanoparticle concentration. N = 3 replicates, linear regression 







Figure 6.5. Non-deformable Body Stribeck Curves. A) Stribeck curves for nanolubricant 
with nanoparticles suspended at a concentration of 11 wt%, as well as two controls, BSF 
and Synvisc. Error bars represent standard deviation, N = 3 replicates. B) Average 
boundary mode coefficient of friction for the nanolubricant at 11 wt% nanoparticles and 
two controls, BSF and Synvisc. Error bars represent standard deviation, N = 3 replicates; 
one-way ANOVA used to compare groups, statistical difference indicated by asterisk, 






Figure 6.6. A) Viscosity values for controls, Synvisc and BSF, and nanolubricant at 11 
wt%, viscosity as a function of shear rate. B) Storage and loss moduli Storage and loss 
moduli at a frequency of 2.5Hz. Moduli averaged over 11 logarithmically spaced data 





Figure 6.7. Cartilage Lubrication. A) Equilibrium coefficient of friction with an 8N load 
and rotational speed of 36 deg/second, for controls, saline and BSF, and nanolubricant at 
11wt% concentration. B) Equilibrium coefficient of friction with a 30N load and rotational 
speed of 360 deg/second for controls, saline and BSF, and nanolubricant at 11wt% 
concentration. Error bars represent standard deviation, N = 4 replicates; one-way ANOVA 






Figure 6.8. Cartilage Wear. A) Percent decrease in tissue volume using healthy bovine 
cartilage subject to a wear cycle of articulations for 105 minutes with a 30N load, lubricated 
with either controls, saline and BSF, or nanolubricant at 11 wt%. B) Percent decrease in 
tissue volume using trypsin degraded bovine cartilage subject to aforementioned wear 
cycle. Error bars represent standard deviation, N = 4 replicates; one-way ANOVA used to 





CHAPTER VII: Conclusion 
7.1 Part I.  
Plain radiography remains the most accessible tool and the current standard of care 
to diagnose OA. While it is accessible and inexpensive, it cannot directly visualize soft 
tissues or cartilage, and diagnoses are based solely on boney changes such as joint space 
narrowing, osteophytes, sclerosis, joint incongruity, and malalignment. Nanotechnology 
offers significant potential to enhance current OA management through new diagnostic 
capabilities. And while application of nanotechnology in orthopaedics remains in its 
infancy, a number of new technologies are in pre-clinical development to address the many 
facets of OA.  
Specifically, nanoparticles of various compositions are explored in Chapter 1 for 
their use as 1) MRI and CT contrast agents to provide quantitative assessment of a tissue 
component other than GAG; 2) functional MRI or CT agents that provide information on 
the biochemical or metabolic state of the tissue; 3) nanotracers for specific cells types; and 
4) theranostics, which act simultaneously as a diagnostic agent and a therapy. However, 
there is currently no FDA approved nanotechnology for the diagnosis or treatment of OA 
and while advances in the synthesis of nanoparticles are yielding various types of 
nanoparticles for medical imaging, their use as has been restricted to non-quantitative 
imaging of soft tissues. 
To advance the capabilities of contrast-enhanced CT imaging of articular cartilage 
for OA diagnosis, this work presents further development of a nanoparticle-based contrast 




content) and mechanical integrity (e.g., E). Specifically, the ability of the cationic and 
neutral nanoparticle formulations to disseminate throughout the layers of cartilage to allow 
direct visualization of the soft tissue is initially established using an ex vivo human 
metacarpal phalangeal joint model (Chapter 2).  The contrast-enhanced CT (CECT) with 
either of the nanoparticle contrast agents, cationic or neutral, is effective at determining 
GAG content and equilibrium modulus. Furthermore, in tandem with the sensitivity of the 
nanoparticle contrast agents for quantitative metrics of cartilage health, CT retains the 
ability to examine boney changes, presenting the potential for comparative studies of the 
crosstalk between cartilage and bone. CECT’s sensitivity to biochemical and 
biomechanical properties, in conjunction with its ability to evaluate boney changes, 
signifies its utility as a diagnostic and monitoring agent for progression of OA, and 
potential as a research tool for both in vivo animal and human use.  Additionally, results 
indicate the nanoparticle formulations described function to assess cartilage health 
minimally invasively.  
In vivo experiments are warranted to next establish this technique as a potential 
alternative to histology. Specifically, an in vivo study that assesses NP enhanced 
attenuation to accurately measure cartilage properties throughout the progression of OA, 
with groups of animals euthanized at time points beginning from the very-early stages of 
OA.  Diffusion kinetics of the three separate cartilage layers indicate the passive diffusion 
of the neutral nanoparticles does not follow an exponential model, and further experiments 
and modeling are necessary to parse out the effects of water, collagen, and 




nanoparticles actively diffuse into the cartilage due to electrostatic interactions with the 
negatively charged glycosaminoglycans. How glycosaminoglycan, collagen, and water 
content impact the active diffusion of the cationic particles requires further 
experimentation. Specifically, diffusion experiments for both nanoparticle formulations, 
using cartilage degraded with enzymes that target specific parts of the cartilage 
extracellular matrix, collagenase to degrade the collagen and hyaluronidase to degrade 
glycosaminoglycans, coupled with finite element modeling. 
Early-stage treatment options are not yet a fully realized reality, as OA is typically 
detected its late stage when little cartilage is left to salvage and any reversible changes are 
long gone. Functional measures of tissue health apart from patient pain, such as the imaging 
technique described herein offer avenues potential to identify early-stage OA when early-
stage treatments and preventative measures may be employed improve patient outcomes 
and the functional lifetime of their synovial joints.  
 
7.2 Part II 
Nanotechnology offers significant potential to enhance current OA management 
through targeted therapeutics, smart scaffolds, and novel viscosupplements. Chapter 3 
describes nano-based approaches to 1) provide delayed, sustained, or triggered drug release 
with increased joint retention, 2) reduce off-target side effects, 3) construct scaffolds 
incorporating nano-designs and structural features to recapitulate cartilage, augment 
biochemical constituents, and enhance biomechanical properties, and 4) to repair 
osteoarthritic tissue with the use of lubricants and engineered scaffolds. However, these 




To date, the two most common, clinically utilized, non-surgical treatment options 
for OA are nonsteroidal anti-inflammatory drugs and viscosupplementation. Current 
viscosupplementation targets HA concentration restoration, increasing viscosity, 
improving lubricity, and enhancing cushioning properties of the SF, while on the 
macroscopic scale providing pain relief and improved ambulation. Viscosupplementation 
effectiveness remains debated, an equal number of studies supporting and rejecting its 
efficacy. Chapter 4 highlights existing viscosupplements along with natural, partial, or 
full synthetic biolubricant formulations and their relationship to cartilage theory of 
lubrication. 
Through this research an intricate understanding of biolubrication and biotribology 
has been gained, and lessons learned have informed the development of lubricants based 
on the concept of ball bearings between articulating surfaces — one out of single 
macromolecules (Chapter 5) and the other from nanoparticles (Chapter 6). The 
lubrication strategies presented in this dissertation have been tribologically and 
mechanically investigated for their ability to reduce friction and prevent wear between non-
deformable and deformable materials. The macromolecule lubricant appears to be the first 
example of a lubricant composed of single particle, ultra-high molecular weight, 
macromolecules. Tribological results indicate these polymers lubricate via a mechanism 
independent of viscosity and by a method separate from a traditional mixed mode lubricant 
(i.e., synovial fluid) or a fluid lubricant (i.e., the HA viscosupplement Synvisc-One ®), 
functioning as small, interposed ball bearings between articulating surfaces to reduce 




This tribological of ball bearings between articulating surfaces was further probed 
through the development of a biocompatible nanolubricant (Chapter 6). The nanolubricant 
described herein is capable of multimodal lubrication for non-deformable materials, in 
conjunction with reducing friction and wear between articulating poroelastic materials 
(e.g., articular cartilage). The nanolubricant functions under boundary and mixed mode 
lubrication mechanisms. We suggest the nanolubricant operates by hydration shell 
lubrication, where overlapping regions of water molecules surrounding the cationic 
nanoparticles function as a low viscosity lubricant, and by maintaining a hydrated, 
lubricious layer of associated water and HA molecules at the cartilage surface. It joins a 
class of tribological altering nanomaterials most commonly employed for lubrication of 
machinery (i.e., metal bearings and automotive applications)17,18, but now demonstrates 
applicability to the living bearings of the body, synovial joints.   
There are numerous remaining questions pertaining to these novel lubricants 
ranging from fundamental scientific questions to clinically relevant, biomechanical 
engineering questions. Future studies are required for translation of this device into clinical 
application. Specifically, joint space residence time course studies are necessary to validate 
the long-term presence and efficacy of the described lubricants in an in vivo OA animal 
model. Pertaining to the nanolubricant specifically, ascertaining what synovial fluid 
constituents specifically are adhering to the surface and how this is affecting the lubricating 
abilities requires further investigation. Firstly, we propose adding neutral nanoparticles to 
bovine synovial fluid (BSF) to ascertain if this formulation behaves differently than plain 




the cationic particles by suspending the particles in BSF and allowing aggregation of the 
SF constituents, removing the particles from solution and staining what we postulate is HA 
surrounding the particles via hyaluronic acid binding protein coupled with a streptavidin 
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